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Dystrophic epidermolysis bullosa results from mutations in COL7A1 that 
encodes collagen VII, the major component of anchoring fibrils. General 
paradigms have emerged attributing dominant DEB to heterozygous glycine 
substitutions and recessive DEB to nonsense, frameshift or splice site 
mutations on both COL7A1 alleles. Several aspects of the genotype-phenotype 
heterogeneity encountered in DEB remain unexplained, although genetic, 
epigenetic and environmental modulators have been implicated. In this thesis, 
various aspects of DEB were studied, in a bid to refine genotype-phenotype 
correlation. A detailed analysis of missense GS and non-GS mutations 
identified 57 novel mutations and was in-keeping with the general established 
paradigms. Unique clinical entities such as EB-pr and BDN were studied. The 
role of the matrix metalloproteinase-1 promoter polymorphism, -1607 1G/2G, 
on disease modification in EB-pr was explored, but was shown to be an 
unlikely modulator. A large study of BDN, highlighted that intracytoplasmic 
retention of collagen VII and stellate bodies were not exclusive to BDN and 
can be associated with various subtypes of DEB, non-EB cases and normal 
skin. The first case of revertant mosaicism in DEB was studied revealing 
intragenic cross-over as the underlying mechanism. Finally, intradermal 
injection of allogeneic fibroblasts was shown to result in increased and 
sustained expression of COL7A1 possibly through the upregulation of HB-
EGF. Recognition of disease modifiers in DEB and refinement of genotype–
phenotype correlation will not only further our understanding of DEB but will 
have implications on diagnosis, counselling and prognosis through patient 
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Epidermolysis Bullosa (EB) is a rare genetic skin disorder characterised 
by skin fragility and blistering of the skin and mucous membranes following 
minimal trauma (Fine et al., 2014). It affects close to half a million patients 
worldwide (Uitto, 2009) and has been attributed to mutations in at least 18 
genes encoding various structural proteins crucial for skin integrity. 
Recognition of the associated immunohistochemical and ultrastructural 
alterations to normal skin structure, particularly to the basement membrane 
zone (BMZ), has formed the basis of our understanding of EB pathology. 
 
1.1 Normal skin structure 
The skin is the largest organ in the body and is estimated to cover a 
surface area of about 2m2 (McGrath and Uitto, 2010). Not only does it act as a 
biological barrier to external pathogens and stresses but it also plays an integral 
role in homeostasis, thermoregulation and defence against ultraviolet-induced 
DNA damage. In addition, it has important immunological, endocrinological 
and sensory functions (McGrath and Uitto, 2010).  
 The skin structure, which is 1.5-4mm thick, is composed of 2 
layers; the epidermis and dermis, that overly the subcutaneous tissue. The 
ectodermally derived keratinocytes constitute the majority of the epidermis 
which is arranged in 4 distinct layers following the direction of keratinocyte 
differentiation; the basal, spinous, granular and corneal layers. In order to 
maintain the unique epidermal structure and alignment, the keratinocytes 
possess a cytoskeleton composed of keratin intermediate filaments. These are 
important for maintaining mechanical strength and linkage to desmosomal 
 3 
junctions involved in cell adhesion and signalling (Kirfel et al., 2003; Lee et 
al., 2006; Menon et al., 1985; Menon et al., 1992; Elias, 2012; Elias, 1983; 
Jackson et al., 1993; Braff et al., 2005; Oren et al., 2003; Sorrell and Caplan, 
2004).  
The dermis on the other hand, is composed of cells, appendageal 
structures, nerves and vessels embedded in an extra-cellular matrix (ECM). 
The latter is formed mainly of collagen and elastic connective tissue fibres that 
confer tensile and elastic properties, respectively. The dermis also contains 
non-collagenous proteins of importance to cell adhesion and mobility, as well 
as non-fibrous ground substance that include proteoglycans and 
glycosaminoglycans. 
1.2 The cutaneous basement membrane zone 
In between the epidermis and dermis lies the BMZ, a complex structure 
of interlacing macromolecules integral for fortifying dermal-epidermal 
adhesion and maintaining skin integrity. This biological scaffold extends from 
the basal keratinocyte layer to the papillary dermis and includes the anchoring 
filaments, hemidesmosomes and anchoring fibrils (Figure 1.1). It is formed of 
an upper lamina lucida, which directly abuts the plasma membranes of the 
basal keratinocytes and a lower lamina densa that interacts with the 
mesenchymal matrix of the upper dermis (Fuchs, 2007) (Figure 1.2). 
Disruption in any of the macromolecular links of the BMZ (Figure 1.3) leads to 
various degrees of skin fragility with resultant distinctive phenotypes (Uitto 




Figure 1.1 Diagrammatic representation of the basement membrane zone. 
The components of the BMZ are shown including the tonofilaments, 





Figure 1.2 Anchoring fibril morphology at the basement membrane zone. 
(A) Schematic representation of the hoop-like anchoring fibrils. (B) 
Transmission electron microscopy (TEM) shows the lamina lucida and lamina 
densa, as well as the anchoring fibrils (arrows) that extend from the BMZ into 
the papillary dermis (bar= 0.2μm). 
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Figure 1.3 Diagrammatic representation of the macromolecular 
components of the basement membrane zone. The protein subdomains of 
the basement membrane components are shown as well as their 
intermolecular interactions. (Courtesy of Prof. John McGrath). 
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Keratin intermediate filaments within the basal keratinocytes are linked 
to the inner hemidesmosomal plaque via the bullous pemphigoid antigen 1 
(BPAG1, BP230) and plectin (Wiche et al., 1984; Guo et al., 1995). On the 
other hand, the outer hemidesmosomal plaque via the transmembrane proteins 
bullous pemphigoid antigen 2 (BPAG2, BP180) and α6β4 integrin, connects to 
the underlying anchoring filaments within the lamina lucida of the basement 
membrane (Sonnenberg et al., 1991; Masunaga et al., 1996; Giudice et al., 
1992).  
 The anchoring filaments are composed of the laminin-332 protein  
(Aumailley et al., 2003) that aids in fortifying the BMZ by associating with the 
type IV collagen of the lamina densa (Xia et al., 1996; Mayer et al., 1998). In 
turn, the anchoring fibrils composed of collagen VII, extend from the lamina 
densa into the papillary dermis (Sakai et al., 1986). These structures are 
thought to attach, via the non-collagenous-1 domain (NC1), to collagens I, III, 
and IV, fibronectin and laminin-332, further augmenting dermal-epidermal 
adhesion (Brittingham et al., 2006; Wegener et al., 2013). 
 
1.3  EB classification and patterns of inheritance 
The integrity of the BMZ is dependent on the functional preservation of 
its various components. Any disruption in the macromolecular network at the 
dermal epidermal junction (DEJ) can lead to various planes of skin cleavage 
with resultant cutaneous fragility (Fine et al., 2014) (Figure 1.4). The 
associated clinical features are equally distinct. The plane of cleavage within 
the skin, coupled to other ultrastructural, immunohistochemical, molecular and 
phenotypic findings, determine the various subtypes of EB: EB simplex (EBS), 
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junctional EB (JEB), dystrophic EB (DEB) and the more recently included 
Kindler syndrome  (Fine et al., 2014). Rigorous scrutiny of the clinical findings 
in EB and the identification of novel effector genes has led to an evolving 
classification that has seen the elimination of various eponyms and the 
introduction of new clinical variants (Table 1.1). In the latest 2014 
classification of EB (Fine et al., 2014), some terms that have been used in 
recent studies have been made redundant (for example, RDEB-other has been 
substituted with RDEB- generalised intermediate). However, in citing these 
studies I have chosen to adhere to the nomenclature as described at that time 











Figure 1.4 A schematic outlining the cleavage planes in the main subtypes 
of EB. Three general subtypes are defined based on the plane of cleavage 
within the basement membrane zone. The newly added subtype; Kindler 









Subtypes OMIM Affected gene Gene symbol 
EBS Suprabasal EBS superficialis (EBSS) 607600 unknown unknown 
  Acral peeling skin syndrome (APSS) 609796 Transglutaminase 5 TGM5 
    Acantholytic EBS (EBS-acanth) 609638 Desmoplakin, plakoglobin DSP, JUP 
    EBS, plakophilin deficiency   plakophilin-1 PKP1 
  EBS, plakoglobin deficiency  plakoglobin JUP 
  EBS, desmoplakin deficiency  desmoplakin DSP 
  Basal EBS, localised (EBS-loc) 131800 keratin 5, keratin 14 KRT5, KRT14 
    EBS, muscular dystrophy (EBS-MD) 226670 plectin PLEC1 
    EBS, autosomal recessive K14 (EBS-AR K14) 
         
601001 
keratin 14 KRT14 
  
EBS, autosomal recessive- BP230 deficiency 
(EBS-AR BP230) 
 bullous pemphigoid antigen-1 DST 
  
EBS, autosomal recessive- exophilin 5 deficiency 
(EBS-AR exophilin 5) 
 exophilin 5 EXPH5 
    EBS with pyloric atresia (EBS-PA) 612138 plectin; α6β4 integrin PLEC1, ITGA6, ITGB4 
    EBS with mottled pigmentation (EBS-MP) 131960 keratin-5 KRT5 
    EBS, generalised severe (EBS-gen sev) 131900 keratin 5, keratin 14 KRT5, KRT14 
  
EBS, generalised intermediate (EBS-gen 
intermed) 
131900 keratin 5, keratin 14 KRT5, KRT14 
    EBS, Ogna (EBS-og) 131950 plectin PLEC1 
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    EBS, migratory circinate (EBS-migr) 609352 keratin 5 KRT5 
JEB Generalised JEB, generalised severe (JEB-gen sev) 226700 laminin-332 LAMA3, LAMB3, LAMC2 
  
 
JEB, generalised intermediate (JEB-gen intermed) 226650 laminin-332; collagen XVII 
LAMA3, LAMB3, LAMC2, 
COL17A1 
    
JEB with respiratory and renal involvement (JEB-
RR) 
 Integrin α3 subunit ITGA3 
    JEB, pyloric atresia (JEB-pa) 226730 α6β4 Integrin ITGA6, ITGB4 
    JEB, late onset (JEB-LO) 226440 collagen XVII COL17A1 
 Localised JEB, localised (JEB-loc) 226650 
collagen XVII, α6β4 Integrin, 
laminin-332 
COL17A1, ITGB4, 
LAMA3, LAMB3, LAMC2 
    JEB-LOC syndrome (laryngo-onycho-cutaneous) 245660 laminin-332 α3 subunit LAMA3A 
    JEB, inversa (JEB-i) 226650 laminin-332 LAMA3, LAMB3, LAMC2 
DEB Dominant DDEB, generalised (DDEB-gen)   collagen VII COL7A1 
    





    DDEB, pruriginosa (DDEB-pr) 604129 collagen VII COL7A1 
    DDEB, acral (DDEB-ac)   collagen VII COL7A1 
    DDEB-nails only (DDEB-na) 607523 collagen VII COL7A1 
    DDEB, pretibial (DDEB-pt) 131850 collagen VII COL7A1 
  Recessive RDEB, generalised severe (RDEB-gen sev) 226600 collagen VII COL7A1 
    





  RDEB, localised (RDEB-loc) 226600 collagen VII COL7A1 
    





    RDEB, pruriginosa (RDEB-pr) 604129 collagen VII COL7A1 
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    RDEB, inversa (RDEB-i) 226600 collagen VII COL7A1 
    RDEB, pretibial (RDEB-pt) 131850 collagen VII COL7A1 
    RDEB, centripetalis (RDEB-ce)   collagen VII COL7A1 
Kindler 
syndrome 
Kindler Kindler 173650 
fermitin family homologue 1 
(kindlin-1) 
FERMT1 (KIND1) 
Adapted from the 2014 EB classification (Fine et al., 2014). *Previously known as RDEB-other (RDEB-O). 
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In EBS the plane of cleavage is usually at the level of the basal 
keratinocytes as a result of dominant mutations in keratin 5 or 14 (KRT5, 
KRT14), plakophilin-1 (PKP1), desmoplakin (DSP), plakoglobin (JUP), 
plectin (PLEC1), transglutaminase 5 (TGM5) or α6β4 integrin (ITGA6/ITGB4) 
(Fine et al., 2014). More recently, two new recessive forms have been 
identified secondary to mutations in the dystonin gene (DST) that encodes the 
coiled-coil domain of the bullous pemphigoid antigen 1-e (BP230) isoform 
(Groves et al., 2010) and with mutations in EXPH5 (exophilin-5, also known 
as Slac2-b, a Rab-GTPAse effector protein) (McGrath et al., 2012). 
JEB results in separation at the level of the lamina lucida secondary to 
recessive mutations in the laminin-332 (LAMA3/LAMB3/LAMC2), collagen 
XVII (COL17A1) or α6β4 integrin (ITGA6/ITGB4) genes  (Fine et al., 2014). 
Kindler syndrome, a relatively recent addition to the EB classification, 
involves loss of function mutations in the actin cytoskeleton-associated protein, 
fermitin family homologue 1 (FERMT1), resulting in separation at the basal 
keratinocyte layer (Fine et al., 2014). 
All subtypes of DEB, the main focus of this thesis, result from 
mutations in the collagen VII gene, COL7A1 (Christiano et al., 1997b; Fine et 
al., 2014). Collagen VII is the major component of anchoring fibrils at the DEJ 
and in DEB the anchoring fibrils show variable numerical and/or structural 
abnormalities, leading to blistering beneath the lamina densa. 
In dominant forms of DEB (DDEB), the pathogenic mutations typically 
involve heterozygous (dominant-negative) glycine substitutions (GS) within 
the collagen VII triple helix resulting in a relatively mild phenotype (Uitto et 
al., 1994; Whittock et al., 1999; Dang and Murrell, 2008). In contrast, the 
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molecular pathology of recessive DEB (RDEB) usually comprises nonsense, 
frameshift or splice site mutations on both COL7A1 alleles, which lead, in the 
more severe cases, to mutilating disease and early demise (Uitto et al., 1994; 
Whittock et al., 1999; Dang and Murrell, 2008). 
 
1.4  Clinical manifestations of DEB 
The genetic heterogeneity underlying DEB reflects the variable 
phenotypic features encountered in DEB subtypes. In DDEB patients usually 
present with mild but varying degrees of cutaneous and mucous membrane 
blistering, as well as nail dystrophy (Figure 1.5). Two distinct subtypes of 
DDEB include EB pruriginosa (EB-pr), and bullous dermolysis of the newborn 
(BDN). In EB-pr, an itchy variant of DDEB (and RDEB in some cases), the 
pruritus can result in skin changes resembling acquired disorders such as 
nodular prurigo or hypertrophic lichen planus (Figure 1.6). However, in BDN 
another subtype of DDEB and RDEB, the blistering usually improves 












Figure 1.5 Clinical features of dominant dystrophic EB. A 10-year-old girl 





Figure 1.6 Clinical features of EB pruriginosa (EB-pr). A 45-year-old male 
of Pakistani origin with evidence of excoriations on both shins with scarring 




Figure 1.7 Clinical features of bullous dermolysis of the newborn (BDN). 
(A) A 1-month-old infant with evidence of skin fragility, which was present 
at birth (shown here on the right inner leg). (B) Skin blistering settled by the 
first year of life leaving areas of hypopigmentation (shown here on the right 
foot).  
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RDEB on the other hand, usually results in a more severe phenotype. 
The severe generalised from of RDEB; RDEB-sev gen (previously known as 
Hallopeau-Siemens RDEB) results in generalized blistering culminating in 
mutilating scars, with subsequent joint contractures and fusion of the digits 
(Figure 1.8). Adding to the morbidity are extracutaneous manifestations 
affecting the gastrointestinal, urological and ophthalmic systems amongst 
others (Figure 1.9). This eventually leads to squamous cell carcinomas (Figure 
1.10), a leading cause of mortality in RDEB patients and thought to result in 
the death of 55% of severe RDEB patients by the age of 40 years  (Fine, 2009a; 
Fine et al., 2009b; Fine and Mellerio, 2009c).  
Other subtypes of RDEB include the less severe forms; RDEB-other 
(encompasses the newly classified entities; RDEB- generalised intermediate 
and RDEB-localised) (Figure 1.11), EB-pr and BDN. 
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Figure 1.8 Clinical features of severe recessive dystrophic EB (RDEB-sev 
gen). An 18-year-old male with evidence of widespread skin fragility and 
scarring (A), as well as flexion contractures of the digits (B). 
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Figure 1.9 Extracutaneous features of severe RDEB. There is involvement 
of the oral and conjunctival mucosae with the development of synechiae (A, 










Figure 1.10 Squamous cell carcinoma complicating severe RDEB. A 28-
year-old male with an advanced fungating SCC on the dorsum of the right 






Figure 1.11 Clinical features of mild RDEB. (A) A10-year old and (B) 2-
year old girls with evidence of moderate skin fragility and scarring with milia 
at sites of trauma on the knees and dorsum of the right hand, respectively. 
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However, despite striking clinical differences, the nature of the 
underlying pathogenic COL7A1 mutations in both DDEB and RDEB may 
overlap, and to date limited paradigms of DEB have been established 
(Christiano et al., 1996c).  
Understanding the molecular, immunohistochemical and ultrastructural 
alterations in DEB including the nature, type and location of COL7A1 
mutations, as well as potential genetic and non-genetic modifiers is crucial in 
attempting to establish a better genotype-phenotype correlation in EB. 
 
1.5 Immunohistochemical and ultrastructural abnormalities in 
DEB 
The plane of cleavage within the skin, as well as the degree of collagen 
VII expression can be established by immunofluorescence labelling of collagen 
VII along the basement membrane, as well as by direct visualisation of the 
anchoring fibril number and morphology on transmission electron microscopy 
(TEM). The level of abnormality in most cases, mirrors the degree of clinical 
severity. The LH7.2 monoclonal anti- collagen VII antibody is often used for 
direct immunofluorescence (DIF) and targets the non-collagenous, NC1 
domain of collagen VII. This usually reveals near normal, reduced or absent 
labelling at the DEJ in DDEB, mild RDEB and RDEB-sev gen, respectively 
(Heagerty et al., 1986; McGrath et al., 1993a) (Figure 1.12). Labelling of other 
basement membrane components in patients with DEB such as type IV 
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collagen, laminin-332, β4 integrin subunit and collagen XVII is usually normal 
(Bruckner-Tuderman et al., 1988). 
The immunofluorescence findings in DEB are mirrored by 
ultrastructural changes on TEM. Patients with RDEB usually have complete 
absence or significant reduction in anchoring fibril numbers with only 
occasional wisp-like structures, whereas patients with DDEB have anchoring 
fibrils of near-normal morphology but reduced density (McGrath et al., 1993b) 
(Figure 1.13). 
Moreover, some subtypes of DEB have unique ultrastructural and 
immunohistochemical features. In BDN there is variable reduction in collagen 
VII labelling at the DEJ, as well as characteristic intracytoplasmic deposits of 
collagen VII within basal and suprabasal keratinocytes (Hashimoto et al., 1985; 
Hashimoto et al., 1989; Fine et al., 1990). Ultrastructurally, there may be sub-
lamina densa blistering with reduced or absent anchoring fibrils, in 
combination with dilated rough endoplasmic reticulum and intracytoplasmic 
stellate bodies. In Kindler syndrome, TEM typically reveals reduplication of 
the lamina densa but normal hemidesmosomes and anchoring fibrils   
 
 25 
Figure 1.12 Immunofluorescence findings in RDEB. Basement membrane 
labelling with the LH7.2 monoclonal anti-type VII collagen antibody reveals 
bright linear labelling in normal skin (A) but complete absence in severe 
RDEB (B, arrows). RDEB sev gen- recessive dystrophic epidermolysis 
bullosa- severe generalised. Bars = 50 μm. 
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Figure 1.13 Transmission electron microscopy findings in RDEB. The 
dermal-epidermal separation (asterix) is shown below the level of lamina densa 
(arrows). Only wisp-like rudimentary anchoring fibrils are visible (arrow 




1.6 Collagen VII overview 
Collagens are divided into 2 major types; fibrillar and non-fibrillar 
collagens based on their suprastructural ability to form macromolecular fibrils. 
The fibrillar collagens are fibre-forming collagens with a highly conserved 
genetic makeup (Boot-Handford and Tuckwell, 2003; Myllyharju and 
Kivirikko, 2004; Prockop and Kivirikko, 1995). They are composed of 
monofibril, glycine-rich triple helices with uninterrupted Gly-X-Y repeats and 
predictable exon lengths. Non-fibrillar collagens on the other hand, are more 
heterogeneous. They contain multiple interruptions to the Gly-X-Y repeats and 
show a less well-conserved genetic makeup. Both groups however, share a 
triple helical structure that is formed of 3 α-polypeptides, in addition to a high 
glycine index with repeated Gly-X-Y sequence. Glycine, the smallest of the 
amino acids, is usually centred within collagen triple helices, whereas the X-Y 
residues are positioned exteriorly (Persikov et al., 2004; Fritsch et al., 2009). 
As a consequence, glycine amino acids are integral to triple helical stability. 
Any disruption or substitution with a bulkier amino acid is likely to result in 
abnormal suprastructural conformation and subsequent clinical pathology 
(Prockop and Kivirikko, 1995; Myllyharju and Kivirikko, 2001; Myllyharju 
and Kivirikko, 2004; Boot-Handford and Tuckwell, 2003; Fritsch et al., 2009; 
Persikov et al., 2004).  
Collagen VII is a member of the non-fibrillar collagens characterised by 
high glycine content. The collagen VII gene (COL7A1) is a complex and 
unusually compact gene located on chromosome 3p21 (Ryynanen et al., 1991; 
Parente et al., 1991). It consists of 118 exons spanning 32kb and is transcribed 
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into a 9.2-kb mRNA transcript, among the largest DNA:mRNA ratio of any 
gene (Christiano et al., 1994b; Christiano et al., 1994c). Collagen VII 
molecules are homotrimers, composed of 3 identical α1 chains (Figure 1.14). 
Each chain contains a central 145-kD collagenous domain, which is flanked by 
non-collagenous regions; the NC1 amino and NC2 carboxy domains. The NC1 
domain consists of various sub-modules with homology to adhesive proteins; 
cartilage matrix proteins (CMP), fibronectin-III domain, von-willebrand factor 
A-like motif and a proline and cysteine rich domain (Christiano et al., 1994c; 
Burgeson et al., 1990). The central collagenous domain contains 19 non-
collagenous interruptions, the largest of which measures 39aa. This area, 
termed the ‘hinge region’ is thought to confer flexibility necessary for collagen 
VII suprastructural folding (Christiano et al., 1994c; Christiano et al., 1994b). 
The 20-kDa NC2 domain (exon 112-118) contains conserved cysteine 
residues that are important for the formation of disulphide bonds within the 
collagen VII triple helix and antiparallel dimer assembly during fibrillogenesis 
(Burgeson, 1993; Greenspan et al., 1993; Christiano et al., 1993; Chen et al., 
2001). It is subsequently proteolytically removed by bone morphogenetic 
protein-1 (Rattenholl et al., 2002). The function of this domain has not been 
fully elucidated but it was found to have a segment with homology to the 
Kunitz protease inhibitor (Greenspan et al., 1993), which was postulated to 
result upon cleavage in negative feedback towards tissue proteinases 










Figure 1.14 A schematic of the collagen VII homotrimers. (A) 3 
identical α1 chains form a triple helical structure. Abnormality in any of 
the chains will lead to disruption to the collagen VII suprastructure. (B) A 
nonsense mutation results in a truncated protein whereas a missense 
mutation (C) usually results in full-length but unstable protein. (Courtesy 
of Prof. John McGrath). 
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Collagen VII, which is produced from keratinocytes and fibroblasts to a 
lesser extent (Ryynanen et al., 1991; Chen et al., 1994; Stanley et al., 1985) is 
secreted from the intracellular space as pro-collagen homotrimers. The 
homotrimers then undergo processing to become collagen VII before 
incorporation into anchoring fibrils found in the stratified squamous epithelium 
of the skin and mucous membranes.  These pro-collagen homotrimers initially 
form antiparallel dimers, which are secured by disulphide bonds at the carboxy 
termini following cleavage of the NC2 domain. These staggered structures then 
undergo polymerisation and ultrastructural folding to form loop-like anchoring 
fibrils, which attach through the NC1 termini to the basement membrane (BM) 
(Burgeson, 1993). By trapping fibrous dermal tissue, these 800nm anchoring 
fibrils help to fortify the dermal-epidermal adhesion. Therefore, disruption to 
any aspect of the collagen VII fibrillogenesis can lead to structural or 
numerical alteration of the collagen fibrils resulting in deleterious effects on 
dermal-epidermal adhesion. This eventually manifests in a sub-lamina densa 
plane of cleavage characteristic of DEB. However, despite the deleterious 
effects of abnormal anchoring fibrils, only low levels of wild-type collagen VII 
expression are required to maintain skin integrity as evident by observations 
that perhaps a 30-40% level of expression is adequate for skin stability (Fritsch 
et al., 2008). 
 
1.7  Collagen VII gene expression 
The regulation of COL7A1 expression is influenced by various 
cytokines including tumour necrosis factor-α (TNF-α), transforming growth 
factor-β1 (TGF-β1) and interleukin-1β (IL-1β) which were found to increase 
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collagen VII gene and protein expression by dermal fibroblasts in culture 
(Chen et al., 1994; Amano et al., 2007; Mauviel et al., 1994). In contrast, 
COL7A1 and protein expression by epidermal keratinocytes is reduced by 
TNF-α and IL-1β. However, in the presence of TGF-β1, these cytokines 
enhance TGF-β induced COL7A1 gene and protein expression (Takeda et al., 
2005). TGF-β and TNF-α response elements were identified in distinct regions 
of the COL7A1 promoter area and are regulated by transcription factors SMAD 
and NF-kappaβ (Kon et al., 1999; Vindevoghel et al., 1998). JUN and FOS, as 
part of the activator protein-1 (AP-1) transcription complex were also found to 
increase COL7A1 gene expression following ultraviolet radiation through 
binding to AP-1 binding sites in the COL7A1 promoter region (Nakano et al., 
2001).  
 
1.8  COL7A1 mutations 
All subtypes of DEB result from mutations in the collagen VII gene, 
COL7A1 (Fine et al., 2014) and paradigms for genotype-phenotype correlation 
have emerged. In DDEB the pathogenic mutations typically involve 
heterozygous (dominant-negative) missense mutations and owing to the high 
glycine content the majority are GS mutations within the collagen VII triple 
helix (Uitto et al., 1994; Whittock et al., 1999; Dang and Murrell, 2008). The 
resulting macromolecular and functional consequences are variable and include 
effects on helix formation, protein folding, thermal stability, intracellular 
transport, secretion, and assembly into anti-parallel dimers. However, although 
only 1.6% of anchoring fibrils are wholly formed of wild type trimeric 
molecules, the phenotype is typically mild as despite the presence of a mutant 
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allele, full-length polypeptides and anchoring fibrils are formed (Kon et al., 
1997b). 
 In contrast, the molecular pathology of RDEB generally comprises 
nonsense, frameshift or splice site mutations on both COL7A1 alleles (Uitto et 
al., 1994; Whittock et al., 1999; Dang and Murrell, 2008). The severe form of 
recessive DEB; RDEB-sev gen, usually results from homozygous or compound 
heterozygous loss of function mutations leading to truncated collagen 
polypeptides and mRNA decay (Christiano et al., 1994a). Inheritance of 
recessive missense mutations on one or both alleles results in a milder 
phenotype mirroring an attenuated immunohistochemical and ultrastructural 
expression of collagen VII. 
However the mRNA, protein and subsequent phenotypic expression is 
not solely determined by the type of mutation and has to be studied in 
conjunction with the location of this mutation within the collagen VII gene, the 
effects of other confounding mutations, as well as potential genetic and 
epigenetic modifiers. 
 
1.9  Genotype-phenotype heterogeneity 
Although all forms of DEB result from COL7A1 mutations, there is vast 
genotype-phenotype heterogeneity with both intra- and inter-familial 
variability. The nature of the various COL7A1 mutations whether nonsense, 
missense or splice site, primarily reflect functional impairment. However, other 
characteristics might play a role in phenotypic expression including the 
position of the COL7A1 mutations within the triple helix, particularly the 
proximity to the ‘hinge’ domain and to highly conserved cysteine regions  (van 
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den Akker et al., 2011), as well as the relation to the non-collagenous NC1 or 
NC2 terminals (Chen et al., 2001; Woodley et al., 2008). Moreover, genetic, 
epigenetic and environmental factors are likely to play a significant role in 
disease expression. 
The nature and location of some mutations have been associated to 
some degree with particular subtypes of DEB. RDEB-inversa (RDEB-I) for 
example, is a unique subtype of DEB characterised by involvement of the 
flexures. This has been associated with mutations affecting the thermal stability 
of COL7A1, particularly arginine substitution mutations within the hydrophilic 
highly conserved motifs of the triple helical domain or GS mutations at the 
borders of the collagenous subdomains (Chiaverini et al., 2010). 
EB-pr another form of DEB characterised by itchy prurigo-like lesions 
on the limbs has been associated with GS mutations within the triple helical 
domain as well as splice site mutations resulting in the skipping of exon 73 
(Fine et al., 2014; McGrath et al., 1994). 
BDN is characterised by skin fragility at birth that ameliorates or ceases 
completely within the first year of life. This subtype has been typically 
associated with GS substitutions affecting secretion of collagen VII leading to 
intracytoplasmic collections of collagen VII (Fine et al., 2014; Hashimoto et 
al., 1985). 
In addition, some recurrent mutations or ‘hotspots’ have been identified 
in specific populations such as the p.Arg578Stop, c.7786delG and 
p.Arg2814Stop mutations in British families (Mellerio et al., 1997; 
Mohammedi et al., 1999); c.2470insG in Mexican families (Salas-Alanis et al., 
2000; Salas-Alanis and McGrath, 2006); c.5818delC, c.6573+1G→C and 
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Glu2857Stop in Japanese families (Tamai et al., 1999), p.Gly1664Ala in Italian 
families (Gardella et al., 2002), as well as the mutation p.G2043Arg in exon 73 
and c.425A→G worldwide (Murata et al., 2004; Mellerio et al., 1998). 
Moreover, there appears to be a clustering of mutations, in particular 
GS mutations, within exon 73 however, the nature of these pathogenic 
mutations in both DDEB and RDEB, is similar, and to date no definite 
correlation has been found between the type or location of the mutations and 
the resulting subtype (Christiano et al., 1996c). 
 
1.9.1 Mutations resulting in variable expression: the intra- and inter-
familial phenotypic heterogeneity 
Of interest is the degree of phenotypic heterogeneity associated with an 
identical mutation. This is not only described among unrelated individuals but 
also within same pedigrees, where for example a glycine substitution mutation 
can result in mild skin blistering, nail dystrophy only, variable subtypes of 
DEB or no clinical pathology. This could be explained by the presence of a yet 
unidentified effector mutation or incomplete penetrance. However, metabolic, 
genetic, epigenetic, or environmental factors are likely to have a role in 
modulating disease expression.  
1.9.2 Mutations resulting in variable inheritance 
Adding to the dilemmas of phenotypic heterogeneity are reports of 
variable genetic inheritance even within same families. Missense mutations, 
namely GS substitution mutations, are typically associated with DDEB leading 
to a dominant negative effect. GS mutations are also associated with recessive 
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DEB to a lesser degree and these are typically silent when heterozygous but 
pathogenic when inherited on both alleles or in trans with another loss-of-
function mutation in COL7A1. However, some GS mutations result in both 
dominant and recessive DEB adding to the diagnostic dilemmas. Although, it is 
not surprising that GS mutations account for the vast majority of mutations in 
the COL7A1 and collagen genes in general, owing to their high glycine content, 
the presence of both dominant and recessive GS mutations in the same 
gene/protein is unusual. The factors influencing the varied inheritance patterns 
are yet to be determined but could reflect confounding genetic or epigenetic 
factors. 
 
1.9.3 Revertant mosaicism: individual genotypic and phenotypic 
heterogeneity 
Revertant mosaicism (RM) refers to the occurrence of two genetically 
distinct populations of cells due to a spontaneous genetic correction that occurs 
during mitosis (Hall, 1988; Jonkman et al., 1997). It has been described in 
various inherited conditions including severe combined immunodeficiency, 
Bloom’s syndrome, Fanconi’s anaemia, X-linked Wiscott–Aldrich syndrome, 
Duchenne muscular dystrophy and tyrosinemia type I (Hirschhorn, 2003). It 
has also been described in non-Herlitz JEB and EBS, as a result of in-vivo 
revertant mutations in LAMB3, COL17A1 and KRT14 (Darling et al., 1999; 
Schuilenga-Hut et al., 2002; Smith et al., 2004; Pasmooij et al., 2005; 
Pasmooij et al., 2007; Jonkman and Pasmooij, 2009). This phenomenon is 
thought to be under recognised and perhaps occurs in all cases of generalised 
intermediate JEB (Jonkman and Pasmooij, 2009; Pasmooij et al., 2012). 
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Proposed corrective mechanisms include back mutations, intragenic 
crossovers, mitotic gene conversions, and second-site mutations (Pasmooij et 
al., 2005; Jonkman et al., 1997; Frank and Happle, 2007). This phenomenon of 
natural gene repair is likely to be over looked in patients with DEB as well. If 
proven, then RM in individuals with RDEB could have significant implications 
for future gene and cell therapy. 
 
1.9.4 The role of modifiers in genotype-phenotype correlation 
Several studies have explored the role of metabolic, genetic, epigenetic, 
or environmental factors in modulating disease expression and severity. 
Understanding factors contributing to genotype expression will not only refine 
genotype-phenotype correlation but will have significant therapeutic 
implications. 
  Metabolic factors influencing pruritus have been explored in EB-pr in 
an effort to explain this distinctive pruritic subtype. These include biochemical 
and endocrinological abnormalities, iron deficiency, IgE, presence of atopy and 
filaggrin mutations. However, none of these have been found to directly 
influence disease expression (Mellerio et al., 1997; Drera et al., 2006; 
Schumann et al., 2008; Ee et al., 2007; Lapinski et al., 1998; Ren et al., 2008). 
The degree of skin fragility can also be influenced by epigenetic 
mechanisms affecting the level of protein expression in the BMZ including the 
variable degradation of intracellularly accumulated mutant proteins, as well as 
the effects of endoplasmic reticulum stress and unfolded protein on apoptosis 
and gene expression (Bateman et al., 2009). In a recent in vitro study by Knaup 
et al., the gene expression profiles of EBS-MD, RDEB and a subtype of JEB 
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previously called generalized atrophic benign epidermolysis bullosa were 
analysed (Knaup et al., 2012). All revealed up-regulation of COL16A1 and 
FN1 (fibronectin gene); in addition to accumulation of cholesterol 
intracellularly, factors known to confer greater resistance towards mechanical 
forces and stabilisation of the cell membrane respectively. In addition there 
was down-regulation of ribosomal protein S27A, a ubiquitin fusion protein, 
which could potentially result in increased degradation of mutant alleles by 
ubiquitin (Knaup et al., 2012; Redman and Rechsteiner, 1989). 
At a transcriptional level, various modulators of collagen VII 
expression have been studied including the variable splicing of transcriptional 
RNA (Nissim-Rafinia and Kerem, 2005) where some splice site mutations 
result in the production of alternatively spliced isomers and a variable level of 
functional proteins with subsequent clinical effects. Another novel mechanism 
involves translationally silent mutations in exonic splicing enhancer (ESE) 
sequences that are capable of causing exon skipping/exon definition. These 
sequences are capable of selecting splicing sites in a cascade that starts with 
binding of ESE to members of the serine⁄arginine-rich protein family and 
culminating in recruitment of spliceosomes and exon skipping (Covaciu et al., 
2011). An example is the c.2470insG mutation in COL7A1 that results in 
skipping of exon 19 with a subsequent downstream premature termination 
codon in exon 20 (Salas-Alanis et al., 1998; McGrath et al., 1999). Therefore, 
mutations in previously unrecognised ESE sequences could also modulate 
COL7A1 expression. Similarly, undetected COL7A1 mutations including large 
genomic deletions could also contribute to variable disease expression (Kern et 
al., 2009a).  
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Moreover, mutations in genes other than COL7A1 are likely to be 
involved in disease modification. In a recent study, a single nucleotide 
polymorphism (1G/2G) in the matrix metalloproteinase-1 (MMP-1) gene 
promoter was implicated in a more severe RDEB phenotype. MMP-1, a zinc 
metallo-endopeptidase capable of degrading extracellular proteins, was found 
to be transcriptionally upregulated, resulting in increased degradation of 
collagen VII with subsequent severe disease (Titeux et al., 2008). 
In the future, particularly with the introduction of whole genome and 
exome sequencing as well as data mining studies, previously unrecognised 
modifiers are likely to be revealed (Reverter et al., 2008). 
 
1.10  Therapeutic Options at the time of this study 
To date no definitive treatment is available for EB and management is 
conservative aimed at preventing infection and trauma, wound care, pain 
management and early detection of squamous cell carcinoma. This has led to a 
high burden of morbidity in almost all affected individuals. The median 
survival in milder forms of RDEB ranges between 55-60 years (Fine, 2009a), 
whereas there is an increased rate of mortality in severe RDEB cases secondary 
to metastatic squamous cell carcinomas (SCCs), which usually leads to early 
demise by the 4th decade of life in around 50% of cases (Fine et al. 1999).  
So far, understanding of the molecular and ultrastructural pathologies 
underlying EB has led to advances in diagnostic applications such as pre-
implantation and pre-natal genetic DNA testing utilising chorionic villus 
sampling and amniocentesis, as well as in vitro testing of embryos (Fassihi et 
al., 2006; Cserhalmi-Friedman et al., 2000; Pfendner et al., 2003) and possible 
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analysis of foetal DNA in maternal plasma (Uitto et al., 2003; Chiu and Lo, 
2003). In addition, the plethora of recent data relating to collagen VII structure 
and expression, ultrastructural and functional effects of various COL7A1 
mutations, potential genetic and epigenetic modifiers, as well as keratinocyte, 
fibroblast and stem cell biology have paved the way for exciting in vivo and ex 
vivo therapeutic applications utilising gene, protein and cell based therapies.  
 
1.10.1 Protein based therapy 
This mode of therapy utilises recombinant proteins in topical, injectable 
or systemic forms for the replacement of defective or absent molecular 
proteins. Intradermal injection of recombinant collagen VII into 
immunocompromised mice with DEB xenografts was attempted initially 
resulting in increased expression of collagen VII along the basement membrane 
with reduced skin fragility (Woodley et al., 2004a; Woodley et al., 2004b).  
 
1.10.2 Cell therapy 
The understanding of the molecular genetics underlying DEB has 
provided a platform for the delivery of cell-based therapy utilising 
keratinocytes and fibroblasts. 
At the time this thesis began, cultured keratinocyte allografts, then 
combined keratinocyte and fibroblast grafts were utilised in the treatment of 
intractable skin ulcers in RDEB patients (McGrath et al., 1993b; Falabella et 
al., 2000; Falabella et al., 1999). Subsequently, a cultured allogeneic dermal 
substitute containing fibroblasts, hyaluronic acid and collagen was used in both 
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animal models and humans (Kubo and Kuroyanagi, 2004; Natsuga et al., 2010; 
Hasegawa et al., 2004). Although this topical treatment induced re-
epithelialisation in the intractable skin ulcers, the level of collagen VII 
expression mostly remained unchanged as evidenced by TEM and IF studies. 
This led to optimisation in the delivery of cell therapy in the form of 
intradermal injection in transgenic mice (Ortiz-Urda et al., 2003; Woodley et 
al., 2004b), paving the way for intradermal allogeneic fibroblasts injections in 
RDEB patients (Wong et al., 2008; Yan and Murrell, 2010). In addition, 
intravenous injection of human fibroblasts was also attempted in transgenic 
RDEB mice following which fibroblasts were shown to home to skin with 
subsequent improvement in wound healing (Goto et al., 2006; Woodley et al., 
2007; Kern et al., 2009b).  
 
1.10.3 Gene therapy 
Translational applications in the form of ex vivo and in vivo gene 
therapy for the treatment of EB have aimed to correct defective genes in 
keratinocytes and fibroblasts. Viral and non-viral vectors, as well as 
microinjection techniques have been utilised to introduce wild-type COL7A1 
into DEB cells (Ortiz-Urda et al., 2003; Mecklenbeck et al., 2002). In one 
study, gene-corrected fibroblasts injected intradermally into RDEB organotypic 
skin-equivalents grafted onto immunodeficient mice resulted in restoration of 
collagen VII expression at the DEJ (Ortiz-Urda et al., 2003; Woodley et al., 
2003). Subsequently intravenous injection of genetically engineered fibroblasts 
in animal models was also shown to lead to over-expression of collagen VII 
(Woodley et al., 2007). 
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 Genetically modified fibroblasts and keratinocytes have also been used 
to create bioengineered skin grafts to improve skin fragility. However this is a 
non-definitive localised method of treatment, which is limited by difficult gene 
transfer into epidermal keratinocytes, low level of maintained collagen VII 
expression as well as variable success of engraftment (Sat et al., 2000; 
Ghazizadeh et al., 1999). Therefore, to enhance delivery and increase 
bioavailability in vivo, gene transfer of COL7A1 into transgenic mice was 
attempted. This also resulted in functional correction of COL7A1 with 
sustained tissue-specific production of full-length collagen VII (Sat et al., 
2000). Regeneration of normal skin was also demonstrated in vivo by the 
application of lentivirus-transduced DEB keratinocytes and fibroblasts onto the 
skin of SCID mice (Chen et al., 2002b).  
More recently, genetic correction of stem cells was attempted for the 
treatment of JEB. Epidermal stem cells harbouring compound heterozygous 
LAMB3 mutations were transduced with full-length wild-type transgene and 
then propagated in culture to form epithelial grafts that were transplanted onto 
the same patient with resultant functional correction in grafted sites (Mavilio et 
al., 2006). In principal, this approach could provide corrected stem cells 
capable of differentiating into functional, mutation free cells. However, the use 
of some DNA-vectors has the potential for inducing carcinogenesis, thus 
limiting its therapeutic potential.  
In addition, natural gene therapy in the form of revertant mosaicism has 
emerged as an exciting therapeutic resource in patients with JEB. These 
individuals -as a result of spontaneous genetic correction- were found to 
harbour 2 populations of genetically distinct cells leading to functional protein 
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expression with clinically normal patches of skin. This phenomenon has led to 
the use of naturally corrected autologous keratinocytes to create epidermal 
sheets or grafts that were then transplanted onto the same patients 
circumventing issues related to genetic transduction and carcinogenesis 
(Pasmooij et al., 2007; Pasmooij et al., 2005; Jonkman et al., 1997; Darling et 
al., 1999; Gostynski et al., 2009).  
 
1.10.4 Drug therapy 
At the time of this thesis, pharmacologic therapies in the form of 
antimicrobials and anti-inflammatory agents had been used widely to reduce 
bacterial load and promote wound healing in DEB including phenytoin 
(Caldwell-Brown et al., 1992), trimethoprim (Lara-Corrales et al., 2012) and 
tetracyclines (Humbert et al., 1989) with variable success. Many of these 
agents however, are thought to also possess anti-collagenase activity, which 
can augment wound-healing properties. Some immunosuppressant agents such 
as ciclosporin (Husz et al., 1989), have also been used due to their 
immunomodulatory effect but the exact mechanism by which they ameliorate 
skin fragility is not understood. Furthermore, topical and systemic agents were 
specifically used to modulate the disabling pruritus associated with EB-pr with 
some effect. These include topical and systemic corticosteroids, cryotherapy, 
topical tacrolimus, ciclosporin and thalidomide (Yamasaki et al., 1997; Ozanic 
Bulic et al., 2005; Banky et al., 2004; Das et al., 2005). However, these were 
largely aimed at symptomatic relief rather than definitive therapy.  
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In conclusion, advances in molecular, immunohistochemical and 
ultrastructural diagnostics as well as in depth understanding of EB has led to 
exciting advances in protein, cell and gene therapies. However, several aspects 
of the genotype and phenotype heterogeneity encountered in DEB are yet to be 
explained, although genetic, epigenetic and environmental modulators of 
COL7A1 expression have been implicated. As a consequence, the ideal therapy 
of DEB is likely to involve a combination of agents targeting various patient-
specific aspects of DEB modulation. The refining of genotype-phenotype 
correlation will not only increase our understanding of EB pathology and 
phenotypic heterogeneity but will also enable us to identify modulators of 
disease expression and ultimately achieve more effective, patient specific and 















1.11 Hypothesis and aims of the thesis 
The hypothesis of this thesis is that more detailed analysis of the 
molecular and cellular pathology of the skin in individuals with clinically 
unusual or diverse forms of DEB will help refine genotype-phenotype 
correlation with relevance to further improving the classification of EB.  
 
The thesis addresses the following specific aims:  
[1] To investigate the molecular pathology in COL7A1 associated with 
intra-epidermal retention of collagen VII and to determine the clinical 
ramifications. 
[2] To update and expand the spectrum of dominant and recessive 
glycine substitution mutations in dystrophic EB. 
[3] To review and investigate the role and clinicopathologic 
consequences of non-glycine missense substitutions in collagen VII in both 
dominant and recessive forms of EB. 
[4] To investigate the role of genetic modifiers on disease expression in 
EB.  
[5] To explore the possibility of revertant mosaicism in RDEB.  
[6] To investigate the role of intradermal allogeneic fibroblasts on 
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This MD project was undertaken following ethical approval by the 
Guy’s and St Thomas’ Hospital local Ethics’ Committee, reference number 
07/H0802/104. Informed consent was obtained from the involved subjects. 
The work included in this thesis refers to my work except where 
retrospective analysis of archival data was conducted. In Chapters 3, 4 and 5 
the majority of the DNA mutation analyses, immunofluorescence and electron 
microscopy studies where performed previously in the Robin Eady National 
Diagnostic Epidermolysis Bullosa Laboratory in London. The studies were 
conducted as part of the patients’ routine clinical care in most cases, where 
samples were sent from local, national and international medical teams. 
However, for individuals linked to separate research projects, studies were 
undertaken with Ethics’ Committee approval. Patient ethnicities included white 
Caucasian, Middle-Eastern, South American, South-East Asian and Asian.  
Clinical information was obtained from the medical records, relevant 
publications or by contacting the referring clinician(s) where possible. 
However, in many cases, particularly for historic samples, clinical data was 
obtained from the information supplied with the original referral forms or from 
the laboratory logbook. Due to the required technical expertise, electron 
microscopy studies were done by Patricia Dopping-Hepenstal in the Robin 
Eady National Diagnostic Epidermolysis Bullosa Laboratory in London. 
I performed all MMP-1 mutation analyses and statistical studies 
described in Chapter 6. In additional to the laboratory work, I performed the 
clinical work described in Chapters 7 and 8 including skin biopsies and 
allogeneic fibroblast injections. 
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2.1 Molecular Biology Techniques 
2.1.1 Genomic DNA extraction from peripheral blood leukocytes 
Genomic DNA was extracted from peripheral blood using the QIAmp 
Blood Midi Kit (Qiagen, Crawley, UK). Blood samples were initially 
equilibrated to room temperature. 1ml of blood was mixed briefly with 100μl 
of proteinase K (QIAGEN Protease). 1.2ml of lysis buffer (Buffer AL) was 
then added to the mixture, which was mixed thoroughly by inversion followed 
by vigorous shaking for 1minute. The mixture was then incubated in a 70ºC 
water bath for 10minutes. 1ml of 100% ethanol was added to the sample and 
mixed again by inversion followed by vigorous shaking for 1minute. All of the 
solution was then applied carefully to the QIAmp midi column within a 15ml 
centrifuge tube. The cap was the closed and the tube centrifuged at 3000rpm 
for 3minutes. The filtrate was discarded and 4mls of washing buffer (Buffer 
AW1) was then added to the column, which was again centrifuged for 
3minutes. This step was followed by the application of 4mls of a second 
washing buffer (Buffer AW2) as for Buffer AW1. To dry the membranes the 
tubes were vacuum-dried for 15minutes. Each column was then placed in a 
15ml centrifuge tube. 200μl of Buffer AE equilibrated to room temperature 
was added onto the membrane and the tube was incubated at room temperature 
for 5minutes then centrifuged for 2minutes at 5000rpm. The eluted DNA was 
then analysed using the Nanodrop ND1000 UV-Vis Spectrophotometer 
(Labtech International Ltd., Ringmer, UK) to determine DNA concentration. 
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2.1.2 Genomic DNA extraction from skin biopsies 
DNA was extracted from skin biopsies using the QIAamp DNA Mini 
Kit (Qiagen). Samples were homogenised using a hand-held rotor-stator 
homogeniser in Buffer ATL. 20μl proteinase K was then added to the mixture 
then mixed by vortexing. The suspension was then incubated at 56°C with 
occasional shaking until the tissue is completely lysed. The tube containing the 
suspension was briefly centrifuged to ensure fluid in the lid is removed. To 
remove undesired RNA 4μl RNAse A (100mg/ml) was then added and mixed 
by pulse-vortexing for 15seconds followed by incubation at room temperature 
for 2minutes. The tube was again briefly centrifuged, then 200 μl Buffer AL 
was added to the sample then mixed as for RNAse A followed by incubation at 
70°C for 10minutes. Following brief centrifugation 200μl of Buffer AL was 
added to the sample then mixed and incubated as in the previous step. 200μl of 
ethanol (96–100%) was then added to the sample, and mixed by pulse-
vortexing for 15seconds followed by brief centrifugation in a 1.5ml 
microcentrifuge tube. The mixture was then applied to the QIAamp Mini spin 
column, which was then closed and centrifuged at 8000 rpm for 1minute. The 
tube containing the filtrate was now discarded and the column placed in a clean 
2ml collection tube. 500μl of Buffer AW1 was then applied to the column 
followed by the same procedure outlined in the last step. This was followed by 
the addition of 500μl of Buffer AW2. The cap was closed and the tube was 
centrifuged at 14,000 rpm for 3minutes.  The column was then placed in a 
clean 1.5ml microcentrifuge tube and 200μl Buffer AE was added to the 
column. The tube was then incubated at room temperature for 1 min, and then 
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centrifuged at 8000 rpm for 1minute to elute the DNA. This step was repeated 
again to increase DNA yield. 
 
2.1.3 Genomic DNA and RNA extraction from cell cultures 
Total RNA was extracted using the TRIzol reagent method (Invitrogen, 
Paisley, UK). 1ml of TRIzol reagent was added per 10cm2 of plated monolayer 
culture. The suspension was then repeatedly aspirated to lyse the cells 
thoroughly and then allowed to stand at room temperature for 5minutes to 
ensure complete dissociation of the nucleoprotein complexes. 0.2ml of 
chloroform was added per 1ml of TRIzol reagent used. The suspension was 
then centrifuged at 12000rpm for 15minutes at 4°C resulting in the separation 
of the mixture into 3 phases; the aqueous phase containing RNA, the interphase 
containing DNA and the organic phase containing proteins.  
For RNA isolation the aqueous phase was then carefully transferred 
into a new falcon tube with the addition of 0.5ml of isopropranolol per 1ml of 
Tri Reagent used. The suspension was then allowed to stand for 10minutes at 
room temperature then centrifuged at 12000rpm for 10 minutes at 4°C. This 
results in an RNA precipitate at the bottom and sides of the tube. The 
supernatant was then aspirated and the precipitate washed with 1ml of 75% 
ethanol. This was followed by centrifugation at 7500rpm for 5minutes at 4°C. 
The supernatant was then aspirated and discarded and the RNA pellet air-dried 
at room temperature for 10minutes. The pellet was then resuspended in 50ul of 
RNAse free water then stored if needed at -80°C. 
For DNA isolation and following careful removal of the aqueous phase, 
0.3mL of 100% ethanol per 1mL of TRIzol reagent used for the initial 
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homogenization was added and then mixed by inversion. Samples were then 
incubated at 15 to 30°C for 2-3minutes followed by centrifugation at 2,000 x g 
for 5minutes at 4°C. The pellet was then washed twice in 0.1M sodium citrate 
in 10% ethanol (1mL per 1mL of TRIzol Reagent used for the initial 
homogenization). On each wash the sample was incubated for 30minutes at 15 
to 30°C with frequent mixing and centrifuged at 2,000 x g for 5minutes at 4°C. 
The DNA pellet was then suspended in 75% ethanol (1.5-2mL of 75% ethanol 
per 1mL TRIzol Reagent), and then incubated for 10-20minutes at 15 to 30°C 
with frequent mixing then centrifugation at 2,000 x g for 5 minutes at 4°C. The 
pellet was then air dried for 5 to 15minutes in an open tube then dissolved in 
8mM NaOH. The insoluble material was removed by centrifugation at >12,000 
g for 10 minutes and the supernatant containing the DNA was transferred to a 
new tube then stored if needed at -80°C. 
 
2.1.4 Extraction of total RNA from skin biopsies 
RNA extraction was performed using the RNeasy fibrous tissue kit 
(Qiagen). The samples, originally stored in RNA later (Qiagen) at -20°C were 
thawed at room temperature. Samples were then homogenised using a hand-
held rotor-stator homogeniser in RLT lysis buffer and β-mercaptoethanol 
solution. The mixture was then added to the RNeasy spin column where RNA 
adsorbs onto the membrane. This is then washed with various washing buffers 
according to the manufacturer’s instructions and the RNA eluted in 30µl of 
RNase free water (Qiagen) and stored at -80°C. 
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2.1.5 DNA and RNA quantification and quality control 
The concentration of extracted total DNA or RNA was measured using 
the Nanodrop ND1000 UV-Vis Spectrophotometer (Labtech). This was 
assessed through the optical density at 260nm and 280nm. The ratio of light 
absorbance at 260nm:280nm was used to indicate the degree of purity of the 
DNA and RNA samples. Only samples with an ideal 260nm:280nm absorption 
ratio between 1.8 and 2.1 were used for subsequent experiments. 
 
2.1.6 Reverse transcription  
cDNA was synthesized from RNA using the SuperScript II RT protocol 
(Invitrogen). Each reaction mixture consists of 2μg of total RNA, 50ng of 
random primers, 1ul of 10nM dNTP mix and RNAse and DNAse free water to 
a total volume of 12μl. The mixture was then heated to 65C for 5minutes then 
rapidly cooled on ice. A brief centrifugation was then followed by the addition 
of 4μl of 5X First Strand Buffer, 2μl of 0.1M DTT and 1μl (40units/μl) of 
RNAseOut (Invitrogen). This was mixed gently then incubated at room 
temperature for 2minutes. 1μl (200units) of SuperScript II Reverse 
Transcriptase was subsequently added and mixed by gentle pipetting. The 
mixture was then incubated further at room temperature for 10minutes 
followed by heating to 42C for 50minutes. The reaction was finally 
inactivated by heating at 70C for 15minutes. 
In some experiments the cDNA was generated using the iScript cDNA 
generation kit (Biorad, Hemel Hempstead, UK). 4μl of 5x iScript select 
reaction mix were added to 2μl random primer, 1μg of RNA, 1μl iScript 
reverse transcriptase and nuclease free water to a total of 20μl. The mixture 
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was then incubated for 5 min at 25°C, 30minutes at 42°C then 5minutes at 
85°C to inactivate the reverse transcriptase. The samples were stored at this 
stage between –20°C and +4°C. 
 
2.1.7 Polymerase chain reaction (PCR) amplification of DNA 
The Qiagen PCR Core Kit was used for the PCR. 2µl of cDNA was 
added to 10µM of each primer (MWG Biotech, Ebersberg, Germany), 2.5mM 
of dNTP, 2.5µl of 10x buffer, 5µl of Q buffer, 0.2µl of Taq polymerase and 
10.375µl of water to a total volume of 25µl. The GeneAmp PCR System 9700 
thermal cycler (Applied Biosystems, Warrington, Cheshire, UK) was used for 
amplification under specific conditions; 95°C for 5minutes, followed by 35 
cycles of 95°C for 15seconds, 55-60°C for 30seconds then 72°C for 30seconds. 
This was followed by a final extension step at 72ºC for 10minutes, and then 
held at 4ºC.  
 
2.1.8 Analysis of PCR products by agarose gel electrophoresis 
The PCR products were analysed using a 2% agarose gel. This was 
prepared by mixing 2.4g of agarose powder and 120ml of 1x tris-borate-EDTA 
(TBE) (Sigma-Aldrich, Dorset, UK). The solution was heated in a microwave 
at full power for about three minutes to facilitate dissolution of the agarose. 
The difference in final volume was then corrected with distilled water. The 
solution was cooled under running tap water after which 5l ethidium bromide 
(Sigma-Aldrich) was added to the solution. The ethidium bromide interacts 
with nucleic acids and fluoresces on exposure to ultraviolet light. The solution 
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was then poured in a plastic gel tray and allowed to set. The gel was then 
transferred to a horizontal gel electrophoresis system and immersed in 1x TBE 
buffer. 5µl of PCR product was prepared for loading by adding 1l of DNA 
loading dye (Gelpilot Loading Dye 5x, Qiagen). φX174 DNA–Hae III Digest 
DNA ladder was also loaded onto the gel by addition to 3l of a random PCR 
product (New England Biolabs, Hertfordshire, UK). Gel electrophoresis was 
carried out at 80V for 30minutes or until the PCR products can be visualised 
under an ultraviolet light source. The image was then captured using a gel 
documentation system (Syngene EV700, Cambridge, UK). 
 
2.1.9 Purification of PCR product 
Purification of PCR products was done using the Qiagen PCR 
purification kit. 100l of binding buffer (PB Buffer) was added to each PCR 
product and the mixture was transferred into a spin column then centrifuged at 
1200 rpm for two minutes. The effluent was discarded and 750µl wash buffer 
(PE Buffer) was added and centrifuged for a further two minutes. The effluent 
was discarded again and the column was centrifuged for another minute to 
ensure removal of any residual wash buffer. The purified DNA was then eluted 
in 20µl of distilled water and stored at -80°C. 
 
2.1.10 Direct nucleotide sequencing  
Bi-directional nucleotide sequencing was performed using the ABI 
PRISM® 310 Genetic Analyser (Applied Biosystems, Warrington, U.K.). A 
mixture was prepared for each sequencing reaction consisting of 2µl of purified 
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PCR product, 1µl of Big Dye (Applied Biosystems), 1µl of either forward or 
reverse primer, 1.5µl of 5X buffer and 4.5µl of nuclease free water (Sigma-
Aldrich). The mixtures were placed in a 96-well plate and then incubated for 
amplification at 96°C for one minute followed by 25 cycles of incubation at 
96°C for ten seconds, 50°C for ten seconds and 60°C for one minute, then held 
at 4°C. The amplified products were then purified using DNA precipitation.  
25µl of 100% ethanol, 1µl of 125mM EDTA and 1µl of 3M sodium acetate 
were added carefully to the sequence mixture then incubated at room 
temperature for 15minutes followed by centrifugation at 2500rpm for thirty 
minutes at 4°C. The plate was then inverted to remove excess solution then 
centrifuged at 185rpm for 10seconds. 70µl of 70% ethanol was added, then 
centrifuged again at 1650rpm for 15minutes then inverted again with gentle 
centrifugation leaving behind the DNA pellet at the bottom of the wells. The 
plate was then left to dry at room temperature for 2minutes. 10µl of highly 
deiodinised (HiDi) formadide (Applied Biosystems) was then added to each 
well and dried on a heat block for 2minutes at 95°C. The plate was 
subsequently loaded into the ABI PRISM® 310 Genetic Analyser (Applied 
Biosystems) for sequencing analysis.  
 
2.1.11 Quantitative real-time PCR using Taqman 
Real-time q-PCR using Taqman was used to validate the microarray 
results by determining the expression of a gene of interest against the 
expression of one or more house-keeping genes. Taqman probes are 
fluorogenic probes with a reporter dye on the 5’ end and a quencher dye on the 
3’ end. As Taq polymerase extends the forward primer, the probe is cleaved, 
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leading to the release of the reporter molecule from the close vicinity of the 
quencher. This results in an increase in fluorescence as PCR progresses. 
Taqman primers and probes (Applied Biosystems) were obtained for FOS 
Hs00170630_m1, JUN Hs01103582_s1, IL1R2 Hs01030385_m1, LAMC2 
Hs01043707_m1, GAL Hs01032385_m1, STAT1 Hs01014002_m1, TNFSF13B 
Hs00198106_m1, IRF1 Hs00971960_m1, VCAM1 Hs01003372_m1, COL1A1 
Hs01076756_g1, COL4A1 Hs01007434_g1, COL7A1 Hs01574745_g1, 
COL17A1 Hs00166711_m1, CCL18 Hs00268113_m1 and HB-EGF 
Hs00181813_ml purchased from Applied Biosystems (Foster City, CA, USA). 
18S was used as internal control (18S Hs03003631_g1) and water as a no 
template control to check for any contamination. The experiments were 
triplicated and the mean average for each sample was calculated.  
For each 25µl reaction, 0.5μl of cDNA, 10.75μl of H2O, 12.5μl of 
Taqman MasterMix (Applied Biosystems) and 1.25μl of Taqman assay was 
used making up a total volume of 25μl. The reaction mixes were carefully 
pipetted into a dedicated ninety-six well plate and heated to 50ºC, followed by 
95ºC for 10minutes to activate AmpliTaq Gold, followed by 40 cycles of 
sample denaturation at 95ºC for 15seconds then annealing and extension at 
60ºC for one minute using the ABI prism 7000 Sequence Detection System 
(Applied Biosystems). The gene expression was normalized against the 
expression of 18S internal control and expressed relative to the average of 
control skin samples. 
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2.1.12 Whole genome gene expression microarray and data analysis  
Gene expression microarray was performed using total RNA extracted 
from skin biopsy samples as outlined above. Whole genome gene expression 
microarray in each extracted RNA sample was performed using the Sentrix 
Human-6 Whole Genome Expression Beadchips (Illumina Inc, San Diego, CA, 
USA).  
The data were normalised using a cubic spline function of Beadstudio 
software version 3.0 (Illumina Inc). Differential gene expression was 
calculated based on the expression difference score (DiffScore) of >13 or ≤13, 
which takes into account the background noise, sample variability and a 
differential fold change of two or greater. In addition, the average signal 
intensity for each probe was considered significant if its detection p value was 
<0.05. Any probe with a signal intensity p value of >0.05 was excluded from 
the analysis. Average signal intensity for each probe was calculated for both 
subjects (S) and controls (N). Fold change was calculated according to the 
formula S (average probe signal intensity) / N(average probe signal intensity).  
 
2.1.13 Quantitative real-time PCR (qRT-PCR) using SYBR-Green  
Quantitative real time polymerase chain reaction (qRT-PCR) using 
SYBR-Green q-PCR mastermix (Applied Biosystems) was performed to assess 
the expression of a genomic area of interest. Uracil-N-Glycosylase which is 
included in the SYBR-Green mastermix helps to remove any contaminating 
DNA that might still be present. SYBR-Green fluoresces when bound to 
double stranded DNA generated by the PCR and hence fluorescence intensity 
will be proportional to the PCR product concentration.  
   
 
57 
 Two sets of collagen VII cDNA primers located at the 3’ and 5’ ends 
were designed to overlap exons in order to minimise the possibility of 
amplifying contaminating genomic DNA. Normal fibroblast cDNA was used 
as the comparative standard and water was used as a negative control sample to 
ensure there was no DNA contamination in the mixture. TaTa box binding 
protein (TBP) was used to as the normalisation control. The experiments were 
triplicated and the mean average calculated. Each 25µl reaction was composed 
of 12.5l of 2x reaction buffer (contains dNTPS, HotGoldStar DNA 
polymerase, MgCl2, Uracil-N-Glycosylase, SYBR Green I), 2.5l (100nM) of 
forward and reverse primers, 6.5l of water and 1l (100ng) of cDNA 
template. 
 The reaction mixtures were carefully pipetted into dedicated PCR tubes 
and analysed using the Corbett Rotor-Gene 6000 series and the Corbett Rotor-
Gene 6000 series software version 1.7. The optimum annealing temperature 
was initially determined by testing the primers using normal fibroblast cDNA, 
over a range of 58C–68C. The amplification conditions were two minutes at 
50C to activate uracil-N-glycosylase (UNG), followed by ten minutes at 95C 
to inactivate UNG and activate HotGoldStar DNA polymerase. Subsequently, 
45 cycles of fifteen seconds at 95C (denaturation), thirty seconds at 60C 
(annealing) and thirty seconds at 72C (extension/DNA polymerisation phase) 
and a final extension at 72C for ten minutes. The melting curve was read 
every 0.3C between 72C and 90C. 
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2.2 Direct immunofluorescence microscopy studies 
5μm frozen skin sections were cut from skin biopsies obtained from 
patients with EB. The skin sections were air-dried for 30minutes before being 
rehydrated in phosphate buffered saline (PBS) for a further 15minutes. The 
sections were then blocked with 20% goat serum (Sigma-Aldrich) for 
20minutes and then incubated with mouse monoclonal anti- collagen VII 
antibody (clone LH 7.2; Sigma-Aldrich) diluted 1:1,000 in PBS, for 45minutes 
at 37ºC. The sections were then washed three times with PBS before being 
incubated with fluorescein isothyocyanate-labelled goat anti-mouse secondary 
antibody (Invitrogen). For a further 45minutes at 37ºC. Following PBS washes, 
the sections were air-dried and mounted with Vectashield Hard Set with Dapi 
(Vector Laboratories, Peterborough, UK) and viewed under a fluorescent 
microscope.  
 
2.2.1 Quantification of collagen VII fluorescence 
Mean fluorescence intensity was calculated for each sample using 
Image J (Rasband W.S., National Institutes of Health, Bethesda MD; 
http://rsb.info.nih.gov/ij/, 1997-2007) as described previously  (Wong et al., 
2008). Ten measurements were taken at regular intervals using an area of 8x8 
pixels and measuring every 50pixels along the DEJ, starting from the 
outermost edge of the image. The mean average values and standard errors 
were calculated for each image.  
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2.3 Transmission electron microscopy and morphometric 
analysis of anchoring fibrils at the DEJ 
TEM was kindly performed by Mrs Patricia Dopping-Hepenstal at the 
Robin-Eady national epidermolysis bullosa diagnostic laboratory at St Thomas’ 
Hospital. Skin biopsy specimens were cut and fixed in half-strength Karnovsky 
fixative for 4 hours at room temperature. After washing in 0.1M phosphate 
buffer, the samples were immersed in 1.3% osmium tetroxide (TAAB 
Laboratories, Berkshire, UK) for 2hours, followed by incubation in 2% uranyl 
acetate (BioRad) and gradually dehydrated using increasing concentrations of 
ethanol (50%, 70%, 95%) for 15minutes each time. Samples were then washed 
3x 15minutes in 100% ethanol followed by 2x 15minutes in propylene oxide 
(TAAB laboratories). Similarly, increasing concentrations of resin/propylene 
oxide were used, 1:1 initially for 1hour then 3:1 overnight to gradually harden 
the samples. Following 2x 2hours of exposure to pure resin (812 embedding 
resin, medium, (TAAB laboratories) the samples were transferred into labelled 
moulds and allowed to polymerise for 18hours at 60C. Ultrathin sections were 
stained with uranyl acetate and lead citrate and examined in a JEOL 100CX 
transmission electron microscope. Anchoring fibril numbers were determined 
over two separate 25-mm stretches of continuous lamina densa using the 
morphometric technique and anchoring fibril criteria previously described by 
Tidman and Eady (Tidman and Eady, 1985). 
  Special care was taken to dispose of radioactive uranyl acetate and 
osmium tetroxide into dedicated waste containers and also all equipment 
exposed to resin were polymerised before discarding as clinical waste. 
Following completion of handling radioactive material, the mini-Geiger meter 
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(Mini Instruments Ltd, Burnham on Crouch, Essex, UK) was used to monitor 
and record readings over dedicated areas in the laboratory for audit and health 
and safety purposes. Ultrathin sections were stained with uranyl acetate and 
lead citrate and examined in a JEOL 100CX transmission electron microscope. 
 
2.4 Cell culture 
2.4.1 HaCaT keratinocyte cell culture 
  HaCaT cells lines are spontaneously immortalized human 
keratinocytes  (Boukamp et al., 1988). The cells were cultured to 70–80% 
confluence in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) 
supplemented with 10% foetal bovine serum (FBS; Invitrogen). 
  
2.4.2 Isolation of primary keratinocytes and fibroblasts from skin biopsies 
Skin biopsies were immersed in EpiLife containing x1 concentration of 
streptomycin and penicillin antibiotics as well as amphotericin C (Invitrogen) 
for 1 hour at room temperature. Each sample was then cut into 2-3mm2 pieces 
then incubated in 1mg/ml dispase overnight at 4C (Roche Applied Science). 
To isolate keratinocytes the upper epidermal layer containing the keratinocytes 
was then separated from the dermis, vortexed at low speed for 1 minute and 
placed on mitomycin C-treated 3T3 cells. The flasks were then placed in a 
humidified cell culture incubator at 37C in with 5% CO2. EpiLife medium 
supplemented with defined growth supplement (EDGS; Invitrogen) was added 
and was refreshed every other day until the cell culture reached a near 
confluent state.  
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To isolate fibroblasts, the dermis was cut into very small pieces using 
sterile scalpel on a plastic tray and then immersed in 5ml trypsin-EDTA 
(Invitrogen). Tissue was then incubated at 37C for 30 minutes and agitated 
every 10 minutes. Trypsin was inactivated by the addition of 10ml of 10% 
foetal bovine serum (FBS) (Biosera, Ringmer, East Sussex, UK). The 
suspension was then filtered through a cell strainer into a sterile falcon tube. 
The contents from the cell strainer contained the fibroblasts which were 
transferred carefully to a petri dish and incubated in collagenase D, 0.5mg/ml 
(Sigma-Aldrich) overnight at 37˚C in 5% CO2 in air. The following day, the 
contents were filtered, centrifuged at 1000rpm for five minutes and the pellet 
re-suspended in fibroblast culture media consisting of Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen) and 10% foetal calf serum (FCS, 
Biowest, East Sussex, UK). Passages two to five were used for the 
experiments.  
 
2.4.3 Maintenance and passage of keratinocytes and fibroblasts 
Primary fibroblast and keratinocyte cultures were maintained by 
changing the growth medium every other day. When culture cells reached near- 
confluence, they were washed with sterile PBS then passaged. This process 
includes the creation of a single cell suspension by incubating the cells in 5ml 
of trypsin-EDTA for 5minutes at 37˚C. An equivalent volume of DMEM 
containing 10% FCS was added to inactivate trypsin. The suspension was then 
centrifuged at 1000rpm for five minutes and the filtrate was aspirated carefully 
leaving the cell pellet at the bottom of the falcon tube. The cells were then 
   
 
62 
washed in sterile PBS then re-seeded into new flasks using a cell concentration 
ratio of 1:5 or alternatively stored in liquid nitrogen.  
 
2.4.4 In vitro HB-EGF and TGFβ1 studies 
Subconfluent cultures of keratinocytes and fibroblasts were fed with 
fresh DMEM medium without FBS supplementation and were cultured for 
2hours before the addition of either recombinant human heparin binding 
epidermal growth factor (HB-EGF; Cat No.: 259-HE; R&D Systems; 
Abingdon, UK) or transforming growth factor beta 1 (TGFβ1; Cat No.: 240-B; 
R&D Systems). 10ng/ml of TGFβ1 and 100ng/ml of HB-EGF were added to 
the cells as described previously (Calonge et al., 2004; Higashiyama et al., 
1993). Samples were then collected 15, 90 and 180minutes after the application 
of HB-EGF or TGFβ1.  
 
2.5 Skin Biopsies 
Informed written consent was obtained for 4mm punch biopsies. Using 
an aseptic technique, 1% lignocaine with adrenaline was injected into each of 
the biopsy sites. In most cases the biopsy specimen was immediately divided 
into three parts. One was placed into Michel’s medium for future 
immunofluorescence studies, another into EM fixative and the third part into 
RNA later. Pressure was applied to the wound for haemostasis and suturing 
was not required. In view of skin fragility non-adhesive dressing was applied. 
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Bullous dermolysis of the 
newborn: immunohistochemical, 















In patients with inherited skin blistering, the finding of intra-epidermal 
collagen VII immunostaining is often taken as a hallmark of a specific subtype 
of DEB; bullous dermolysis of the newborn (BDN), which usually has a good 
prognosis with spontaneous and sometimes complete clinical resolution. 
However, not all cases regress and there is a need for an improved 
clinicopathological and molecular correlation with better determination of 
prognosis. The aim of the study in this Chapter was to review cases of 
suspected EB referred to the National Diagnostic EB Laboratory over a 10-year 
period in which skin immunofluorescence microscopy revealed presence of 
intra-epidermal collagen VII labelling. The objective was to correlate the 
pattern of the collagen VII immunostaining with ultrastructural, molecular and 
clinical data and thereby improve understanding of the significance of intra-
epidermal collagen VII labelling. Out of 570 skin samples reviewed, 35 cases 
(33 kindreds) were identified with intracytoplasmic collagen VII. BDN 
accounted for 14 cases while the remainder comprised other forms of 
dystrophic EB (n=10), junctional EB (n=4), EB simplex (n=4), aplasia cutis 
(n=1) and 2 undiagnosed cases. Variability in the pattern of intra-epidermal 
labelling as well as the ultrastructural morphology of intracytoplasmic 
inclusions was also noted in the different groups. In conclusion, intra-
epidermal collagen VII immunolabelling in suspected cases of EB is not 
synonymous with a diagnosis of BDN. Careful assessment of the 
immunostaining pattern, in combination with ultrastructural, molecular and 
clinical data, is helpful in establishing more accurate diagnoses and prognoses. 




Bullous dermolysis of the newborn (BDN) is a rare variant of DEB first 
described in 1985 (Hashimoto et al., 1985) in which there are well-defined 
immunohistochemical and ultrastructural abnormalities (Fine et al., 2014). 
Direct immunofluorescence shows a variable reduction in collagen VII 
labelling at the DEJ as well as characteristic intracytoplasmic deposits of 
collagen VII within basal and suprabasal keratinocytes (Hashimoto et al., 1985; 
Hashimoto et al., 1989; Fine et al., 1990). Ultrastructurally, there may be sub-
lamina densa blistering with reduced or absent anchoring fibrils in combination 
with dilated rough endoplasmic reticulum (RER) and intracytoplasmic stellate 
bodies which represent perinuclear inclusions of collagen VII (Fine et al., 
1990; Hashimoto et al., 1985; Hashimoto et al., 1989). Proposed 
pathophysiological mechanisms in BDN include abnormal retention, secretion, 
transport or phagocytosis of collagen VII (Smith and Sybert, 1990; Fine et al., 
1993; Hammami-Hauasli et al., 1998b; Fassihi et al., 2006; Fassihi et al., 
2005). 
The skin blistering in BDN, which usually presents at birth or in the 
neonatal period, typically improves markedly or even regresses completely 
within the first year of life. Thus, the condition was known initially as transient 
BDN (Hashimoto et al., 1985). The clinical features, however, are not transient 
in all cases and therefore in the 2008 reclassification of EB, the word 
“transient” was dropped from the disease nomenclature (Fine et al., 2008). 
Reports also pointed to variability in inheritance patterns with either autosomal 
dominant or recessive transmission (Christiano et al., 1997b; Hammami-
Hauasli et al., 1998b; Fassihi et al., 2005; Sawamura et al., 2006a; Nakano et 
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al., 2007; Oh et al., 2007; Almaani et al., 2011; Almaani et al., 2009; 
Hashikawa et al., 2009; Murase et al., 2011) (Table 3.1). Moreover, the 
immunohistochemical finding of intra-epidermal collagen VII labelling was 
found not to be exclusive to BDN (Table 3.2). It has also been reported as a 
transient finding during wound healing in recessive dystrophic EB (McGrath et 
al., 1992), in the blister roof of some cases of dystrophic EB (Muramatsu et al., 
1999), in some forms of dystrophic EB other than BDN (Smith and Sybert, 
1990; Phillips et al., 1992; Konig et al., 1994) and in vitro in association with 
certain dominant dystrophic EB mutations, for example p.Arg2008Gly (Chen 
et al., 2002a) (Table 3.2). 
Collectively, it is clear that BDN and intra-epidermal collagen VII do 
not represent a single clinicopathological and molecular entity. Therefore, in 
this Chapter, the implications of finding intra-epidermal collagen VII 
immunostaining in a diagnostic EB setting was studied with the aim of 
establishing a better understanding of the clinical and prognostic implications 
of this immunohistochemical finding.  
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Table 3.1 Reported COL7A1 mutations associated with bullous dermolysis of the newborn. 9 dominant and 5 recessive COL7A1 mutations 
have been described in BDN, the majority of which are missense glycine substitution mutations. 
 
No. Diagnosis 
Allele 1 Allele 2 
Reference exon/ 
intron 
cDNA protein type 
exon/ 
intron 









intron 5 + 
p.Pro228fsX32 
SS E68  c.5728G>A p.Gly1910Ser missense 





E18 c.2392G>A p.Gly798Arg MS E75 c.6246del27 
 in frame 
deletion 











SS /  /  / / 









E44 c.4556G>A p.Gly1519Asp MS E86 c.6752G>A p.Gly2251Glu missense 









E54 c.5017G>A p.Gly1673Arg MS  /  /  / /  (Frew et al., 2011) 






E73 c.6023G>A p.Arg2008His MS E64 








E73 c. 6110G>A p.Gly2037Glu MS /  /  / / 












/  /  / / 
 (Wertheim-

















E112 c.8341G>A p.Gly2781Arg MS E51 c.4894C>T p.Arg1632Stop PTC  (Almaani et al., 2011) 
BDN- bullous dermolysis of the newborn, DDEB- dominant dystrophic epidermolysis bullosa; RDEB- recessive DEB; MS-missense; SS-splice site; PTC-
premature termination codon. 
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Table 3.2 Reported cases of BDN and dystrophic EB associated with intracytoplasmic retention of collagen VII including BDN. The 
literature contains 19 publications (33 subjects) describing BDN with intracytoplasmic retention of collagen VII, as well as 11 publications (20 









Electron Microscopy Clinical Outcome Reference 
1 BDN ?AD ND 
prominent focal granular 
intracytoplasmic retention 
of collagen VII and 
interrupted collagen VII 
labelling along the DEJ 
ND complete resolution 
(Radkevich-Brown 
and Shwayder, 2013) 
2 BDN ?AD ND 
focal granular 
intracytoplasmic retention 
of collagen VII 
ND complete resolution 
(Radkevich-Brown 
and Shwayder, 2013) 
3 BDN sporadic ND 
no intracytoplasmic 
retention of collagen VII 
ND complete resolution 
(Radkevich-Brown 
and Shwayder, 2013) 
4 BDN ?AR ND 
prominent focal granular 
intracytoplasmic retention 






and Shwayder, 2013) 
5 DEB ND ND 
absent collagen VII 
labelling at DEJ with 
intracytoplasmic retention 
of collagen VII 
ND ND  (Berk et al., 2013) 
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6 RDEB-I AR 
 
p.Gly2695Ser/        
p.Gly2695Ser 
intracytoplasmic retention 
of collagen VII in basal 
keratinocytes 
reduced numbers of 
abnormal or rudimentary 
AF. RER vesicles were 
seen 
chronic 
involvement of the 
inversa pattern 
 (van den Akker et al., 
2011) 
7 RDEB-I AR 
p.Gly2602Glu/        
p.Gly1907Glu 
intracytoplasmic retention 
of collagen VII in basal 
keratinocytes 
reduced numbers of 
abnormal or rudimentary 
AF 
chronic 
involvement of the 
inversa pattern 
 (van den Akker et al., 
2011) 
8 RDEB-I AR 
p.Gly1761Ala/          
p.Gly1761Ala 
intracytoplasmic retention 
of collagen VII in basal 
keratinocytes 
reduced numbers of 
abnormal or rudimentary 
AF 
improved initially 
within a few 
months of life then 
worsened by 1 year 
 (van den Akker et al., 
2011) 
9 BDN ND ND 
granular deposits within the 
epidermis 
ND reduced blistering 
(Oppenheimer and 
Hallas, 2011) 
10 BDN AD p.Gly1673Arg 
granular deposits within the 
epidermis 
reduced AF with dilated 
RER and stellate bodies in 
basal keratinocytes 
complete resolution  (Frew et al., 2011) 
11 BDN AD p.Gly2242Glu 
granular deposits within the 
epidermis 
reduced AF with stellate 
bodies in basal and 
suprabasal keratinocytes 
complete resolution  (Murase et al., 2011) 
12 BDN AR 
c.682+1G>A/ 
p.Gly1910Ser 
granular deposits within 
basal keratinocytes  
 reduced and poorly formed 
AF. Large stellate bodies in 
basal keratinocytes 
complete resolution 
 (Hashikawa et al., 
2009) 
13 BDN AR 
p.Gly798Arg/ 
c.6246del27 
ND ND complete resolution  (Oh et al., 2007) 
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reduced and poorly formed 
AF. Dilated RER in the 
basal and suprabasal layers 
complete resolution  (Nakano et al., 2007) 
15 BDN AD p.Gly2037Glu 
intracytoplasmic deposits 
within the epidermis 
reduced AF reduced blistering 
 (Sawamura et al., 
2006b) 
16 BDN AD p.Gly1522Glu 
widespread and granular 
deposits within the 
epidermis 
reduced and poorly formed 
AF. Large, granular 
perinuclear stellate bodies 
in basal and suprabasal 
keratinocytes 
complete resolution  (Fassihi et al., 2005) 
17 BDN AD p.Gly1522Glu 
focal intraepidermal 
deposits of collagen VII 
within some basal 
keratinocytes 
AF reduced, thin and 
wispy. Small 
intracytoplasmic inclusions 
in some basal 
keratinocytes. 
complete resolution  (Fassihi et al., 2005) 
18 BDN AD p.Gly1522Glu 
focal intraepidermal 
deposits of collagen VII 
within some basal 
keratinocytes 
AF reduced, thin and 
wispy. Small 
intracytoplasmic inclusions 
in some basal keratinocytes 
complete resolution  (Fassihi et al., 2005) 
19 RDEB-O AD 
p.Gly2316Arg/ 
p.Gly2287Arg 
weak labelling at BM with 
basal and suprabasal 
retention of collagen VII at 
3 days of age. At 10 years; 
normal BM labelling with 
infrequent punctuate 
labelling within the 
epidermis 
ND reduced blistering  (Shimizu et al., 1999) 
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basal and suprabasal 
retention of collagen VII 
Reduced and abnormal AF. 
Dilated RER in 
keratinocytes with vacuoles 
containing electron dense 
and filamentous aggregates. 
reduced blistering 
 (Hammami-Hauasli et 
al., 1998a) 
21 BDN AD c.4120-1G>C  
granular intracytoplasmic 
staining in basal 
keratinocytes 
ND complete resolution  
 (Christiano et al., 
1997a) 
22 BDN sporadic ND 
intense intracytoplasmic 
collagen VII 
sublamina densa blister complete resolution   (Hanson et al., 1999) 
23 BDN sporadic ND 
granular deposits within the 
epidermis 
subepidermal vesicles and 
decreased numbers of AF 
reduced blistering  (Hanson et al., 1999) 
24 BDN sporadic ND 
focal granular deposits 
within the epidermis 
subepidermal vesicles and 
decreased numbers of AF 
complete resolution   (Hanson et al., 1999) 
25 BDN sporadic ND 




reduced rudimentary AF. 










of collagen VII in cultured 
keratinocytes stimulated by 
TGF-β2 
dilated RER cisternae of 
vesicular appearance filled 
with electron dense content 
reduced blistering  (Konig et al., 1994) 
27 RDEB-I sporadic ND ND 
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of collagen VII 
complete resolution   (Fine et al., 1993) 




of collagen VII 
complete resolution   (Fine et al., 1993) 
30 BDN ND ND ND ND complete resolution   (Fine et al., 1993) 
31 BDN ND ND 
granular intracytoplasmic 
deposits 
ND reduced blistering  (Fine et al., 1993) 
32 BDN ND ND ND ND complete resolution   (Fine et al., 1993) 
33 BDN AD ND 
granular intracytoplasmic 
deposits 
ND reduced blistering  (Fine et al., 1993) 
34 BDN AD ND ND ND NA  (Fine et al., 1993) 
35 BDN AD ND ND ND reduced blistering  (Fine et al., 1993) 
36 BDN AD ND ND ND reduced blistering  (Fine et al., 1993) 
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37 BDN sporadic ND 
granular deposits in all 
layers of the epidermis 
abnormal AF. Dilated RER, 
containing amorphous 
material and electron dense 
stellate bodies 
complete resolution   (Okuda et al., 1993) 
38 BDN sporadic ND 
intracytoplasmic deposits 
within keratinocytes 
reduced AF. Deposits of a 
granular material with focal 
densities seen within the 
RER of the keratinocytes 
reduced blistering  (Phillips et al., 1992) 
39 DEB sporadic ND 
 patchy intracytoplasmic 
deposits within 
keratinocytes 
AF sparse and wispy. No 
split or granular deposits 
were seen 
blisters continues at 
2m, milia scarring, 
nails unaffected 
 (Phillips et al., 1992) 
40 DDEB-pt AD ND 
granular intracytoplasmic 
deposits within basal 
keratinocytes 
 normal AF. Lipid droplets 
were present in basal 
keratinocytes but no 
granular deposits were seen 
reduced blistering  (Phillips et al., 1992) 
41 DEB ?AD ND 
prominent intraepidermal 
deposits 




reduced blistering  (Phillips et al., 1992) 
42 DEB ?AD ND 
few discrete deposits within 
the epidermis 
abnormal AFs. No 
intracytoplasmic granular 
deposits could be found 
pregnancy 
terminated 
 (Phillips et al., 1992) 







absent collagen VII staining 
pre-wounding.  At day 10-
13 intracytoplasmic 
retention of collagen VII 
was noted in basal and 
suprabasal keratinocytes. 
ND ND  (McGrath et al., 1992) 
44 BDN sporadic ND ND 
reduced and abnormal AF. 
Dilated RER containing 
filamentous aggregates. cell 
membrane-bound structures 
with phagocytosed collagen 
VII was noted 
complete resolution  
 (Eng et al., 1991; 
Hashimoto and Eng, 
1992) 
 
45 DDEB AD ND 
granular perinuclear 
intracytoplasmic deposits 
sublamina densa blister reduced blistering 
 (McCollough et al., 
1991) 
46 RDEB AR ND 
intracytoplasmic retention 
of collagen VII in basal and 
suprabasal keratinocytes 
abnormal AFs, dilated RER 
cisternae with vesicles 
filled with electron dense 
content 
ND 
(Smith and Sybert, 
1990) 
47 DEB ND ND 
granular intracytoplasmic 
deposits within basal 
keratinocytes 




only one blister 
since aged 6 
months; no further 
skin fragility. 
 (Fine et al., 1990) 
48 DDEB AD ND 
granular intracytoplasmic 
deposits within basal 
keratinocytes  
ND complete resolution   (Fine et al., 1990) 
49 DDEB AD ND 
granular intracytoplasmic 
deposits within basal 
keratinocytes 
ND complete resolution   (Fine et al., 1990) 
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50 DEB ND ND 
granular intracytoplasmic 
deposits within basal 
keratinocytes 
ND complete resolution   (Fine et al., 1990) 
51 DEB sporadic ND ND 
reduced AF. stellate 
inclusions within basal and 
suprabasal keratinocytes 
complete resolution  
 (Hashimoto et al., 
1989) 
52 DEB ND ND ND 
reduced AF. stellate 
inclusions within basal and 
suprabasal keratinocytes 
complete resolution  
 (Hashimoto et al., 
1989) 
53 BDN sporadic ND ND 
reduced AF. Dilated RER. 
Vacuoles containing 
electron dense amorphous 
material within basal 
keratinocytes 
complete resolution  
 (Hashimoto et al., 
1985) 
DEB, dystrophic epidermolysis bullosa, DDEB, dominant DEB; DDEB-pt, DDEB-pretibial; BDN, bullous dermolysis of the newborn; RDEB, recessive 
DEB; RDEB-I, RDEB-inversa, RDEB-O, RDEB-other; RDEB-sev gen, RDEB severe generalised; AD, autosomal dominant; AR, autosomal recessive; 
ND, not determined; AF, anchoring fibrils; RER, rough endoplasmic reticulum; BM, basement membrane.                                                                                                                                    
Note: the following mutations were found to result in intracytoplasmic retention of collagen VII in in vitro studies: p.Arg2008Gly (Hammami-Hauasli et 
al. J Biol Chem 1998; 273: 1928-1934, Chen et al. J Biol Chem 2002; 277: 2118-2124, Woodley et al. J Biol Chem 2008; 283: 17838-17845), 
p.Gly1776Arg (Fritsch et al. Biol Chem 2009; 284: 30248-30256), p.Gly2006Asp & p.Gly2015Glu (Bruckner-Tuderman et al. Matrix Biol. 1999; 18:43-
54, Fritsch et al. Biol Chem 2009; 284: 30248-30256), p.Gly2034Arg (Bruckner-Tuderman et al. Matrix Biol. 1999;18:43-54). 
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3.2 Patient selection and methods 
I reviewed the reports of 570 skin samples sent to the Robin Eady National 
Diagnostic Epidermolysis Bullosa Laboratory in London over a 10 year-period 
for the investigation of a possible subtype of EB. The population investigated 
included white Caucasians, Middle-Eastern, South-East Asian and Asian 
subjects. Immunofluorescence (IF) microscopy reports were examined from all 
cases demonstrating intra-epidermal collagen VII on IF microscopy. The 
ultrastructural findings were re-examined in those cases to review the 
anchoring fibrils and intracytoplasmic inclusions. The clinical information was 
obtained from the clinical notes where possible, details supplied with the 
original referral letters or the EB diagnostic lab logbook. Detailed follow up 
information was not available for some patients, particularly in historic cases 
and ones from overseas. Immunofluorescence studies, transmission electron 
microscopy and DNA sequencing analysis had been performed previously as 
described in Chapter 2. 
 
3.3 Results 
570 archival EB skin biopsy reports were reviewed and 
intracytoplasmic retention of collagen VII on immunofluorescence microscopy 
was documented in 35 cases (33 kindreds).  
Overall, several different patterns of collagen VII labelling were 
identified within the epidermis and along the basement membrane. The 
distribution of intra-epidermal collagen VII labelling ranged from basal only, 
basal and suprabasal to pan-epidermal and in the majority of cases the more 
focal intra-epidermal labelling was concentrated above the dermal papillae. 
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Furthermore, most cases demonstrated reduced levels of collagen VII 
expression along the DEJ, although labelling ranged from normal to 
completely absent.  
The first question was to ask what type(s) of EB the intra-epidermal 
collagen VII occurred in. Using a combination of IF microscopy, TEM, the 
clinical features and COL7A1 (and other) gene analysis, I was able to sub-
divide the 35 cases into 14 cases of BDN, 1 case of EB pruriginosa (EB-pr), 9 
cases of recessive dystrophic EB (RDEB), 4 cases of EB simplex (EBS), 4 
cases of junctional EB (JEB), 1 case of aplasia cutis congenita and 2 
undiagnosed cases. Full details are shown in Tables 3.3 and 3.4. Of note, these 
findings indicated that intra-epidermal collagen VII was not exclusive to BDN 
or even other variants of dystrophic EB.  
  I then assessed whether the intra-epidermal collagen VII appearances 
by IF microscopy alone represented a useful means of sub-classifying the 
diagnosis and prognosis (Figure 3.2). Of the 14 cases diagnosed as BDN, the 
intra-epidermal collagen VII labelling along the basal layer was focal in 13 
cases; in only 1 case was there a more diffuse staining appearance. In 10 cases 
the intra-epidermal labelling occurred in basal and suprabasal keratinocytes, 
whereas in the other 3 it was pan-epidermal (Figure 3.3). Clinically, 11 out of 
14 cases of BDN showed complete resolution of skin fragility as indicated by 
the clinician’s supplied information, while blistering improved but did not 
resolve completely in 3 cases (follow up information was available beyond 1 
year for 2 patients but only for 4 months in the 3rd case). With regards to 
prognosis in BDN, however, the IF microscopy appearances per se did not 
correlate with the final clinical outcome.  
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Next I examined whether any of the other non-BDN cases had intra-
epidermal collagen VII labelling patterns on IF that overlapped with the cases 
of BDN or if a complete distinction was possible (Figures 3.4 and 3.5). Based 
on the expression of collagen VII along the DEJ, non-EB cases had completely 
normal collagen VII immunostaining, whereas non-BDN cases of DEB showed 
variable levels of expression. DEB cases associated with absent collagen VII 
immunostaining or a moderate reduction of labelling in association with a loss 
of function mutation on both alleles developed RDEB-sev gen. on the other 
hand, cases with mild to moderate reduction generally developed BDN or 
RDEB-O depending on the degree of intra-epidermal expression of collagen 
VII. Generally, pan-epidermal retention of collagen VII was associated with a 
milder phenotype. This might indicate that the extent of intra-epidermal 
retention of collagen VII in BDN cases is sufficient to restore collagen VII 
expression as it is eventually secreted into the DEJ, whereas the level of 
retention is insufficient to normalize the severely reduced collagen VII 
expression in non-BDN cases. This would support observations that defective 
storage and delayed secretion/transport of collagen VII underlie the pathology 
in BDN rather than phagocytosis of collagen VII  (Smith and Sybert, 1990; 
Fine et al., 1993; Hammami-Hauasli et al., 1998b; Fassihi et al., 2006; Fassihi 
et al., 2005). 
Immunohistochemical and ultrastructural features typically associated 
with BDN were noted (Figure 3.1), including intracytoplasmic retention of 
collagen VII within the basal and suprabasal layers of the epidermis on 
immunofluorescence, as well as, dilated RER and peri-nuclear granular stellate 
bodies on electron microscopy. Although immunohistochemical variations 
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were noted (Figure 3.3) typical stellate bodies were identified in 7 out of 14 
cases of BDN (TEM was not performed in 4 cases). There were no clear 
immunohistochemical or ultrastructural differences in the cases of BDN that 
failed to have complete clinical resolution compared to those that resolved 
completely.  
On the other hand intracytoplasmic retention of collagen VII was 
associated with atypical inclusion bodies in other forms of DEB and non-DEB 
cases as well as normal skin, ranging from empty vacuoles to homogenous or 
granular inclusion bodies.  
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Figure 3.1 Classical immunohistochemical and ultrastructural 
features of BDN in a patient heterozygous for the COL7A1 splice site 
deletion mutation IVS73-3del6. (A) IF studies show collagen VII 
labelling at the DEJ (arrows) as well as intracytoplasmic retention of 
collagen VII within the basal and suprabasal layers of the epidermis. (B) 
TEM reveals dilated RER, and large peri-nuclear stellate bodies (asterix) 
containing granular inclusions. There is also a reduced number of 
anchoring fibrils beneath the lamina densa. Bars in a= 50 μm; bars in b= 
2.5 μm. 
 




Table 3.3 Molecular pathology, immunofluorescence and ultrastructural findings associated with cases of bullous dermolysis of the 
newborn identified in this study. 
No. Diagnosis 








Pattern of Collagen VII 
Staining 



















COL7A1  p.Gly1522Glu/-a E45 MS  AD 2m 
blistering 










































































COL7A1  IVS73-3del6/- I73 SS AD* 17d 
blistering 




















COL7A1  p.Gln2072Arg/- E74 MS AD 14d 
blistering 
improved but 














COL7A1  p.Gly2186Glu/-b E81 MS AD* 2m 
blistering 
ceased at 2m 
reduced, 
no blister 





dilated RER and 
typical granular 


































AR 5 days 
blistering 


















































present at 4m 
reduced, 
no blister 
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 *de novo; ND -not determined; EB, epidermolysis bullosa; DEB, dystrophic EB; DDEB, dominant DEB; BDN, bullous dermolysis of the newborn; RDEB, recessive DEB; 
DEJ, dermal-epidermal junction; IVS, intervening sequence (intron); MS, missense; PTC, premature termination codon; SS, splice site; AD, autosomal dominant; AR, 
autosomal recessive. a Three members of the same family (3 generations) Fassihi et al. Br J Dermatol. 2005; 153:1058-63; bAlmaani et al. Acta Derm Venereol. 
2011;91:262-6. 
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Figure 3.2 A schematic outlining a possible correlation between the 
patterns of immunofluorescence labelling and subsequent diagnosis in 
cases of intracytoplasmic retention of collagen VII. 
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Figure 3.3 immunohistochemical and ultrastructural appearances of BDN 
cases analysed in this study. Descriptive details of the DIF and TEM findings 
are presented in Table 3.3. IMF bars = 50 μm; TEM bars = 2.5 μm. 
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Pattern of Collagen VII 
Staining 
Ultrastructural findings on 
electron microscopy 


















ND ND ND ND ND No  normal 




2 RDEB-O COL7A1  
p.Gly1347Trp/ 
p.Gly1347Trp 
E34 MS/MS AR No 
reduced, 
maps to roof 
of blister 




3 RDEB-O COL7A1  
p.Gly1347Trp/ 
p.Gly1347Trp 
E34 MS/MS AR No 
reduced, 
maps to roof 
of blister 




4 RDEB-O COL7A1  
p.Gly1483Asp/ 
p.Gly1483Aspa 
E42 MS/MS AR No 
reduced, no 
blister 









5 RDEB-O COL7A1  
IVS55-1G>T/ 
IVS55-1G>T 
I55 SS/SS AR No 
reduced, 
maps to roof 
of blister 

















MS/SS AR No 
reduced, 
maps to roof 
of blister 




























PTC/PTC AR No 
reduced, 
maps to roof 
of blister 
















E61 MS/MS AR No 
reduced, 
maps to roof 
and base of 
blister 






























in basal layer  
Non-dystrophic epidermolysis bullosa  
11 EBS-DM KRT5 p.Glu477Lys E7 MS AD* No 
normal, 
maps to base 
of blister  




12 EBS-DM KRT14 p.Asn123Ser E1 MS AD* No 
normal, 
maps to base 
of blister  





13 EBS-DM KRT14 p.Arg125His E1 MS AD No 
normal, no 
blister 









bodies in  
basal layer. 
Dilated RER 
14 EBS KRT14 
c.1140-
1170dup31 
E6 PTC  AD No 
normal, no 
blister 















PTC/PTC AR No 
normal, 
maps to base 
of blister  




16 HJEB LAMA3 
p.Trp3241Stop/ 
p.Trp3241Stop 
E74 PTC/PTC AR No 
normal, 
maps to base 
of blister  




17 nHJEB LAMB3 
IVS8+1G>C/ 
p.Arg635Stop 
I8/E14 SS/PTC AR No 
normal, 
maps to base 
of blister  




18 HJEB LAMB3 
c.3162delG/ 
c.3162delG 
E21 PTC/PTC AR No 
normal, 
maps to base 
of blister  




19 aplasia cutis ND ND ND ND ND No 
normal, no 
blister 
generalised                           
basal/ 
suprabasal 













20 unknown ND ND ND ND ND No 
normal, no 
blister 
focal                                     
basal/   
suprabasal 
slight variation 










21 unknown ND ND ND ND ND No 
normal, no 
blister 
focal                                     
basal/   
suprabasal 







bold, novel mutations; ND -not determined; EB, epidermolysis bullosa; DEB, dystrophic EB; DDEB, dominant DEB; RDEB, recessive DEB; EB-pr, EB pruriginosa; 
RDEB-O, RDEB other; RDEB-sev gen,  RDEB severe generalised; EB-DM, EB Dowling Meara; EBS, EB simplex; HJEB, Herlitz junctional EB, nHJEB, non-Herlitz 
junctional EB; DEJ, dermal-epidermal junction; IVS, intervening sequence (intron); MS, missense; PTC, premature termination codon; RER, rough endoplasmic reticulum; 
SS, splice site; AD, autosomal dominant; AR, autosomal recessive. aAlmaani et al. Acta Derm Venereol. 2011;91:262-6. 
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Figure 3.4 Immunohistochemical and ultrastructural appearance of non-
BDN cases of DEB in which intra-epidermal collagen VII was detected in 
this study. Descriptive details of the DIF and TEM findings are presented in 















Figure 3.5 Immunohistochemical and ultrastructural appearances of non-
DEB cases that displayed intra-epidermal collagen VII in this study. 
Descriptive details of the DIF and TEM findings are presented in Table 3.4. 









Figure 3.6 Immunofluorescence and ultrastructural findings in 2 non-
BDN cases with intracytoplasmic retention of collagen VII. (A) In a case of 
RDEB-sev gen, basal and suprabasal retention of collagen VII is demonstrated 
on DIF. This is associated with typical perinuclear stellate bodies on TEM. (B) 
A case of aplasia cutis with intraepidermal retention of collagen VII on DIF 
and a large granular stellate body on TEM. This highlights that the presence of 
intracytoplasmic retention within the epidermis could occur in cases unrelated 




Although most reported cases of BDN improve clinically, not all cases 
demonstrate complete resolution of skin fragility, prompting the change of the 
original nomenclature from TBDN to BDN (Fine et al., 2008; Fine et al., 
1990). The data outlined above supports this, as 3 out of 14 cases of BDN did 
not show complete resolution of skin blistering. Moreover, although 
intracytoplasmic retention of collagen VII is classically associated with BDN, 
this study demonstrates that intra-epidermal collagen VII is not exclusive to 
cases of BDN, which only represented about one-third of cases in the studied 
cohort. In addition to the previously reported examples of non-BDN associated 
intra-epidermal collagen VII, this IF pattern was also noted in cases of EB 
simplex, junctional EB and 1 case of aplasia cutis. Precisely why this IF 
finding occurred in these cases, all of which lacked any primary pathology in 
collagen VII, is unclear although disruption of hemidesmosomes and/or the 
cytoskeleton could conceivably lead to secondary impairment of collagen VII 
transport and secretion from keratinocytes to basement membrane and, indeed, 
some degree of intra-epidermal collagen VII within basal keratinocytes has 
been noted in the majority of cases of JEB in which hemidesmosomes are 
fewer and hypoplastic (R. Eady and J. McGrath unpublished observations). It is 
worth noting that some technical and chronological factors might contribute to 
the presence or absence of intracytoplasmic collagen VII, including the stage at 
which the biopsy was taken, as well as, gestational age. Samples taken at a 
later stage of wound evolution and at an older gestational age are likely to be 
associated with a reduced expression of collagen VII perhaps relating to 
restoration of collagen VII expression as it is eventually secreted into the DEJ. 
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At a molecular level, intracytoplasmic accumulation of collagen VII has 
been largely associated with missense substitution mutations in the triple 
helical domain of collagen VII (Tables 3.1 and 3.2) (Hammami-Hauasli et al., 
1998b; Jonkman et al., 1999; Chen et al., 2002a; Sawamura et al., 2006a; 
Nakano et al., 2007). Notably, the missense mutations p.Gly2006Asp, 
p.Gly2034Arg, p.Gly2015Glu (Hammami-Hauasli et al., 1998b) and 
p.Arg2008Gly (Chen et al., 2002a) in exon 73 have been shown to interfere 
with collagen VII folding and secretion. In addition, confocal laser studies and 
semiquantitative immunoblotting determined that DEB keratinocytes retained 
up to 2.5-fold more procollagen VII within the rough endoplasmic reticulum 
than controls causing intracellular accumulation of mutant collagen VII 
molecules (Hammami-Hauasli et al., 1998b). This was also supported by in 
vitro studies demonstrating the effects of certain missense mutations on type 
VII procollagen assembly (p.Arg2622Gln and p.Gly2623Cys)  (Brittingham et 
al., 2005) and secretion (p.Arg2008Gly) (Chen et al., 2002a). In this study, 
cases with intracytoplasmic retention of collagen VII generally and BDN 
specifically demonstrated genetic heterogeneity (Table 3.3). Mutational 
analysis was performed on 30 out of 35 cases. Heterozygous mutations were 
demonstrated in 5 patients with BDN: p.Gly1522Glu, c.2021insG and IVS73-
3del6, illustrating a missense glycine substitution mutation, loss of function 
mutation and a splice site mutation respectively. 3 cases demonstrated 
recessive inheritance: p.Arg2008His/ p.Arg2008His, p.Gly2781Ser/ 
p.Arg1632Stop and p.Gly2372Val/ p.Gly2372Val. The majority of DEB cases 
with intracytoplasmic retention of collagen VII were due to heterozygous or 
homozygous GS mutations. However, there was no demonstrable genotype-
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phenotype correlation based on the nature and location of the GS mutations. 
With regards to the non-DEB cases, the clinical picture and underlying 
mutations were quite variable and the number of patients was too small to 
make a distinct correlation.   
However, I acknowledge that due to the retrospective nature of this 
study, detailed clinical information was not available for all cases resulting an 
element of ascertainment bias, for example, a case of mild-RDEB that could 
represent RDEB-BDN if followed up for a prolonged period of time. 
Longitudinal studies would overcome this limitation and would provide a more 
accurate measure of clinical outcome and genotype-phenotype correlation. 
Furthermore, BDN cases included in this study were selected retrospectively 
based on the presence of the intracytoplasmic collagen VII. This selection 
might have excluded genuine cases of BDN that lacked intraepidermal 
retention of collagen VII due to various reasons; including the age and wound 
stage at the time of skin sampling. 
Ultrastructurally, most reports of intracytoplasmic retention of collagen 
VII describe anchoring fibrils with reduced number and abnormal morphology, 
in addition to dilated RER. The stellate body which has been used as a proxy 
for BDN refers to dilated RER which have fused to form single cystic spaces or 
vacuoles containing electron dense amorphous material shown to represent 
collagen VII molecules (Hashimoto et al., 1985; Hashimoto et al., 1989; Fine 
et al., 1990). In this study the ultrastructural findings were quite variable. All 
cases showed some degree of RER dilatation particularly in basal 
keratinocytes. However, the nature of the intracytoplasmic bodies ranged from 
empty vesicles, homogenous inclusion bodies and the classical granular stellate 
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bodies. Although a few non-BDN cases showed some structures similar to the 
classical stellate bodies (Figure 3.6), this was only observed in cases of BDN, 
whereas the more homogenous inclusion bodies were observed in all other 
cases including BDN and normal skin and therefore, their significance is yet to 
be determined. Therefore, our findings show that in cases of intracytoplasmic 
retention of collagen VII, the presence of the typical stellate body represents a 
consistent discriminator between cases of BDN and non-BDN cases. However,  
its absence does not rule out BDN. 
Thus, the definition of the stellate body, which has been used 
synonymously with BDN, might be somewhat confusing and perhaps should 
be referred to as a variant of dilated RER. Furthermore, although TEM is a 
useful tool in assessing intra cytoplasmic retention of collagen VII, it is not 
widely available and requires experience and close analysis to visualize the 
classical stellate body. Numerous semithin sections are usually required to 
visualize these bodies and TEM correlation with IF would still be performed in 
all cases. In addition, other factors might influence the presence and abundance 
of intracytoplasmic inclusion bodies immunohistochemically and 
ultrastructurally including the time at which the biopsy was taken in relation to 
the onset of skin fragility, wound healing and technical factors relating to tissue 
staining. 
In conclusion, intracytoplasmic retention of collagen VII is not 
exclusive to cases of BDN and can be associated with DDEB, RDEB, JEB, 
EBS as well as normal skin. Thus the finding of intra-epidermal retention of 
collagen VII can have diverse diagnostic, phenotypic and prognostic 
implications. Immunofluorescence and electron microscopy studies can 
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potentially provide insight into future clinical outcome. In particular, the 
presence of the classical stellate body seems to represent a good discriminator 
between BDN and non-BDN cases as evidenced by its presence in BDN cases 
only. However, definitive diagnosis will always require molecular mutational 
































The spectrum of dominant and 
recessive glycine substitution 





DEB results from mutations in COL7A1 leading to structural or 
numerical disruption of anchoring fibrils at the basement membrane zone. This 
leads to loss of dermo-epidermal integrity with blistering beneath the lamina 
densa. Dominant forms of DEB usually result from heterozygous (dominant-
negative) glycine substitution (GS) mutations within the collagen VII triple 
helix. In contrast, recessive DEB is a consequence of nonsense, frameshift or 
splice site mutations on both COL7A1 alleles. However, some cases of 
recessive DEB also involve GS mutations which are usually silent when 
inherited on one allele, but pathogenic when inherited on both alleles or in 
trans with another loss-of-function mutation. This poses a challenge when 
trying to differentiate between dominant and recessive cases of DEB with 
important implications on diagnosis and genetic counselling. In addition, some 
unusual phenotype-genotype patterns add to the diagnostic dilemmas including 
some GS mutations resulting in both dominant and recessive DEB. Also, the 
same GS mutation can result in variable disease expression that can range from 
normal skin, to nail dystrophy alone or widespread skin fragility. In this study, 
I report 25 novel dominant and 15 novel recessive COL7A1 GS mutations 
underlying DEB, including 4 that result in both dominant and recessive 
disease. These findings highlight phenotypic and genotypic heterogeneity 






Fibrillar and non-fibrillar collagens are formed of 3 distinct α- 
polypeptide chains that are characterised by a high glycine index due to a 
repeated Gly-X-Y triplet sequence within the central collagenous domain. This 
sequence is uninterrupted in fibrillar collagens such as collagen I, whereas 
there are interruptions within non-fibrillar collagens including collagen VII that 
confer flexibility to the suprastructural conformation but also increase its 
susceptibility for non-specific protease degradation. As mentioned in Chapter 
1, the collagen VII central collagenous domain contains 19 non-collagenous 
interruptions, including the ‘hinge region’, which is thought to confer 
flexibility necessary for collagen VII suprastructural folding (Christiano et al., 
1994c; Christiano et al., 1994b; Chung and Uitto, 2010). The central 
collagenous domain is flanked by the NC1 domain, which is thought to affect 
collagen VII attachment to the BMZ  (Chen et al., 2001) and the NC2 domain, 
that contains highly conserved cysteine residues and has been found to initiate 
the assembly of collagen VII triple helices and formation of anti-parallel 
dimers (Chen et al., 2001). 
Integral to the collagen VII suprastructure is glycine, the smallest 
amino acid that is positioned towards the core of the triple helix, whereas the X 
and Y motifs are aligned at the surface of the helical collagen VII structure. As 
a result, any disruption to the glycine residue or substitution with a bulkier 
amino acid is likely to result in abnormal triple-helical conformation and 
subsequent clinical pathology (Prockop and Kivirikko, 1995; Myllyharju and 
Kivirikko, 2004; Myllyharju and Kivirikko, 2001; Boot-Handford and 
Tuckwell, 2003). This is supported by results showing that any type of GS is 
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capable of causing disease (Persikov et al., 2004), reflecting the disruptive and 
destabilising effects on the collagen VII triple helix as well as the extent of 
evolutionary conservation at the Gly positions (Kivirikko et al., 1996). 
However, although any GS mutation can cause pathology, there is vast 
genotype and phenotype heterogeneity.  
Around 140 COL7A1 GS mutations have been reported in the literature 
(Figure 4.1). Dominant forms of DEB usually result from heterozygous 
(dominant-negative) GS mutations within the collagen VII triple helix. In 
contrast, recessive DEB is a consequence of nonsense, frameshift or splice site 
mutations on both COL7A1 alleles (Uitto et al., 1994; Whittock et al., 1999; 
Dang and Murrell, 2008) but can result from GS mutations which are usually 
silent when inherited on one allele, but pathogenic when inherited on both 
alleles or in trans with another loss-of-function mutation (Shimizu et al., 1996; 
Uitto et al., 1994). In addition, some unusual phenotype-genotype patterns add 
to the diagnostic dilemmas including some GS mutations resulting in both 
dominant and recessive DEB (Christiano et al., 1996a; Hammami-Hauasli et 
al., 1998a; Shimizu et al., 1999; Lee et al., 2000; Sato-Matsumura et al., 2002; 
Varki et al., 2007; Murata et al., 2000; Nakamura et al., 2004; Dang et al., 
2007; Sambrook et al., 2001; Christiano et al., 1997b). Furthermore, the same 
GS mutation can result in a variable disease expression that can range from 
normal skin or nail dystrophy alone to widespread skin fragility (Lee et al., 
2000; Murata et al., 2000; Varki et al., 2007). 
 
The aim of this Chapter is to explore the nature of GS mutations in the 
collagen VII gene, their functional effects as well as potential factors 
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Figure 4.1 A schematic outlining the position of GS mutations within the COL7A1 triple helix. Novel dominant 
and recessive mutations identified in this study are highlighted in red and blue respectively. Mutations that result in 









For this study I collected and evaluated DNA mutation analysis data 
retrospectively, via the Robin Eady National Diagnostic Epidermolysis Bullosa 
Laboratory database in London. Blood samples from patients with clinically 
suspected or histologically proven DEB (and their parents if available), were 
provided historically by local, national and international referrers. Patient 
ethnicities included white Caucasian, Middle-Eastern, South American, South-
East Asian and Asian. Prior to my work on this thesis, the DNA extraction and 
COL7A1 mutation analysis had been performed by Dr. Lu Liu at the Robin 
Eady National Diagnostic Epidermolysis Bullosa Laboratory, as part of the 
patients’ routine clinical care in most cases. However, for individuals linked to 
separate research projects, DNA screening was undertaken with Ethics’ 
Committee approval (St Thomas’ Hospital Ethics’ committee; 07/H0802/104) 
with informed consent and carried out in accordance with the Declaration of 
Helsinki principles. DNA extraction and sequencing was performed as 
discussed in Chapter 2. 
 
4.3 Results  
The COL7A1 gene was sequenced in >200 individuals with different 
forms of DEB leading to the identification of 46 new glycine substitution 
mutations resulting in either dominant DEB (n=31; p.Gly1483Asp, 
p.Gly1649Arg, p.Gly1734Asp, p.Gly1755Val, p.Gly1764Asp, p.Gly1770Ser, 
p.Gly1770Asp, p.Gly1773Asp, p.Gly1776Glu, p.Gly1860Arg, p.Gly1913Arg, 
p.Gly2003Glu, p.Gly2009Ala, p.Gly2028Glu, p.Gly2046Asp, p.Gly2067Ala, 
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p.Gly2159Glu, p.Gly2186Glu, p.Gly2213Arg, p.Gly2227Arg, p.Gly2233Glu, 
p.Gly2239Val, p.Gly2260Asp, p.Gly2290Ala, p.Gly2360Arg, p.Gly2428Asp, 
p.Gly2508Asp, p.Gly2517Asp, p.Gly2680Asp, p.Gly2722Arg, p.Gly2743Arg) 
(Table 4.1) or recessive DEB (n=15; p.Gly174Arg, p.Gly1338Arg, 
p.Gly1483Asp, p.Gly1572Ala, p.Gly1770Ser, p.Gly1851Glu, p.Gly1940Asp, 
p.Gly2213Arg, p. Gly2221Arg, p.Gly2272Ala, p.Gly2369Ser, p.Gly2372Val, 
p.Gly2375Ser, p.Gly2620Val, p. Gly2781Arg)  (Table 4.2).  
Four of these novel GS mutations in COL7A1 (p.Gly1483Asp, 
p.Gly1770Ser, p.Gly2213Arg and p.Gly2369Ser) were also noted to function 














cDNA   Reference 
DDEB-BDN 42 p.Gly1483Asp c.4448G>A This Study 
DDEB 45 p.Gly1522Glu c.4565G>A  (Whittock et al., 1999) 
DDEB-gen 48 p.Gly1557Arg c.4669G>A  (Christiano et al., 1996a) 
DDEB-na 50 p.Gly1595Arg c.4783G>C  (Sato-Matsumura et al., 2002) 
DDEB-gen 53 p.Gly1649Arg c.4945G>C This Study 
DDEB-pr                    
DDEB-gen 
56 p.Gly1700Asp c.5099G>A  (Deng et al., 2008) 
DDEB-gen 58 p.Gly1734Asp c.5201G>A This Study 
DDEB-pr 59 p.Gly1755Asp* c.5264G>C  (Posteraro et al., 2005) 
DDEB-gen 59 p.Gly1755Val c.5264G>T This Study 
DDEB-gen 60 p.Gly1764Asp c.5291G>A This Study 
DDEB-na/                 
DDEB-pt 
61 p.Gly1770Ser c.5308G>A This Study 
DDEB-pr 61 p.Gly1770Asp c.5309G>A This Study 
DDEB-gen 61 p.Gly1773Asp c.5318G>A This Study 
DDEB 61 p.Gly1776Arg c.5326G>A  (Whittock et al., 1999) 
DDEB-gen 61 p.Gly1776Trp* c.5326G>T  (Bursztejn et al., 2008) 
DDEB-gen 61 p.Gly1776Glu c.5327G>A This Study 
DDEB-pr 61 p.Gly1791Glu c.5372G>A  (Mellerio et al., 1999) 
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DDEB-na 63 p.Gly1815Arg c.5443G>A  (Sato-Matsumura et al., 2002) 
DDEB-pr 66 p.Gly1860Arg c.5578G>A This Study 
DDEB-pr 69 p.Gly1913Arg c.5737G>C  This Study 
DDEB-gen 73 p.Gly2003Arg c.6007G>A   (Christiano et al., 1996b) 
DDEB-gen 73 p.Gly2003Glu c.6008G>A This Study 
DDEB-gen 73 p.Gly2006Ser* c.6016G>A  (Mallipeddi et al., 2003) 
DDEB-gen 73 p.Gly2006Asp c.6017G>A  (Hammami-Hauasli et al., 1998b) 
DDEB 73 p.Gly2006Ala c.6018G>C  (Whittock et al., 1999) 
DDEB-gen 73 p.Gly2009Ala c.6026G>C This Study 
DDEB 73 p.Gly2012Ser* c.6034G>A  (Gardella et al., 2002) 
DDEB-gen 73 p.Gly2012Asp* c.6035G>A  (Matsuba et al., 2002) 
DDEB-gen 73 p.Gly2015Glu c.6044G>A  (Hammami-Hauasli et al., 1998b) 
DDEB-gen 73 p.Gly2028Arg c.6082G>A  (Lee et al., 2000) 
DDEB-gen 73 p.Gly2028Trp c.6082G>T  (Varki et al., 2007) 
DDEB-gen 73 p.Gly2028Ala c.6083G>C  (Murata et al., 2000) 
DDEB-gen 73 p.Gly2028Glu c.6083G>A This Study 
DDEB-gen 73 p.Gly2034Arg c.6100G>A  (Kon et al., 1997a) 
DDEB-gen 73 p.Gly2034Trp c.6100G>T  (Rouan et al., 1998) 
DDEB 73 p.Gly2034Glu c.6101G>A  (Kern et al., 2006) 
DDEB-gen 73 p.Gly2037Arg c.6109G>A  (Iwata et al., 2006) 
DDEB-gen 73 p.Gly2037Glu c.6110G>A  (Jonkman et al., 1999) 
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DDEB-gen 73 p.Gly2040Ser c.6118G>A  (Christiano et al., 1994d) 
DDEB 73 p.Gly2040Asp c.6119G>A  (Whittock et al., 1999) 
DDEB-gen 73 p.Gly2040Val* c.6119G>T  (Rouan et al., 1998) 
DDEB 73 p.Gly2043Arg* c.6127G>A  (Christiano et al., 1995b) 
DDEB-gen 73 p.Gly2043Trp* c.6127G>T  (Mecklenbeck et al., 1999) 
DDEB 73 p.Gly2046Val c.6137G>T  (Whittock et al., 1999) 
DDEB-gen 73 p.Gly2046Asp c.6137G>A This Study 
DDEB-gen 73 p.Gly2055Glu c.6164G>A  (Christiano et al., 1996a) 
DDEB-pt 73 p.Gly2059Glua c.6137G>Ab  (Hamada et al., 2009) 
DDEB-gen 74 p.Gly2061Val c.6182G>T  (Escamez et al., 2010) 
DDEB-gen 74 p.Gly2064Arg c.6190G>A  (Rouan et al., 1998) 
DDEB-gen 74 p.Gly2064Val c.6191G>T  (Kern et al., 2009a) 
DDEB 74 p.Gly2064Glu c.6191G>A  (Sawamura et al., 2005) 
DDEB 74 p.Gly2067Arg* c.6199G>A  (Posteraro et al., 2005) 
DDEB-gen 74 p.Gly2067Ala c.6200G>C This Study 
DDEB-gen 74 p.Gly2070Arg c.6208G>A  (Zhang et al., 2003) 
DDEB 74 p.Gly2070Glu c.6209G>A  (Gardella et al., 2002) 
DDEB-pr 75 p.Gly2073Val c.6218G>T  (Drera et al., 2006) 
DDEB-gen 75 p.Gly2076Asp* c.6227G>A  (Kon et al., 1997a) 
DDEB 75 p.Gly2079Arg c.6235G>A  (Christiano et al., 1999) 
DDEB-gen 75 p.Gly2079Glu* c.6236G>A  (Kon et al., 1997a) 
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DDEB-gen 75 p.Gly2079Val c.6236G>T  (Kern et al., 2009a) 
DDEB-pr 79 p.Gly2159Glu c.6476G>A This Study 
DDEB-BDN 81 p.Gly2186Glu c.6557G>A This Study 
DDEB-gen 83 p.Gly2207Arg c.6619G>A  (Kon et al., 1997a) 
DDEB-gen 83 p.Gly2210Val c.6629G>T  (Dang et al., 2007) 
DDEB-pr 83 p.Gly2213Arg c.6637G>A This Study 
DDEB-gen 84 p.Gly2227Arg c.6679G>A This Study 
DDEB-gen 84 p.Gly2230Glu c.6689G>A  (Kern et al., 2009a) 
DDEB-pr 84 p.Gly2233Glu c.6698G>A This Study 
DDEB-pr 85 p.Gly2239Asp c.6716G>A  (Tamai et al., 1998) 
DDEB-pr 85 p.Gly2239Val c.6716G>T This Study 
DDEB-pr 85 p.Gly2242Arg c.6724G>A  (Lee et al., 1997) 
DDEB-pr 85 p.Gly2242Trp c.6724G>T (Shi and Feng, 2009) 
DDEB-pr 85 p.Gly2242Glu c.6725G>A  (Tamai et al., 1998) 
DDEB-na 86 p.Gly2251Glu c.6752G>A  (Hammami-Hauasli et al., 1998a) 
DDEB-gen 86 p.Gly2260Asp c.6779G>A This Study 
DDEB-na 87 p.Gly2287Arg c.6859G>A  (Shimizu et al., 1999) 
DDEB 87 p.Gly2287Val c.6860G>T  (Posteraro et al., 2005) 
DDEB-pr 87 p.Gly2290Ala c.6869G>C This Study 
DDEB-gen 91 p.Gly2347Arg * c.7042G>C  (Cserhalmi-Friedman et al., 1999) 
DDEB-gen 91 p.Gly2351Arg c.7051G>A  (Christiano et al., 1996a) 
 121 
DDEB-pr 92 p.Gly2360Arg c.7078G>A This Study 
DDEB-pr 92 p.Gly2366Val c.7097G>T  (Chuang et al., 2004) 
DDEB-pr 93 p.Gly2369Ser c.7105G>A  (Mellerio et al., 1999) 
DDEB-gen 95 p.Gly2428Asp* c.7283G>A This Study 
DDEB-gen 95 p.Gly2434Arg c.7300G>A  (Cuadrado-Corrales et al., 2009) 
DDEB-pr 100 p.Gly2508Asp c.7523G>A This Study 
DDEB-pr 100 p.Gly2517Asp c.7550G>A This Study 
DDEB-pt 105 p.Gly2623Cys c.7867G>T  (Christiano et al., 1995a) 
DDEB-pr 105 p.Gly2623Val* c.7868G>T  (Schumann et al., 2008) 
DDEB-pr 106 p.Gly2626Asp c.7877G>A  (Wang et al., 2007) 
DDEB 106 p.Gly2632Arg c.7894G>A  (Posteraro et al., 2005) 
DDEB-pr 108 p.Gly2680Asp c.8039G>A This Study 
DDEB-pr 110 p.Gly2713Arg c.8137G>C  (Mellerio et al., 1999) 
DDEB-gen 110 p.Gly2713Asp c.8138G>A  (Rouan et al., 1998) 
DDEB-pr 110 p.Gly2719Asp c.8156G>A  (Riedl et al., 2009) 
DDEB-gen 110 p.Gly2722Arg c.8164G>C  This Study 
DDEB-gen 110 p.Gly2743Arg c.8227G>C This Study 
DDEB: dominant dystrophic epidermolysis bullosa; DDEB-BDN: bullous dermolysis of the newborn; DDEB-gen: 
generalized; DDEB-na: nail atrophy; DDEB-pr: pruriginosa; DDEB-pt: DDEB-pretibial; MS: missense; bold: new 
mutations. * de novo mutations. ap.Gly2059Glu, bc.6137G>A but corrected nomenclature should be: p.Gly2058Glu, 
c.6173G>A respectively. 
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Table 4.2 Novel and reported recessive GS mutations in the collagen VII gene. 







cDNA Type Protein Reference 
RDEB-O 4 p.Gly150Arg c.448G>A IVS5 c.682+1G>A SS 
predicted retention 
of intron 5 + 
p.Pro228fsX32 
 (Drera et al., 2009) 
RDEB-sev 
gen 
4 p.Gly174Arg c.520G>A 4 c.520G>A GSa p.Gly174Arg This study 
RDEB-O 32 p.Gly1314Arg c.3940G>A 78 c.6422delG PTC p.G2141EfsX64  (Kern et al., 2009a) 
RDEB 33 p.Gly1332Asp c.3995G>A ND ND ND ND  (Garcia et al., 2009) 
RDEB-O 34 p.Gly1338Arg c.4012G>A IVS34 c.4048-1G>A SS 
Predicted skipping 
of exon 35 (in-
frame; 24aa) 




34 p.Gly1338Val c.4013G>Tb ND ND ND ND  (Dang et al., 2007) 
RDEB-O 34 p.Gly1347Arg c.4039G>C 70 c.5820G>A  SS 
Predicted skipping 
of exon 70 (in-
frame; 16aa) 
 (Terracina et al., 1998) 
RDEB-O 34 p.Gly1347Trp c.4039G>T IVS30  c.3832-2A>G SS in-frame deletion  (Kern et al., 2006) 
RDEB-O 36 p.Gly1383Arg c.4147G>A 80 c.6527insC PTC p.Pro2176fsX113  (Escamez et al., 2010) 
RDEB-O 42 p.Gly1483Asp c.4448G>A 42 c.4448G>A GS  p.Gly1483Asp This study 




44 p.Gly1519Asp c.4556G>A 86 c.6752G>A GS p.Gly2251Glu  
 (Hammami-Hauasli et al., 
1998a) 
RDEB-O 45 p.Gly1522Arg c.4564G>C ND ND ND ND  (Kern et al., 2006) 
RDEB-pr 48 p.Gly1572Ala c.4715G>C 104 c.7786delG PTC p.Gly2596fsX49 This study 
RDEB-O 50 p.Gly1595Arg c.4783G>C 115 c.8479C>T PTC p.Gln2827Stop 
 (Sato-Matsumura et al., 
2002) 
RDEB-O 50 p.Gly1604Arg c.4810G>A 72 c.5964insC PTC p.Gly1988fsX110  (Whittock et al., 1999) 
RDEB-O 51 p.Gly1616Arg c.4846G>A 51 c.4846G>A GS p.Gly1616Arg  (Kern et al., 2006) 
RDEB-O 53 p.Gly1652Arg c.4954G>A 3 c.425A>G SS p.Lys142Arg 
 (Cserhalmi-Friedman et 
al., 1997) 
RDEB-O 53 p.Gly1655Gly c.4965C>Tb 74  c.6187C>T MS p.Arg2063Trp  (Gardella et al., 2002) 
RDEB-O 54 p.Gly1664Ala c.4991G>C 54 
c.4991G>C or           
c.497insA or            
c.425A>G         
GS                  
PTC                
SSc 
p.Gly1664Ala                               
p.Gln166fsX51                                  
p.Lys142Arg 
 (Gardella et al., 2002) 
RDEB-O 54 p.Gly1673Arg c.5017G>A ND ND ND ND  (Dang et al., 2007) 
RDEB-O 56 p.Gly1696Glud c.5090G>A 84 c.6691insC PTC p.Pro2231fsX58  (Salas-Alanis et al., 2000) 
RDEB-O 56 p.Gly1703Glu c.5108G>A 69 c.5772delG PTC  p.Glu1924fsX50  (Whittock et al., 1999) 
RDEB-O 58 p.Gly1719Arg c.5155G>C 58 c.5155G>C  GS p.Gly1719Arg  (Kern et al., 2006) 
RDEB-sev 
gen 
61 p.Gly1770Ser c.5308G>A 61 c.5308G>A GSe p.Gly1770Ser This study 
RDEB-O 61 p.Gly1782Arg c.5344G>A 73 c.6081delC PTC  p.Pro2027fsX178  (Christiano et al., 1996a) 
RDEB 61 p.Gly1782Val c.5345G>T 3 c.425A>G SSc p.Lys142Arg  (Kern et al., 2006) 
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RDEB-O 63 p.Gly1812Arg c.5434G>C 31 c.3857delA   PTC  p.Gln1286fsX38  (Masunaga et al., 2000) 
RDEB-O 63 p.Gly1815Arg c.5443G>A 70 c.5818delC PTC p.Pro1940fsX64 
 (Sato-Matsumura et al., 
2002) 
RDEB-O 65 p.Gly1845Arg c.5533G>A 3 c.425A>G SSc p.Lys142Arg  (Jerabkova et al., 2010) 
RDEB-sev 
gen 
66 p.Gly1857Glu c.5570G>A 66 c.5570G>A GS p.Gly1857Glu  (Kern et al., 2009a) 
RDEB-i 68 p.Gly1907Glu c.5720G>A 105 c.7805G>A GS p.Gly2602Glu 
 (van den Akker et al., 
2009) 
RDEB-i 68 p.Gly1907Asp 
c.5720-21 
GA>AT 
54 c.5047C>T PTC p.Arg1683Stop This study 
RDEB-O 68 p.Gly1907Aspf c.5723G>A 
13                               
76 
c.1732C>T or           
c.6311del2 
PTC                             
PTC 
p.Arg578Stop                                                  
p.Ser2104fsX11 
 (Varki et al., 2007) 
RDEB-
BDN 
68 p.Gly1910Ser c.5728G>A IVS5 c.682+1G>A SS 
predicted retention 
of intron 5 + 
p.Pro228fsX32 
 (Hashikawa et al., 2009) 
RDEB-sev 
gen 
72 p.Gly1982Trp c.5944G>T 5 c.553C>T PTC p.Arg185Stop  (Hovnanian et al., 1997) 
RDEB-O 72 p.Gly1982Glu c.5945G>A 12 c.1573C>T PTC p.Arg525Stop This study 
RDEB-O 73 p.Gly2009Arg c.6025G>A 115 c.8523del14 SS 
predicted skipping 
of exon 115 (in-
frame; 29aa) 
 (Winberg et al., 1997) 
RDEB 73 p.Gly2025Ser c.6073G>A ND ND ND ND  (Pfendner et al., 2003) 
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RDEB-O 73 p.Gly2025Ala c.6074G>C 105 c.7828C>A PTC p.Arg2610Stop  (Hovnanian et al., 1997) 
RDEB-O 73 Gly2028Trp 6082G>T 117 8698del11 PTC p.Ser2900fsX19  (Varki et al., 2007) 
RDEB- sev 
gen 
73 p.Gly2028Arg c.6082G>A 13 c.1661del57  PTC NR  (Varki et al., 2007) 
RDEB- sev 
gen 
73 p.Gly2031Ser c.6080G>Ag 73 c.6080G>A  GS p.Gly2031Ser  (Nordal et al., 2001) 
RDEB-sev 
gen 
73 p.Gly2049Glu c.6146G>A 34 c.4027C>T PTC p.Arg1343Stop  (Hovnanian et al., 1997) 
RDEB-O 73 p.Gly2058Ala c.6173G>C 102 c.7621C>T PTC p.Arg2541Stop  (Kern et al., 2009a) 
RDEB-sev 
gen 
74 p.Gly2061Glu c.6182G>A IVS116 c.8620+26G>A SS ND (Chao and Lee, 2007) 
RDEB-O 75 p.Gly2073Asp* c.6218G>A 13 c.1732C>T PTC p.Arg578Stop  (Dunnill et al., 1996) 
RDEB-i 75 p.Gly2088Arg c.6262 G>A 5 c.676 C>T PTC p.Arg226Stop  (Chiaverini et al., 2010) 
RDEB-O 75 p.Gly2088Glu c.6263G>A 116 c.8569G>T PTC p.Glu2857Stop  (Suzuki et al., 2006) 
RDEB-O 78 p.Gly2132Ser c.6394G>A IVS5 c.682+1G>A SS 
predicted retention 
of intron 5 + 
p.Pro228fsX32 
 (Kern et al., 2009a) 
RDEB-O 78 p.Gly2132Asp c.6395G>A 58 c.5188C>T PTC p.Arg1730Stop  (Whittock et al., 1999) 
RDEB-O 82 p.Gly2192Ser c.6574G>A 73 c.6081delC PTC p.Pro2027fsX178  (Whittock et al., 1999) 
RDEB-sev 
gen 




83 p.Gly2210Val c.6629G>T 113 c.8371C>T MS p.Arg2791Trp  (Varki et al., 2007) 
RDEB-O 83 p.Gly2213Arg c.6637G>A 52 c.4918delG PTC p.Gly1640fsX69 This study 
RDEB-O 84 p.Gly2221Arg c.6661G>A 49 c.4748delG PTC p.Gly1583fsX126 This study 
RDEB-O 84 p.Gly2221Ala c.6662G>C IVS106 c.7930-1G>C SS 
predicted skipping 
of exon 106 (in-
frame, 18aa) 
 (Escamez et al., 2010) 
RDEB-O 84 p.Gly2233Cys c.6697G>T 84 c.6695C>G MS p.Pro2232Arg  (Ryoo et al., 2001) 




p.Gly2251Ala/                           
p.P1458L 
c.6752G>C 103 c.7723G>A GS p.Gly2575Arg  (Varki et al., 2007) 
RDEB-
BDN 
86 p.Gly2251Glu c.6752G>A 44 c.4556G>A GS p.Gly1519Asp 
 (Hammami-Hauasli et al., 
1998a) 
RDEB-O 86 p.Gly2263Val c.6788G>T 13 c.1732C>T PTC p.Arg578Stop  (Whittock et al., 1999) 
RDEB-O 86 p.Gly2272Ala c.6815G>C 21 ND ND ND This study 
RDEB-O 87 p.Gly2287Arg c.6859G>A 89 c.6946G>A GS p.Gly2316Arg   (Shimizu et al., 1999) 
RDEB-O 87 p.Gly2296Glu c.6887G>A 12 c.1573C>T PTC p.Arg525Stop  (Jerabkova et al., 2010) 
RDEB-O 89 p.Gly2316Arg  c.6946G>A 87 c.6859G>A GS p.Gly2287Arg  (Shimizu et al., 1999) 
RDEB-sev 
gen 
91 p.Gly2351Arg c.7051G>A 56 c.5103delCCinsG PTC  p.Gly1701fsX8  (Christiano et al., 1996a) 
RDEB-O 92 p.Gly2357Ser c.7069G>A ND ND ND ND  (Varki et al., 2007) 
RDEB-O 92 p.Gly2357Arg c.7069G>C IVS64 c.5487+4delAGTG PTC  in-frame deletion This study 
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RDEB-O 92 p.Gly2366Cys c.7096G>T 70 c.5818delC PTC  p.Pro1940fsX64  (Sawamura et al., 2005) 
RDEB-O 92 p.Gly2366Ser c.7096G>A 74 c.6187C>T MS p.Arg2063Trp  (Hashimoto et al., 1999) 
RDEB-sev 
gen 
92 p.Gly2366Asp c.7097G>A 80 c.6527insC PTC p.Prol2176fsX113  (Escamez et al., 2010) 
RDEB-sev 
gen 
93 p.Gly2369Ser c.7105G>A 93 c.7105G>A GS p.Gly2369Ser This study 
RDEB-
BDN 
93 p.Gly2372Val c.7115G>T 9 c.7115G>T GS p.Gly2372Val This study 
RDEB-sev 
gen 
93 p.Gly2375Serh NR 55 c.5097G>A SS in-frame deletion  (Fassihi et al., 2006) 
RDEB-sev 
gen 
94 p.Gly2395Asp c.7184G>A 2 c.154delG del in frame deletion  (Mayama et al., 1999) 
RDEB-O 94 p.Gly2413Arg c.7237G>A 20 c.2699G>A PTC p.Trp900Stop 
 (van den Akker et al., 
2009) 
RDEB 94 p.Gly2413Glu 7238G>A 3 c.425A>G SSc p.Lys142Arg  (Kern et al., 2006) 
RDEB-O 94 p.Gly2422Val 7265G>T 94 c.7265G>T GS p.Gly2422Val  (Kraemer et al., 2006) 
RDEB-O 95 p.Gly2434Arg 7300G>A 80 c.6527insC PTC p.Prol2176fsX113  (Escamez et al., 2010) 
RDEB-sev 
gen 
96 p.Gly2449Arg c.7345G>A 96 c.7345G>A GS p.Gly2449Arg  (Kern et al., 2009a) 
RDEB-i 97 p.Gly2472Asp c.7415G>A 14 c.1874del2 PTC p.Ser625fsX4  (Chiaverini et al., 2010) 
RDEB-pt 101 p.Gly2520Val c.7559G>T 110 c.8209G>C GS p.Gly2737Arg  (Escamez et al., 2010) 




102 p.Gly2557Arg c.7669G>A 34 c.4027C>T PTC p.Arg1343Stop  (Jerabkova et al., 2010) 
RDEB-O 103 p.Gly2569Arg c.7705G>C 103 c.7705G>C GS p.Gly2569Arg  (Christiano et al., 1996a) 
RDEB-O 103 p.Gly2569Ser c.7705G>A 6 c.846+1G>A SS 
predicted skipping 
of exon 6 (in-
frame; 55aa) 
 (Kern et al., 2009a) 
RDEB-O 103 p.Gly2576Argi c.7723G>A 116 c.8569G>T PTC p.Glu2857Stop  (Shimizu et al., 1996) 
RDEB-sev 
gen 
104 p.Gly2587Asp c.7760G>A 80 c.6527insC PTC p.Prol2176fsX113  (Escamez et al., 2010) 
RDEB-O 104 p.Gly2590Asp c.7769G>A 33 c.4011G>A SS p.Pro1337Pro 
 (van den Akker et al., 
2009) 
RDEB-i 105 p.Gly2602Glu c.7805G>A 68 c.5720G>A GS p.Gly1907Glu 
 (van den Akker et al., 
2009) 
RDEB-O 105 p.Gly2620Val c.7859G>T 105 c.7864C>T MS p.Arg2622Trp This study 
RDEB-O 105 p.Gly2623Ser c.7867G>A 70 c.5818delC PTC p.Pro1940fsX64  (Sawamura et al., 2006a) 
RDEB-O 107 p.Gly2653Arg c.7957G>A 97 c.7411C>T PTC p.Arg2471Stop  (Christiano et al., 1996a) 
RDEB-pr 107 p.Gly2656Val c.7967G>T 65 c.5564ins28   PTC p.Arg1855fsX34 This study 
RDEB-sev 
gen 
108 p.Gly2671Val c.8012G>T 108 c.8012G>T GS p.Gly2671Val  (Kon et al., 1997a) 
RDEB-sev 
gen 
108 p.Gly2674Arg c.8020G>C 79 c.6501G>A SS in-frame deletion  (Christiano et al., 1996a) 
RDEB-O 108 p.Gly2674Asp c.8021G>A 13 c.1732C>T PTC p.Arg578Stop  (Whittock et al., 1999) 
RDEB-O 109 p.Gly2689Arg c.8065G>A 80 c.6527insC PTC p.Prol2176fsX113  (Kern et al., 2006) 




110 p.Gly2719Ala c.8156G>C ND ND ND ND  (Fassihi et al., 2006) 
RDEB 110 p.Gly2737Arg c.8209G>C ND ND ND ND  (Kern et al., 2006) 
RDEB-sev 
gen 
110 p.Gly2740Ala c.8219G>C 104 c.7786delG PTC  p.Gly2596fsX49  (Whittock et al., 1999) 
RDEB-sev 
gen 
111 p.Gly2749Arg c.8245G>A 111 c.8245G>A GS p.Gly2749Arg  (Christiano et al., 1996a) 
RDEB-O 112 p.Gly2775Ser c.8323G>A 3 c.425A>G SSc p.Lys142Arg  (Kon et al., 1998) 
RDEB-
BDN 
112 p.Gly2781Arg c.8341G>A 51 c.4894C>T PTC p.Arg1632Stop This study 
 
RDEB: recessive dystrophic epidermolysis bullosa; RDEB-sev gen: severe generalized; RDEB-O: other; RDEB-BDN: bullous dermolysis of the newborn; 
RDEB-na: nail dystrophy; RDEB-pr: pruriginosa; RDEB-i: inversa; GS: glycine substitution; IVS, intervening sequence (intron); MS: missense; N: normal; 
PTC: premature termination codon; ND: not determined; NR: not recorded; SS: splice site; bold: new mutations. * de novo mutations. awithin donor splice 
site consensus sequence, bresults in a premature termination codon; cresults in the loss of a StyI restriction site with various mRNA isoforms (Gardella et al. 
Am J Hum Genet 1996; 59: 292-300); ewithin acceptor splice site consensus sequence; corrections: dp.Gly1696Glu,  fp.Gly1907Asp, gc.6080G>A,  




Figure 4.2 GS mutations with both dominant and recessive inheritance patterns. 
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4.3.1 The phenotype expression variability of the mutation p.Gly1483Asp  
The p.Gly1483Asp mutation (c.4448G>A) leads to BDN, mild 
localised DDEB or no phenotype when inherited on one allele; but results in 
mild RDEB when inherited on both alleles as detailed below (Figure 4.3). 
BDN was diagnosed in a 7-year-old Kuwaiti female whose parents 
were first cousins. She developed generalised blistering at birth, which healed 
with minimal scarring and a few milia. However, the frequency of blistering 
decreased with age and had completely ceased by the age of 4 months 
suggestive of a diagnosis of BDN. She was found to be heterozygous for the 
GS mutation p.Gly1483Asp.  
A homozygous p.Gly1483Asp mutation was also identified in a 16-
month old Kuwaiti male. His parents were distant cousins and there was no 
known relationship to the previous case. Fragility of the skin was noticed soon 
after birth with spontaneous blistering of the hands, trunk and extremities, 
which healed with minimal scarring and milia formation. This was associated 
with occasional oral erosions. The frequency of blistering decreased with 
advancing age. Collectively, the phenotype was suggestive of mild RDEB and 
mutation analysis confirmed the presence of a homozygous mutation 
p.Gly1483Asp. Neither of his parents, heterozygous for p.Gly1483Asp, had 
any clinical abnormalities.  
Furthermore, a 17-year-old male and his 23-year-old sister of Kuwaiti 
origin, with no relation to the previous 2 cases, were diagnosed with RDEB-O. 
Their parents were first cousins with double consanguinity. Both children had 
generalised blistering at birth with recurrent oral ulcers. The frequency of 
blister formation decreased with age although there was persistent skin fragility 
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as well as albopapuloid lesions on the chest, abdomen and upper back, n 
addition to mild inflammation of the gums. There was nail dystrophy with loss 
of several finger and toe nails suggestive of RDEB-O. Both individuals were 
homozygous for the mutation p.Gly1483Asp. Their parents were heterozygous 




 Figure 4.3 The GS mutation p.Gly1483Asp leads to both dominant 
and recessive DEB. (A) p.Gly1483Asp results in heterogenous 
phenotypes; BDN and RDEB-O. (B) DNA sequencing shows 

























4.3.2 The phenotype expression variability of the mutation p.Gly1770Ser  
Heterozygosity for the mutation p.Gly1770Ser results in no phenotype, 
mild nail dystrophy or pretibial DDEB whereas homozygosity results in severe 
generalised RDEB as detailed below (Figure 4.4).  
The proband is a 9-month-old Pakistani male who is related to two 
affected brothers aged 1 year and 4 years. All three individuals presented with 
skin fragility at birth. They all subsequently progressed to develop typical 
features of RDEB-sev gen. Mutational analysis revealed homozygosity for the 
glycine substitution p.Gly1770Ser, consistent with this being a recessive GS.  
The proband’s parents were both heterozygous carriers with no skin or nail 
pathology. Thus, in both parents the GS p.Gly1770Ser appears to function as a 
recessive allele, which is silent in the heterozygous state. 
However, the brothers’ father was found to heterozygous for 
p.Gly1770Ser but had evidence of nail dystrophy without skin blistering. Their 
mother who is also heterozygous for p.Gly1770Ser had features of pretibial 
DEB and nail dystrophy demonstrating effects of a dominant GS.
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Figure 4.4 The glycine mutation p.Gly1770Ser leads to both dominant and 
recessive disease in two distantly related Pakistani pedigrees. (A-G) 
Clinical illustration of family members showing varying degrees of skin 
fragility as well as a normal phenotype. (H) Pedigree shows the presence/ 
absence of dominant or recessive disease in relation to the genotype. RDEB-
sev gen; recessive dystrophic epidermolysis bullosa-severe generalised, DDEB; 
dominant dystrophic epidermolysis bullosa. 
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4.3.3  The phenotype expression variability of the mutation 
p.Gly2213Arg  
The homozygous p.Gly2213Arg mutation leads to no phenotype or 
dominant EB-pr; but when inherited in trans with a frameshift mutation results 
in  RDEB-O as detailed below (Figure 4.5).  
EB-pr was diagnosed in a 45-year-old British female with blistering and 
itching affecting the lower legs since the age of 37 years. Clinically, there was 
evidence of prurigo-like lesions on her shins and she was found to be 
heterozygous for the GS mutation p.Gly2213Arg, supporting the diagnosis of 
dominant EB-pr. On the other hand, a 24-year-old British male had generalised 
blistering affecting the skin, eyes and oral mucosa. There was also evidence of 
scarring consistent with RDEB-O. He was found to be compound heterozygote 
for the mutation p.Gly2213Arg and the frameshift mutation c.4918delG in 
exon 52. Neither parent, including the carrier of the GS p.Gly2213Arg, had any 





Figure 4.5 The glycine substitution mutation p.Gly2213Arg leads to both 
dominant and recessive disease. (A) A 45-year-old female with dominant EB 
pruriginosa. (B) A 24-year-old male with clinical features of mild RDEB on 
the lower leg. (C) DNA sequencing of both cases compared to wild type.  
 138 
4.3.4 The phenotype expression variability of the mutation p.Gly2369Ser  
The heterozygous mutation p.Gly2369Ser leads to no phenotype or 
dominant EB-pr whereas homozygosity results in RDEB-O as detailed below 
(Figure 4.6).  
EB-pr was diagnosed in a 49-year-old male of Pakistani origin who had 
involvement of the forearms, shins, hands, feet and nails. Onset of EB was 
recorded at 6 months. There were also extensive lichenified prurigo-like 
lesions on the shins associated with itching consistent with EB-pr. Although 
the intense pruritus and a relative widespread involvement favoured the 
diagnosis of EB-pr, the features were also similar to those found in patients 
with pretibial EB, in whom a clear clinical distinction between these two 
overlapping clinical entities is sometimes difficult. 
A heterozygous GS mutation; p.Gly2369Ser indicated dominantly 
inherited disease. An unrelated 6-year-old female had skin fragility mainly 
affecting the ankles and knees with occasional oral involvement. There was 
also evidence of progressive flexion contractures and webbing of her fingers 
suggestive of RDEB-sev gen. She was found to be homozygous for the GS 
mutation p.Gly2369Ser. Her parents were both heterozygous carriers of this 






Figure 4.6 The glycine substitution mutation p.Gly2369Ser leads to 
dominant EB pruriginosa or severe generalised RDEB. (A and B) A 49-
year-old Pakistani male with features of EB-pr on the shins. (C) DNA 





This study revealed that the spectrum of GS substitution mutations is 
quite variable with resultant phenotypic heterogeneity encompassing all DEB 
subtypes. Factors affecting this heterogeneous expression could include the 
nature of the substituted amino acid, the position of the GS in the triple helix, 
the proximity of the GS to the non-helical hinge region in the triple helix or the 
non-collagenous NC1 or NC2 domains, unpredicted consequences of the 
nucleotide substitution on splicing, as well as biochemical changes to the 
collagen affecting helix formation, protein folding, thermal stability, 
intracellular transport, secretion, and assembly into anti-parallel dimers or 
anchoring fibrils (Shimizu et al., 1996; Christiano et al., 1996a; Hammami-
Hauasli et al., 1998b; Lee et al., 2000; Sato-Matsumura et al., 2002; Kern et 
al., 2006; Chiaverini et al., 2010; Chen et al., 2001; Chen et al., 2002a; 
Brittingham et al., 2005; Fritsch et al., 2009; Hyde et al., 2006).  
 
4.4.1 Effects of the type of GS mutations 
Whilst arginine was found to be the most common amino acid (AA) to 
substitute glycine, there is a wide spectrum of GS each resulting in one or more 
DEB subtypes. This is supportive of a previous study by Persikov et al., in 
which the predicted type of GS mutations in COL1A1, COL1A2, COL3A1, 
COL4A5, and COL7A1 -as calculated by using single–base pair substitution 
rates- were compared with the observed GS leading to disease. COL7A1 was 
unique in that no significant difference was noted between the spectrum of GS 
predicted and observed in the α1(VII) chains suggesting that although arginine 
was the most common substitute, any GS in COL7A1 regardless of the type 
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will lead to pathology (Persikov et al., 2004). This is also a reflection of the 
high evolutionary conservation of the COL7A1 structure (Kivirikko et al., 
1996). In some cases glycine can be substituted by different amino acids in the 
same codon resulting in heterogeneous phenotypes. This is particularly evident 
for some GS mutation in exon 73, a frequent region for COL7A1 mutations. 
The substitution of glycine in position p.Gly2028 by arginine can lead to either 
DDEB-gen or DDEB-pr, whereas a substitution by tryptophan, alanine or 
glutamic acid results in DDEB-gen (Lee et al., 2000; Murata et al., 2000; Varki 
et al., 2007). In other cases different amino acid substitutions in the same 
codon had no effect on phenotype. For example, substitution of glycine in 
position p.Gly2242 by either tryptophan, glutamic acid or arginine results in 





Table 4.3 The types of amino acids substituting glycine in COL7A1 GS 
mutations. 
Glycine Substitution Mutations 
Amino Acid  Symbol 
DDEB            
n (%) 
RDEB            
n (%) 
Arginine Arg 29 (29.8) 39 (36.7) 
Aspartic Acid Asp 18 (18.5) 14 (13.2) 
Glutamic Acid Glu 20 (20.6) 12(11.3) 
Valine Val 12 (12.3) 10 (9.4) 
Cysteine Cys 1 (1.0) 2 (1.8) 
Serine Ser 5 (5.1) 16 (15) 
Tryptophan Trp 6 (6.1) 3 (2.8) 
Alanine Ala 6 (6.1) 9 (8.4) 
Glycine Gly 0 (0) 1 (0.9) 
 
Total 97 106 
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4.4.2 Effects of the location of GS mutations 
Some studies have suggested that the location of GS could explain the 
level of protein expression, degree of triple helical instability and subsequent 
disease severity. The NC2 domain and the adjacent collagenous triple helix 
were found to initiate the assembly of collagen VII triple helices and mediate 
the formation of anti-parallel dimers  (Chen et al., 2001). Some GS mutations 
in or near this region (p.Gly2749Arg, p.Gly2569Arg, p.Gly2575Arg or  
p.Gly2623Cys) (Chen et al., 2002a; Woodley et al., 2008; Brittingham et al., 
2005) were found to impair collagen VII triple helix assembly resulting in 
RDEB. However, the novel GS p.Gly2781Arg mutation identified in this study 
is in closest proximity to the NC2 domain and even when inherited in trans 
with the nonsense mutation p.Arg1632Stop leads only to bullous dermolysis of 
the newborn, the mildest form of RDEB. Furthermore, some GS mutations in 
close proximity to the ‘hinge region’ are thought to interfere with protein 
folding (p.Gly2006Asp, p.Gly2034Arg, p.Gly2015Glu and p.Arg2008Glu) 
leading to intracellular retention of collagen VII  (Chen et al., 2002a; 
Hammami-Hauasli et al., 1998a).  However, according to the collective data 
from this study, 43% of dominant GS mutations occur in exons 73-75 which 
are adjacent to the hinge area, and display gross phenotypic variability that 
would be difficult to explain based on intracellular retention alone. 
The effect of GS location in relation to renucleation sequences 
necessary for triple helix formation has also been studied. Nucleation refers to 
an early process in DNA helix formation in which 2 single stranded segments 
of DNA are brought in close proximity prior to propagation. The type and 
location of renucleation sequences at which this process occurs, in relation to 
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missense mutations can affect helical stability and DNA segment elongation, 
with subsequent effects on protein expression (Hyde et al., 2006). Using 
peptide models, the presence of hydroxyproline rich renucleation sequences in 
the collagen I gene resulted in the formation of stable triple helices, whereas 
their absence led to unfolding of the helix N-terminal causing severe 
osteogenesis imperfecta. It was postulated that the distance between mutations 
and the next renucleation sequence might predict the level of folding 
impairment and hence clinical severity (Hyde et al., 2006). 
In addition, some recurrent mutations or ‘hotspots’ have been identified 
in specific populations such as the Arg578Stop, 7786delG and Arg2814Stop 
mutations in British families (Mellerio et al., 1997; Mohammedi et al., 1999); 
2470insG in Mexican families (Salas-Alanis et al., 2000; Salas-Alanis and 
McGrath, 2006); 5818delC, 6573+1G→C and E2857Stop in Japanese families 
(Tamai et al., 1999), Gly1664Ala in Italian families (Gardella et al., 2002), as 
well as the Gly2043Arg mutation in exon 73 and 425A→G worldwide 
(Mellerio et al., 1998; Murata et al., 2004). Moreover, with regards to GS 
mutations in particular, there appears to be a clustering of GS mutations within 
exon 73, however, the nature of these pathogenic mutations in both DDEB and 
RDEB, is similar, and to date no definite correlation has been found between 
the type or location of the substitution and the resulting subtype (Christiano et 
al., 1996c). 
 
4.4.3 Functional effects of GS mutations 
 
As described in Chapter 1, collagen VII fibrillogeneis is a dynamic 
process involving the formation of pro-collagen VII then secretion to the 
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extracellular space where pro-collagen is processed to collagen VII 
homotrimers. This is followed by dimerization, polymerisation and assembly to 
form anchoring fibrils (Burgeson et al., 1990; Burgeson, 1993; Rattenholl et 
al., 2002; Bruckner-Tuderman et al., 1995). Crucial to fibril integrity is the 
unique suprastructural configuration which is facilitated by interruptions to the 
Gly-X-Y repeats that confer flexibility necessary for collagen VII 
suprastructural folding (Christiano et al., 1994c; Christiano et al., 1994b). 
Finally fortification of dermal-epidermal adhesion is mediated by attachment 
of the anchoring fibrils to the BM via the NC1 domains (Burgeson, 1993). 
Mutations affecting any aspect of collagen VII fibrillogeneis will have a 
deleterious effect on basement membrane integrity resulting in dermal-
epidermal cleavage and sub-lamina densa blisters characteristic of DEB. GS 
mutations can lead to secretion of a mutant peptide and incorporation into 
anchoring fibrils to produce dominant negative interference, as typically occurs 
in dominant DEB with resultant impaired stability or transport of the mutant 
collagen VII. Alternatively, GS mutations can result in a non-functional allele 
in RDEB when inherited as a homozygous mutation or in trans with a second 
loss of function mutation on the other COL7A1 allele. 
Although no accurate correlation has been found between the location 
or type of the GS on disease expression (Christiano et al., 1996c; van den 
Akker et al., 2009), evidence is expanding regarding the functional effects of 
various GS mutations on fibrillogenesis, collagen VII suprastructure and 
function (Hovnanian et al., 1997; Hammami-Hauasli et al., 1998b; Hammami-
Hauasli et al., 1998a; Chen et al., 2002a; Woodley et al., 2008; Brittingham et 
al., 2005; Fritsch et al., 2009). Substitution of the glycine residue by a bulkier 
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residue results in structural impairment as evidenced by impaired helix to coil 
formation, protein folding and secretion resulting in intracellular accumulation 
of collagen VII (p.Gly2006Asp, p.Gly2034Arg, p.Gly2015Glu and 
p.Gly2749Arg) (Hammami-Hauasli et al., 1998a; Chen et al., 2002a; 
Hovnanian et al., 1997), as well as abnormal dimer formation (p.Gly2749Arg 
p.Gly2569Arg and p.Gly2575Arg) (Chen et al., 2002a; Woodley et al., 2008; 
Brittingham et al., 2005). This is also reflected in the reduced thermal stability 
of mutant molecules and their increased susceptibility to limited trypsin and 
pepsin digestion (p.Gly2689Arg, p.Gly1776Arg, p.Gly2006Asp, 
p.Gly2015Glu, p.Gly2749Arg, p.Gly2006Asp, p.Gly2034Arg, p.Gly2015Glu, 
p.Gly2569Arg, p.Gly2575Arg and p.Gly2049Glu) (Kern et al., 2006; Fritsch et 
al., 2009; Chen et al., 2002a; Hammami-Hauasli et al., 1998b; Woodley et al., 
2008). The instability caused by some of these mutations (p.Gly1776Arg, 
p.Gly2006Asp or p.Gly2015Glu) was shown in one study to be rescued when 
wild-type collagen VII molecules were over-expressed (Fritsch et al., 2009). 
Furthermore, the stability of the collagen VII triple helix was not only integral 
for precise suprastructural conformation, it was also shown to be crucial for 
keratinocyte motility as evidenced by the effects of the GS mutation 
p.Gly2049Glu in recombinant COL7A1 mutants on triple helix assembly, 
fibroblast adhesion and keratinocyte migration (Woodley et al., 2008). 
 
4.4.4 Genotype-phenotypic heterogeneity 
 
In this study, it was noted that for some GS mutations (p.Gly1483Asp, 
p.Gly1770Ser, p.Gly2213Arg and p.Gly2369Ser), the phenotype may be 
variable and there is often overlap between dominant and recessive cases, a 
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finding reported for some other GS mutations; p.Gly1595Arg, p.Gly1815Arg, 
p.Gly2028Arg, p.Gly2028Trp, p.Gly2251Glu, p.Gly2287Arg and 
p.Gly2351Arg (Hammami-Hauasli et al., 1998b; Sato-Matsumura et al., 2002; 
Christiano et al., 1996c; Varki et al., 2007; Shimizu et al., 1999; Lee et al., 
2000) (Figure 4.2). These GS mutations that can have both dominant and 
recessive patterns of inheritance comprise <10% of all COL7A1 GS.  
The de novo GS mutation p.Gly2028Arg, was described in a Chinese 
patient with DDEB-gen (Lee et al., 2000). It was also described in 2 pedigrees 
with DDEB-na and DDEB-pr (Murata et al., 2000; Nakamura et al., 2004). 
However, the same mutation inherited in trans with a loss-of-function mutation 
c.1661del57 led to RDEB-gen. It was also found to result in RDEB-O when 
inherited in trans with two maternal mutations; p.Gly1580Leu and 
p.Pro2438Leu (Varki et al., 2007). Another GS mutation in the same codon 
p.Gly2028Trp results in RDEB-O when inherited in trans with the loss-of-
function mutation c.8698del11 while the mother, a carrier of the p.Gly2028Trp 
shows features of DDEB-gen (Varki et al., 2007). Furthermore, the mutation 
p.Gly2210Val was described in a patient with RDEB-gen when inherited in 
trans with the missense mutation p.Arg2791Trp but interestingly resulted in 
DDEB-O and DDEB-pr when both mutations were inherited on the same allele 
in separate cases (Varki et al., 2007; Dang et al., 2007). The mutation 
p.Gly2351Arg in trans with the deletion/insertion mutation c.5103delCCinsG 
results in RDEB-O in a monozygotic twins whereas the mother, carrier of the 
p.Gly2351Arg had DDEB-gen (Varki et al., 2007; Christiano et al., 1996c). 
The mutation p.Gly2287Arg in association with p.Gly2316Arg resulted in 
RDEB-O in a Japanese girl but 3 family members, carriers of the 
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p.Gly2287Arg, showed evidence of nail dystrophy only (Shimizu et al., 1999). 
Moreover, two Japanese patients with nail dystrophy had dominantly inherited 
mutations p.Gly1595Arg and p.Gly1815Arg, respectively. However, each had 
an offspring with RDEB (Sato-Matsumura et al., 2002). Heterozygous 
p.Gly2251Glu resulted in dominantly inherited nail dystrophy however when 
inherited in trans with p.Gly1519Asp resulted in BDN (Hammami-Hauasli et 
al., 1998a). 4 novel GS mutations with dominant-recessive inheritance were 
identified in this study; p.Gly1483Asp, p.Gly1770Ser; p.Gly2213Arg and 
p.Gly2369Ser, which have new implications for genotype-phenotype 
correlation.  
These findings highlight the phenotypic and genotypic variability 
encountered in dominant and recessive cases of DEB and demonstrates the 
complexity in establishing accurate paradigms for genotype-phenotype 
correlation in DEB, particularly when a GS mutation on one COL7A1 allele is 
disclosed during diagnostic gene screening. Although, it is not surprising that 
GS mutations account for the vast majority of mutations in the COL7A1 and 
collagen genes in general, owing to the high glycine content, the presence of 
both dominant and recessive GS mutations is unusual. In fact, in addition to 
COL7A1, this bimodal pattern of inheritance in collagen genes has only been 
described for COL1A2 in osteogenesis imperfecta, COL4A3/COL4A4 in 
Alport’s and benign familial haematuria, COL6A1/COL6A2 in Ulrich's 
congenital muscular dystrophy and Bethlem's myopathy and COL11A2 in 
osteochondrodysplasia and autosomal dominant non-syndromic hearing loss 
(De Paepe et al., 1997; Jimenez-Mallebrera et al., 2006; Lemmink et al., 1996; 
Longo et al., 2002; McGuirt et al., 1999; Mochizuki et al., 1994; Nagel et al., 
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2005; Nicholls et al., 1984; Pace et al., 2008; Spotila et al., 1991; Spotila et al., 
1992; van der Loop et al., 2000; Vikkula et al., 1995; Badenas et al., 2002). 
 
4.4.5 Modifiers of disease expression 
 
 The phenotypic heterogeneity associated with GS mutations could, in 
part be explained by genetic and epigenetic modifiers including variable 
splicing and degradation, large genomic deletions and silent mutations as well 
as effects of endoplasmic reticulum stress and mutant proteins on apoptosis and 
gene expression (Covaciu et al., 2011; Nissim-Rafinia and Kerem, 2005; 
Bateman et al., 2009; Knaup et al., 2012; Kern et al., 2009a; Titeux et al., 
2006). 
On a transcriptional level, various genetic factors modulating the level 
of collagen VII expression have been studied including the variable splicing of 
transcriptional RNA associated with splice site mutations (Nissim-Rafinia and 
Kerem, 2005). This results in the production of alternatively spliced isomers 
with subsequent variability in the level of functional proteins and associated 
clinical effects.  
Another mechanism affecting splicing was highlighted by a recent 
study demonstrating that a translationally silent mutation; c.6846G>C 
(p.Leu2282Leu), in an exonic splicing enhancer (ESE) sequence, distant from a 
consensus splice site in exon 87 is capable of causing exon definition and exon 
skipping. These sequences are capable of selecting splicing sites in a cascade 
that starts with binding of ESE to members of the serine⁄arginine-rich (SR) 
protein family and culminating in recruitment of spliceosomes and exon 
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skipping (Covaciu et al., 2011).  Similar mutations in previously unrecognised 
ESE sequences could also modulate COL7A1 expression. Similarly, undetected 
mutations such as large genomic deletions or other silent mutations could also 
contribute to variable disease expression explaining phenotypic heterogeneity 
(Kern et al., 2009a). 
The degree of skin fragility can also be influenced by epigenetic 
mechanisms affecting the level of protein expression in the BMZ including 
variable degradation of intracellularly accumulated mutant proteins as well as 
effects of endoplasmic reticulum stress and unfolded protein response on 
apoptosis and altered gene expression (Bateman et al., 2009). Moreover, matrix 
metalloproteinase-1 (MMP-1), a zinc metallo-endopeptidase capable of 
degrading extracellular proteins, was found to be transcriptionally upregulated 
secondary to a single nucleotide polymorphisms (1G/2G) in the MMP-1 gene 
promoter resulting in a more severe RDEB phenotype (Titeux et al., 2008). 
Furthermore modulation of cellular mechanical stability in response to 
stress could have implications on disease expression in DEB. In a recent in 
vitro study by Knaup et al., the gene expression profiles of EBS-MD, RDEB 
and GABEB were analysed. All revealed up-regulation of COL16A1 and FN1 
(fibronectin gene), in addition to accumulation of cholesterol intracellularly; 
factors known to confer greater resistance towards mechanical forces and 
stabilisation of the cell membrane respectively. In addition there was down-
regulation of ribosomal protein S27A, a ubiquitin fusion protein, which could 
potentially result in increased degradation of mutant alleles by ubiquitin 
(Knaup et al., 2012; Redman and Rechsteiner, 1989). 
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In the future, particularly with the introduction of whole genome and 
exome sequencing as well as data mining studies, previously unrecognised 
modifiers are likely to be revealed (Reverter et al., 2008). 
It is still not clear why some glycine mutations cause pathology when in 
inherited dominantly while others are silent. This is further complicated by the 
fact that some GS mutations are inherited in both dominant and recessive 
mode. Collectively, the hypothesis is that, in addition to the clear cut dominant 
and recessive GS mutations, there exists a new entity of mutations capable of 
causing disease when inherited dominantly or are silent when inherited on one 
allele and only causing pathology when inherited in trans with another 
COL7A1 mutation. Therefore, it is likely that there are 3 types of glycine 
substitution with regards to the genotypic consequences: dominant, recessive or 
a mixed pattern. This has implications for genotype-phenotype correlation and 
accurate genetic diagnosis and counselling. When one known dominant 
COL7A1 GS mutation is found it is imperative to look for another mutation 
particularly where the clinical appearance or mode of inheritance is in doubt.   
However, despite analysis of the data outlined in this study, it is 
difficult to predict which particular mutations are likely to be dominant or 
recessive, as reinforced by the identification of the 12 GS mutations that can be 
either dominant or recessive.  In addition, amino acid substitutions in glycines 
1522, 2009, 2061, 2073, 2233, 2366, 2623 and 2719 may cause dominant or 
recessive disease but with different substituting residues in the different disease 
subtypes. There does not appear to be any specific differences in males or 
females with regards to phenotype. Clinical heterogeneity within a specific 
genotype may reflect influences such as functional polymorphisms within 
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genes such as the matrix metalloproteinase 1 promoter (Titeux et al., 2008) but 
this cannot impact on whether the inheritance pattern is actually dominant or 
recessive. 
In conclusion, although a clear phenotype-genotype correlation for GS 
mutations was not identified, the above data provides a useful cross-
referencing tool for investigators screening for COL7A1 GS mutations. In all 
cases of DEB, a comprehensive screening of the COL7A1 even if a “possible” 
dominant GS mutation has been identified is recommended to ensure that 























Dystrophic epidermolysis bullosa: 
the significance of missense non-
















Glycine amino acids are integral to the COL7A1 triple helical stability 
and suprastructural conformation, while alterations in non-glycine amino acids 
are likely to have a less consequential effect. However, the location of non-GS 
missense mutations, particularly in highly conserved or critical regions, have 
also been found to affect helix formation, protein folding, resistance to protease 
degradation, intracellular transport and secretion, fibroblast adhesion, 
keratinocyte migration as well as assembly into anti-parallel dimers and 
anchoring fibrils. The type of the non-GS mutations might also predict the 
functional consequences and resultant phenotypic severity; however, it is more 
likely that a combination of factors including potential genetic and epigenetic 
modifiers modulate collagen VII expression and the subsequent phenotype.   
In this study I report 16 novel non-GS missense COL7A1 mutations 
underlying DEB and highlight associated phenotypic and genotypic 















DEB results from mutations in COL7A1 leading to qualitative and 
quantitative alterations of the anchoring fibrils at the DEJ with subsequent skin 
fragility. Both autosomal dominant and recessive forms of DEB exist and to 
some extent paradigms for genotype-phenotype correlation have emerged. 
Dominant forms of DEB usually result from heterozygous missense GS 
mutations exerting a dominant negative effect, while recessive forms of DEB 
result from homozygous or compound heterozygous nonsense, frameshift or 
splice site mutations. While missense GS mutations are typically associated 
with dominant forms of DEB, non-GS mutations are also associated with 
DDEB, as well as milder forms of RDEB (Dang and Murrell, 2008; Almaani et 
al., 2011; Hovnanian et al., 1997; Varki et al., 2007; Whittock et al., 1999).  
In this Chapter, 16 novel non-GS mutations are identified, expanding 
on the current COL7A1 non-GS mutations database. The significance of these 
missense mutations on DEB phenotype was studied in the aim of refining 
genotype-phenotype correlation, which will have important implications for 
diagnosis and genetic counselling. 
 
5.2 Patients and Methods 
For this study I collected and evaluated DNA mutation analysis data 
retrospectively, via the Robin Eady National Diagnostic Epidermolysis Bullosa 
Laboratory database in London. Blood samples from patients with clinically 
suspected or histologically proven DEB (and their parents if available), were 
provided historically by local, national and international referrers. Patient 
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ethnicities included white Caucasian, Middle-Eastern, South American, South-
East Asian and Asian. Prior to my work on this thesis, the DNA extraction and 
COL7A1 mutation analysis had been performed by Dr. Lu Liu at the Robin 
Eady National Diagnostic Epidermolysis Bullosa Laboratory, as part of the 
patients’ routine clinical care in most cases. However, for individuals linked to 
separate research projects, DNA screening was undertaken with Ethics’ 
Committee approval (St Thomas’ Hospital Ethics’ committee; 07/H0802/104) 
with informed consent and carried out in accordance with the Declaration of 
Helsinki principles. DNA extraction and sequencing was performed as 
discussed in Chapter 2. Polymorphisms were ruled out by excluding mutations 
in 100 controls and performing in silico analysis where necessary. 
 
5.3 Results and Discussion 
 
This study revealed that non-GS mutations represent around 30% of the 
total COL7A1 missense substitution mutations. However, only 7% occur in 
dominant DEB compared to 40% of recessive DEB cases (Table. 5.1 and 
Figure 5.1) (Almaani et al., 2011). This is a reflection of the uniquely high 
glycine content of COL7A1, which is arranged, in Gly-X-Y repeats along the 
triple helical domain (Whittock et al., 1999; Hovnanian et al., 1997; Ryoo et 
al., 2001; Dang and Murrell, 2008). The glycine residues are centred within the 
COL7A1 triple helix while the X-Y residues are positioned exteriorly (Persikov 
et al., 2004; Fritsch et al., 2009). As a consequence, glycine amino acids are 
integral to the triple helical stability and suprastructural conformation while 
alterations in non-glycine amino acids are likely to have a less deleterious 
effect  (Fritsch et al., 2009; Persikov et al., 2004). Therefore, the higher 
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association of non-GS mutations with RDEB compared to DDEB is related to 
the significantly higher occurrence of GS mutations in cases of DDEB rather 
than a more detrimental effect of non-GS mutations. Also, the association of 
non-GS mutations with a splice site or loss of function mutation on the other 
allele will account for the more severe outcome in cases of RDEB.  However, 
non-GS mutations, particularly in highly conserved or critical regions, have 
also been found to affect helix formation, protein folding, resistance to protease 
degradation, intracellular transport and secretion, fibroblast adhesion, 
keratinocyte migration as well as assembly into anti-parallel dimers and 
anchoring fibrils (van den Akker et al., 2011; Chen et al., 2002a; Brittingham 
et al., 2005; Woodley et al., 2008; Kern et al., 2006; Hovnanian et al., 1997; 
Chen et al., 2001).  
The majority of pathogenic non-GS mutations result from the 
substitution of arginine, a large, hydrophilic amino acid, leading to loss of an 
ionic charge or the introduction of a bulky amino acid at external helical 
surface (Hovnanian et al., 1997). Through alterations in the size and charge of 
amino acids, non-GS mutations result in conformational changes in collagen 
VII leading to deleterious functional effects as outlined above. The 
substitutions which mainly involve arginine residues (~35% of cases) and 
proline to a lesser extent (~20% of cases) (Table. 5.2) lead to mild forms of 
RDEB when inherited on both alleles, however, when inherited in trans with 
non-sense or frameshift mutations, some non-GS mutations lead to a more 
severe phenotype (RDEB-sev gen). Interestingly, two homozygous non-GS 
mutations result in RDEB-sev gen; p.Arg2008Gly and p.Arg2063Trp 
(Hovnanian et al., 1997). This could be explained by the nature of these 
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mutations, particularly the substitution of the positively charged hydrophilic 
arginine residue by a larger hydrophobic tryptophan residue in the 
p.Arg2063Trp mutation with more deleterious effects on COL7A1 
ultrastructural conformation (Woodley et al., 2008; Wessagowit et al., 2005). 
The position of these non-GS mutations in relation to critical or highly 
conserved areas might also play a role in phenotype expression. Both 
p.Arg2008Gly and p.Arg2063Trp mutations in exons 73 and 74, respectively, 
lie in close proximity to the ‘hinge region’ with potential conformational 
changes and increased sensitivity to protease degradation (Woodley et al., 
2008; Wessagowit et al., 2005). However, the homozygous mutation 
p.Arg2008Gly was also found to result in RDEB-i suggesting that other factors 
might also influence phenotype expression (van den Akker et al., 2011). 
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Table 5.1 Reported and novel non-glycine substitution mutations in the collagen VII gene. 
  Allele 1 Allele 2   
Diagnosis Exon cDNA Type Protein 
Exon/ 
Intron 






MS p.Met1Ile 54 c.4997dupG PTC p.Pro1668AlafsX4 
 (van den Akker et 
al., 2009) 
RDEB-pr      
RDEB-na 
1 c.82A>G MS p.Arg28Gly 92 c.7097G>C MS p.Gly2366Arg 
 (Pruneddu et al., 
2011) 
RDEB-O 2 c.112G>T MS p.Asp38Tyr 16 c.2157G>A PTC p.Trp719Stop www.col7a1.org 
RDEB-pr 2 c.130G>A MS p.Asp44Asn 16 c.8569G>T PTC p.Glu2857Stop 




2 c.143C>T MS p.Ser48Proa 27  c.3625del11 PTC p.Ser1209LeufsX6  (Jiang et al., 2005) 
RDEB-pr 2 c.151C>G MS p.Arg51Gly 98 c.7474C>T PTC p.Arg2492Stop  (Drera et al., 2006) 
RDEB-sev 
gen 
2 c.238G>C MS p.Ala80Pro 27 c.3631C > T PTC p.Gln1211Stop  (Varki et al., 2007) 
RDEB-O 2 c.245T>G SS p.Val82Gly ND ND ND ND 
 (Wessagowit et 
al., 2005) 
RDEB-O 3 c.410A>G MS p.Lys137Arg 72 c.5869C>T MS p.Arg1957Trp This study 
RDEB-O 3 c.425A>G SS p.Lys142Arg 95 c.7344G>A SS p.Val2448Val 
 (Gardella et al., 
1996) 
DDEB-gen 7 c.884G>A MS p.Arg295Gln 108 c.8045 A>G SS 
predicted skipping of 
exon 108 (in-frame; 
63aa)  
This study 
RDEB-O 17 c.2126T>C MS p.Val709Ala 13 c.1732C>T PTC p.Arg578Stop This study 
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DDEB  17 c.2278G>A MS p.Val760Met / / / /  (Varki et al., 2007) 
RDEB-O 20 c.2657G>C MS p.Arg886Pro 4 c.497insA PTC p.Val168GlyfsX12 
 (Posteraro et al., 
2005) 
RDEB-O 21 c.2729G>C MS p.Arg910Pro 3 c.425A>G SS p.Lys142Arg 
 (van den Akker et 
al., 2009) 
RDEB-O 22 c.2936T>G MS p.Val979Gly IVS52 4935+2T>G ND ND This study 
RDEB 22 c.2969G>A MS                   p.Arg990Gln      73 c.6023G>A MS p.Arg2008His 
 (Nakano et al., 
2007) 
RDEB-O 25 c.3301C>Tb MS p.Arg1101Trp 34 c.4027C>T PTC p.Arg1343Stop This study 
RDEB-O 25 c.3359G>A SS p.Arg1120Lys ND ND ND ND 
 (Wessagowit et 
al., 2005) 
RDEB-O  28 c.3749A>C MS p.Tyr1250Ser 73 c.6084C>T MS p.Pro2029Ser  (Ryoo et al., 2001) 
RDEB-sev 
gen 
30 c.3809C>T MS p.Pro1270Leu IVS5  c.682+1G>A SS 
predicted retention 




31         
31 
c.3847C>T                          
c.3889G>A 
MS                 
MS 
p.Pro1283Ser                  
p.Glu1297Lysc 
3 c.425insA   PTC p.Lys142fsX42 This study 
RDEB-O  33 c.4011G>A SS p.Pro1337Pro 104 c.7769G>A MS p.Gly2590Asp 
 (van den Akker et 
al., 2009) 
RDEB-O 35 c.4118C>T SS p.Ser1373Leu 116 c.8569G>T PTC  p.Glu2857Stop 












DEB 46 c.4613G>A MS p.Arg1538His ND ND ND ND 
 (Makino et al., 
2012) 
RDEB 47 c.4666A>G MS p.Lys1556Glu IVS22 2858-7del82  PTC ND This study 
RDEB-sev 
gen 
51 c.4879G>A MS p.Val1627Ile 116 c.8569G>T PTC p.Glu2857Stop  (Cho et al., 2009) 
RDEB-O  54 c.5033C>T  SS p.Pro1678Leu 3 c.425 A>G SS p.Lys142Arg 
 (Wertheim-
Tysarowska et al., 
2012) 
RDEB-pt 55 c.5096C>T MS p.Pro1699Leu IVS2  c.267-1G>C SS 
predicted skipping of 
exon 3 (out of frame; 
160aa) 
 (Gardella et al., 
2002) 
RDEB-O 61 c.5314C>T MS p.Arg1772Trp 104 c.7786delG PTC p.Gly2596ValfsX49 
 (Whittock et al., 
1999) 
RDEB-O 63 c.5440C>T MS p.Arg1814Cys  113 c.8386C>T PTC p.Gln2796Stop  (Dang et al., 2007) 
DEB 69 c.5771A>C MS p.Gln1924Pro ND ND ND ND 
(Pulkkinen and 
Uitto, 1999) 
RDEB-O 70 c.5819C>T MS p.Pro1940Leue IVS42 c.4482+1G>A SS 
predicted skipping of 
exon 42 (in frame; 
45aa) 
 (Varki et al., 2007) 
RDEB-O 70 c.5820G>A SS p.Pro1940Pro 34 c.4039G>C MS p.Gly1347Arg 
 (Terracina et al., 
1998) 
RDEB-O 72 c.5869C>T MS p.Arg1957Trp 
3                       
54 
c.410 A>G or        
c.5047 C>T 






RDEB-O 72 c.5870G>A MS p.Arg1957Gln IVS81 c.6573+1G>C PTC p.Gly2192fsX106 




72 c.5942A>G MS p.Lys1981Arg 4 c.497dupA PTC p.Val168GlyfsX12 
 (Jerabkova et al., 
2010) 





73 c.6022C>G MS p.Arg2008Gly 73 c.6072C>G MS p.Arg2008Gly 
 (Hovnanian et al., 
1997) 
RDEB-O 73 c.6022C>T  MS p.Arg2008Cys 70 c.5818delC PTC p.Pro1940ArgfsX65  (Kon et al., 1998) 
RDEB-O 73 c.6080C>T MS p.Pro2027Leu 13 c.1732C>T PTC p.Arg578Stop 
 (Kern et al., 
2009a) 
RDEB-O 73 c.6084C>T MS p.Pro2029Ser 28 c.3749A>C MS p.Tyr1250Ser  (Ryoo et al., 2001) 
RDEB 73 c.6134C>T  MS p.Pro2045Leu 3 c.425 A>G SS p.Lys142Arg 
 (Wertheim-
Tysarowska et al., 
2012) 
RDEB 73 c.6023G>A MS p.Arg2008His 22 c.2969G>A MS                   p.Arg990Gln      
 (Nakano et al., 
2007) 
RDEB-O 73 c.6176A>G MS p.Glu2059Gly 73 c.6176A>G MS p.Glu2059Gly  (Kern et al., 2006) 
RDEB 73 c.6180G>C SS p.Arg2060Ser 5 c.553C>T PTC p.Arg185Stop 
 (van den Akker et 
al., 2009) 
RDEB-i 74 c.6187C>G MS p.Arg2063Gly 6 c.706C>T PTC p.Arg236Stop 




74 c.6187C>T MS p.Arg2063Trp 74 c.6187C>T MS p.Arg2063Trp 
 (Hovnanian et al., 
1997) 
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RDEB-i 74 c.6205C>T MS p.Arg2069Cys 3 c.425 A>G SS p.Lys142Arg 
 (Kahofer et al., 
2003) 
DDEB-O    
DDEB-
BDN 
74 c.6216A>G SS p.Gln2072Arg / / / / This study 
RDEB-Of 80 c.6510G>T MS p.Gln2170Tyr 80 c.6510G>T MS p.Gln2170Tyr 
 (van den Akker et 
al., 2009) 
RDEB-O 84 c.6677T>A MS p.Val2226Glu 84 c.6685C>T MS p.Pro2229Ser  (Ryoo et al., 2001) 
RDEB-O 84 c.6685C>T MS p.Pro2229Ser 84 c.6677T>A MS p.Val2226Glu  (Ryoo et al., 2001) 
RDEB-O 84 c.6695C>G MS p.Pro2232Arg 84 c.6697G>C MS p.Gly2233Cys  (Ryoo et al., 2001) 
RDEB-O 86 c.6767C>T MS p.Pro2256Leu 86 c.6767 C>T MS p.Pro2256Leu This study 
DDEB-pr 87 c.6846G>C SS p.Leu2282Leu / / / / 
 (Covaciu et al., 
2011) 
DDEB-gen 87 c.6899 A>G SS p.Gln2300Arg / / / /  (Kern et al., 2006) 




 (Kern et al., 
2009a) 
RDEB-O 94 c.7245G>A SS p.Met2415Ileg 
large genomic deletion which removes the entire 
COL7A1 gene 




95 c.7268A>G MS p.Glu2423Gly 80 c.6528insC    PTC p.Gly2177TrpfsX113   (Varki et al., 2007) 
RDEB 95 c.7313C>G MS p.Pro2438Argh ND ND ND ND 





95 c.7313C>T MS p.Pro2438Leui 73 c.6082G>A MS p.Gly2028Arg  (Varki et al., 2007) 
RDEB-O 95 c.7344G>A SS p.Val2448Val 3 c.425A>G SS p.Lys142Arg 
 (Gardella et al., 
1996) 
RDEB-pt 103 c.7738C>T MS p.Arg2580Cys IVS90 
c.7023+1G>
A 
SS ND www.col7a1.org 
DDEB-gen 105 c.7846G>A MS p.Val2616Ile / / / / This study 
RDEB-i 105 c.7864C>T MS p.Arg2622Trp 19 c.2482delCT PTC p.Ser828CysfsX37 




105 c.7865G>A MS p.Arg2622Gln ND ND ND ND  (Varki et al., 2007) 
RDEB-i 106 c.7882C>T MS p.Arg2628Trp 10 c.1332C>A PTC p.Tyr444Stop 
 (Chiaverini et al., 
2010) 
DDEB-O 108  c.8045A>G SS p.Lys2682Arg / / / / This study 
RDEB-pr 110 c.8206G>A MS p.Glu2736Lys 3 c.425A>G SS p.Lys142Arg 
 (Schumann et al., 
2008) 
DDEB 113 c.8371C>T MS p.Arg2791Trp / / / / 
 (Whittock et al., 
1999) 
RDEB 113 c.8393T>G MS p.Met2798Arg ND ND ND ND 
 (Rodriguez et al., 
2012) 
RDEB-O 113 c.8393T>A MS p.Met2798Lys 113 c.8393T>A MS p.Met2798Lys 
 (Christiano et al., 
1993) 
RDEB 115 c.8486A>G MS p.His2829Arg ND ND ND ND This study 
RDEB-O 117 c.8627G>T MS p.Cys2875Phej 33 c.4018C>T PTC p.Arg1340Stop 
 (Sawamura et al., 
2005) 
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RDEB-O 117 c.8626T>C MS p.Cys2876Arg 12 c.1564 C>T PTC p.Gln522Stop This study 
RDEB-O 117 c.8644G>A MS p.Glu2882Lys 116 c.8569G>T PTC p.Glu2857Stop 
 (Hanafusa et al., 
2012) 
RDEB-O 117 c.8764C>T MS p.Arg2922Cys 54 c.5047C>T PTC p.Arg1683Stop 




117 c.8780G>A MS p.Arg2927His 52 c.4919delG PTC p.Gly1640ValfsX70   (Varki et al., 2007) 
RDEB-O 117 c.8780G>C MS p.Arg2927Pro 31 c.3840delC PTC  p.Gly1281ValfsX44 This study 
DDEB: dominant dystrophic epidermolysis bullosa; DDEB-BDN: bullous dermolysis of the newborn; DDEB-gen: generalized; DDEB-pr: 
pruriginosa; RDEB: recessive dystrophic epidermolysis bullosa; RDEB-sev gen: severe generalized; RDEB-O: other; RDEB-BDN: bullous 
dermolysis of the newborn; RDEB-na: nail dystrophy; RDEB-pr: pruriginosa; RDEB-i: inversa, IVS, intervening sequence (intron); MS: 
missense; PTC: premature termination codon; ND: not determined; SS: splice site, bold: new mutations. ap.Ser48Pro but corrected 
nomenclature should be: p.Ser48Phe, binherited with the c.5504delA on the same allele, cinherited on the same allele, dinherited with the 
p.Gly2251Ala mutation on the same allele, einherited with the c.5015delA mutation on the same allele, fhomozygous carrier of p.Gln2170Stop 
demonstrating revertant mosaicism in an unaffected patch of skin carrying a homozygous p.Gln2170Tyr mutation, gcan lead to a delayed PTC 
p.Gln2417SerfsX57, hpossible polymorphism, iinherited with the p.Gly1580Asp mutation on the same allele, jp.Cys2875Phe but corrected 
nomenclature should be: p.Cys2876Phe. 
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Figure 5.1 A schematic outlining the position of non-GS mutations 
within COL7A1. Novel dominant and recessive non-GS mutations identified 




Table 5.2 The type and frequency of COL7A1 non-glycine substitution 
mutations identified in this study. Arginine was the most frequently 
substituted amino acid. It was also the most likely to replace other amino acids 
along with leucine. 






Arginine Arg 30 12 
Cysteine Cys 2 7 
Proline Pro 16 7 
Valine Val 8 1 
Tryptophan Trp 0 7 
Glutamine Gln 4 4 
Aspartic Acid Asp 2 0 
Glutamic acid Glu 5 2 
Histidine His 1 3 
Methionine Met 4 1 
Lysine Lys 6 4 
Serine Ser 2 5 
Tyrosine Tyr 1 2 
Phenylalanine phe 0 2 
Isoleucine Ile 0 4 
Glycine Gly not included 8 
Alanine Ala 1 1 
Leucine Leu 1 11 
Asparagine Asn 0 2 
Total    84 84 
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Furthermore, although the majority of non-glycine mutations are 
missense mutations some alter splicing. However, none of these mutations 
resulted in a more severe phenotype (Wessagowit et al., 2005). In addition 2 
novel non-GS splice site mutations were identified in this study that resulted in 
DDEB; p.Gln2072Arg and p.Lys2682Arg. The mutation p.Gln2072Arg is 
predicted to result in skipping of exon 74 leading to mild DDEB (DDEB-O). 
The proband’s mother is also heterozygous for this mutation which resulted in 
transient blistering for 2 years after birth and mild nail dystrophy. The 
dominantly inherited mutation p.Lys2682Arg in exon 108 also resulted in 
DDEB-O. This mutation disrupts the donor splice site, resulting in a leaky site 
as predicted by in silico analysis. Another previously reported splice site 
mutation, p.Gln2300Arg, which is predicted to result in skipping of exon 87, 
was also found in this study cohort. Interestingly, this mutation, which was 
present in 3 generations, was phenotypically heterogeneous. The grandmother 
had dominant EB-pr and the granddaughter demonstrated skin fragility at birth, 
while the daughter was asymptomatic. However, as the splicing anomaly is 
predicted to result in a leaky site, clinical heterogeneity is not unexpected.  
In addition to the type of mutation, the location of the non-GS 
mutations could play a role in determining phenotype expression. Mutations in 
the non-collagenous domains, NC1 and NC2, could affect collagen VII 
attachment to the basement membrane zone and triple helical formation and 
assembly respectively (Chen et al., 2001; Woodley et al., 2008). However, 
non-GS mutations in these two domains are quite variable resulting in DDEB, 
RDEB-O, as well as RDEB-sev gen. Moreover, mutations in close proximity to 
the highly conserved cysteine residues can potentially interfere with disulphide 
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bonding necessary for anti-parallel dimer formation (Dang and Murrell, 2008; 
van den Akker et al., 2011; Brittingham et al., 2005; Chen et al., 2001). The 
mutations p.Arg2622Trp, p.Arg2622Gln and p.Arg2628Trp are in close 
proximity to the only cysteine residue in the triple helix collagenous domain 
(THC) at position 2634 which can lead to unstable antiparallel dimers or 
alteration in the COL7A1 suprastructural conformation  (van den Akker et al., 
2011; Christiano et al., 1994d). On the other hand the p.Met2798Lys, lies in 
close proximity to the cysteine residues in the NC2 domain necessary for triple 
helical and antiparrallel dimer formation (Chen et al., 2001).  However, the 
phenotype for mutations near cysteine residues is also quite variable involving 
RDEB-O, RDEB-pr and RDEB-I. Furthermore, only one cysteine substitution 
mutation has been reported in COL7A1; p.Cys2875Phe, which is inherited in 
trans with a loss of function mutation; p.Arg1340Stop, resulting in mild RDEB 
(Sawamura et al., 2005). This study adds a second COL7A1 cysteine 
substitution mutation, p.Cys2876Arg that is also inherited in trans with the 
nonsense mutation p.Gln522Stop and results in RDEB-O. 
Non-GS mutations within the triple helix collagenous domain, 
particularly in relation to the hinge region, can affect the stability of the triple 
helix, resistance to protease degradation as well as its suprastructural 
conformation and flexibility. There are also effects on collagen VII secretion 
with subsequent intracellular retention of collagen VII (Chen et al., 2002a; van 
den Akker et al., 2011; Woodley et al., 2008). However, phenotype expression 
of non-GS mutations could not be explained solely by location as different 
amino acid substitutions in the same position lead to varying phenotypes 
(p.Arg2008Gly; RDEB-sev gen, p.Arg2008Cys; RDEB-O, p.Arg2063Gly; 
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RDEB-I, p.Arg2063Trp; p.Arg2622Trp; RDEB-I, p.Arg2622Gln; RDEB-sev 
gen, RDEB-sev gen, p.Arg2927His; RDEB-sev gen, p.Arg2927Pro; RDEB-O). 
Furthermore specific DEB subtypes are not related to a particular amino acid 
substitution as one study revealed that the size, water avidity and polarity of the 
amino acids substituting arginine in RDEB-I, had no bearing on the clinical 
phenotype (van den Akker et al., 2011). It is likely however, that phenotypic 
heterogeneity could, in part be explained by genetic and epigenetic modifiers 
including variable splicing and degradation, large genomic deletions and silent 
mutations as well as effects of endoplasmic reticulum stress and mutant 
proteins on apoptosis and gene expression (Covaciu et al., 2011; Nissim-
Rafinia and Kerem, 2005; Bateman et al., 2009; Knaup et al., 2012; Kern et 
al., 2009a; Titeux et al., 2006). 
In conclusion the heterogeneity of non-GS mutations is reflected by a 
variable phenotypic constellation. The type or location of the non-GS 
mutations might predict the functional consequences and resultant phenotypic 
severity; however, it is more likely that a combination of factors including 
potential genetic and epigenetic modifiers modulate collagen VII expression 
and the resultant phenotype. Advances in functional genomics that explore the 
dynamic interplay between genomics, proteomics and subsequent clinical 
expression is likely to yield a more comprehensive understanding of genotype-
phenotype correlation in EB. Coupled to bioinformatic advances, this will help 














Phenotype modulation by genetic 
modifiers: The role of matrix 
metalloproteinase 1 (MMP-1) on the 










Epidermolysis bullosa pruriginosa (EB-pr is an unusual subtype of 
DEB characterised by severe pruritus that leads to striking skin changes 
resembling nodular prurigo or hypertrophic lichen planus. The COL7A1 
molecular pathology underlying EB-pr is similar to that seen in other non-
pruritic (non EB-pr) variants of DEB but the reason for the striking phenotypic 
heterogeneity is still not clear. In this study, the incidence of a common 
functional polymorphism in the matrix metalloproteinase 1 gene promoter (1G 
or 2G at nucleotide -1607) is assessed in patients with EB-pr (n=27) compared 
to non-itchy dominant DEB (n=23), recessive DEB (n=25) and normal controls 
(n=50). The 2G allele was previously  found to result in increased matrix 
metalloproteinase 1 activity, which leads to increased degradation of collagen 
VII and a more severe RDEB phenotype. The aim of the study was to assess if 
the 2G allele could explain the phenotypic heterogeneity encountered in other 
forms of DEB particularly EB-pr It might be that the MMP-1 induced increase 
in collagen VII degradation, triggers an inflammatory response that leads to the 
pruritus characteristic of EB-pr. The frequency of the 2G allele in EB-pr 
patients was 46.3%, greater than in the control group (42.0%) but less than in 
non-itchy dominant DEB (52.1%) or recessive DEB (62.0%). However, none 
of these differences were statistically significant apart from recessive DEB 
compared to controls (p=0.02). In conclusion, this study expands on the current 
database of COL7A1 mutations leading to EB-pr and reveals that a common 
functional polymorphism in the MMP-1 gene promoter does not contribute to 




As discussed in previous Chapters there is often overlap between the 
various sub-categories of DEB particularly in the dominantly inherited group 
where inter- and intra-familial phenotypic heterogeneity is frequently observed  
(Ee et al., 2007; Mellerio et al., 1999; Nakamura et al., 2004; Murata et al., 
2000; Bodemer et al., 2003). Although the type, combination and location of 
mutations within the COL7A1 gene could provide insight into the clinical 
outcome, phenotypic variability suggests that genetic, epigenetic or 
environmental modifiers might play a role in this heterogeneity. 
 One particular subtype of DEB, EB-pr, has been difficult to categorise. 
This unique form of DEB has clinical features overlapping with pretibial DEB 
and is associated with intense pruritus (McGrath et al., 1994). The resultant 
clinical features are striking and resemble lichen simplex chronicus, nodular 
prurigo, immunobullous diseases, hypertrophic lichen planus or even dermatitis 
artefacta (McGrath et al., 1994; Lee et al., 1997; Mellerio et al., 1999). EB-pr 
is usually inherited as an autosomal dominant disease but may be recessive in 
some cases (McGrath et al., 1994; Mellerio et al., 1999; Drera et al., 2006; 
Schumann et al., 2008). However, the nature of the underlying COL7A1 
mutations is not different from other forms of DEB (Mellerio et al., 1999; Lee 
et al., 1997; Drera et al., 2006; Dang et al., 2007; Ee et al., 2007; Jiang et al., 
2002; Murata et al., 2000; Nakamura et al., 2004; Whittock et al., 1999) with 
even some identical mutations resulting in variable forms of EB including EB-
pr (Mellerio et al., 1999; Lee et al., 1997; Drera et al., 2006; Dang et al., 2007; 
Ee et al., 2007; Jiang et al., 2002; Murata et al., 2000; Nakamura et al., 2004; 
Whittock et al., 1999). 
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Studies exploring the influence of potential modifiers on the pruritic 
EB-pr phenotype including increased IgE levels; atopy; renal, hepatic and 
thyroid dysfunction; iron deficiency, interleukin-31 and filaggrin mutations 
have so far failed to establish a definite link (Mellerio et al., 1999; Drera et al., 
2006; Schumann et al., 2008; Ee et al., 2007; Lapinski et al., 1998; Nagy et al., 
2010; Ren et al., 2008). Therefore any contributing metabolic, genetic, 
epigenetic, or environmental factors are yet to be determined.  
However, a recent study by Titeux et al. has demonstrated a significant 
increase in the frequency of a GG single nucleotide polymorphism (SNP) in the 
promoter area of the zinc metalloproteinase MMP-1 gene in patients with the 
most severe type of RDEB; RDEB-sev gen (Titeux et al., 2008). The 
polymorphism, which is found at position -1607 within the MMP-1 promoter 
area occurred as either 1G or 2G, both of which have been shown to occur with 
similar frequency in control populations (Ye et al., 2001; Zinzindohoue et al., 
2005). However, the 2G variant at this site was shown to create an ETS (E26 
transformation specific) transcription factor binding site, 5'-GGA-3', resulting 
in a 2-fold transcriptional up regulation of MMP-1 (Rutter et al., 1998) (Figure 
6.1). The latter is a collagenase secreted by basal keratinocytes and dermal 
fibroblasts and is of particular interest as collagen VII acts as one of its 
substrates (Seltzer et al., 1989). This is in keeping with the finding that 
although the synthesis of collagen VII was found to be normal by Titeux et al., 
there was a reduction at the protein level due to increased MMP-1 induced 
collagen VII degradation. No significant difference in collagen VII expression 
was found between the 2G/1G and 2G/2G SNP variants (Titeux et al., 2008). 
Other studies also observed increased levels of MMP-2, 3 and 9 and a reduced 
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level of tissue inhibitors of metalloproteinases (TIMPs) in the more severely 
affected RDEB cases (Bodemer et al., 2003).  
 
Figure 6.1 The 1G/2G polymorphism in the MMP- 1 gene promoter is 
located at nucleotide -1607 from the MMP1 transcription site. The 2G 
polymorphism creates an ETS (E26 transformation specific) transcription factor 
binding site which increases the transcriptional activity of MMP1. This leads to 
an increased degradation of collagen VII.  
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In this study I sought to determine if the phenotypic heterogeneity 
between classical DDEB and EB-pr could be explained by the MMP-1 
promoter polymorphism. The variability in disease expression could in part be 
explained by the MMP-1 induced increase in collagen VII degradation that 
triggers secondary inflammatory changes and cytokine production leading to 
the pruritus characteristic of EB-pr  (Mellerio et al., 1999; Drera et al., 2006).  
 
6.2 Patient selection and methods 
DNA samples from individuals with EB-pr (n=27), non EB-pr 
dominant DEB (n=23), recessive DEB (n=25), as well as unaffected, unrelated 
and ethnically matched control subjects (n=50) were analysed in this study. 
The controls were not age- or sex- matched. Patient ethnicities included white 
Caucasian, Middle-Eastern, South American, South-East Asian and Asian.  
I sequenced the MMP1 promoter region corresponding to the predicted 
1G/2G polymorphism in all DEB and control samples using the following 
primers: forward primer 5'-gtggaagcttacacctataatcccaacactc-3' (-4008 bp to -
3988 bp; GenBank No NM002421) and reverse primer 5'-
ctgcctggtaccctattgcgatagcaccatggc-3' (-511 bp to -543 bp) using the Sanger 
sequencing technique and with PCR amplification conditions as described 
previously (Mellerio et al., 1998). I compared the frequency of the two alleles 
between the different groups using Fisher’s exact test. 
 The blood samples for DNA mutation analysis were provided 
historically by local, national and international referrers to the Robin Eady 
National Diagnostic Epidermolysis Bullosa Laboratory in London. Prior to my 
work on this thesis, the DNA extraction and COL7A1 mutation analysis had 
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been performed by Dr. Lu Liu at the Robin Eady National Diagnostic 
Epidermolysis Bullosa Laboratory, as part of the patients’ routine clinical care 
in most cases. However, for individuals linked to separate research projects, 
DNA screening was undertaken with Ethics’ Committee approval (St Thomas’ 
Hospital Ethics’ committee; 07/H0802/104) with informed consent and carried 
out in accordance with the Declaration of Helsinki principles. Genomic DNA 
extraction and COL7A1 mutation screening was performed as described in 
Chapter 2.  
 
6.3 Results 
 In the cohort studied, all 27 EB-pr subjects (19 families) included had 
dominant DEB resulting from heterozygous COL7A1 glycine substitution 
mutations  (6 novel), while the 23 non EB-pr dominant cases (20 families) 
were caused by 13 heterozygous glycine substitution mutations (six novel) and 
a new splice site mutation; IVS37+1G>T (Figure 6.2). There was no significant 
difference in the type or location of the COL7A1 GS mutations between the 
dominant EB-pr and non EB-pr groups. In addition, phenotypic heterogeneity 
was observed, as evidenced by the variable disease expression of the 
heterozygous GS mutation p.Gly2043Arg observed in this study. Out of 12 
patients with this mutation, 4 patients had EB-pr while 8 had non EB-pr 
dominant DEB  (Table 6.1). 
On a molecular level, the incidence of the MMP1 polymorphism in the 
various clinical subgroups was analysed. The major allele in the control group 
was 1G (58.0%) while the minor allele was 2G (42.0%). In the EB-pr group, 
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the frequency of the 1G allele was 53.7% and of 2G was 46.3%, whereas in the 
non EB-pr dominant DEB subjects the frequency of 1G and 2G alleles was 
47.8% and 52.1% respectively. 2G was the major allele in the recessive DEB 
group (62.0%) (Table 6.2). There was no significant difference in allelic 
frequency between EB-pr and controls (p=0.61), EB-pr and non EB-pr 
dominant DEB (p=0.56), or non EB-pr dominant DEB and controls (p=0.25). 
However, in keeping with published data the allelic frequency was 
significantly different between the recessive DEB group and controls (p=0.02): 
where the frequency of the 2G allele was found to be higher in the RDEB 
group.  
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Figure 6.2 COL7A1 mutation analysis in individuals with dominant DEB 
in this study. Previously unreported mutations are highlighted in red boxes. 
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EB Pruriginosa (Dominant) 
Patient 
no. 








                
1 M EB-pr  p.Gly1522Glu* c.4565 G>A 45 2G/1G (Whittock et al., 1999) 
2 F EB-pr  p.Gly1770Asp c.5309 G>A 61 2G/2G This study 
3 F EB-pr  p.Gly1791Glu c.5372 G>A 62 2G/1G (Mellerio et al., 1999) 
4 F EB-pr  p.Gly1791Glu c.5372 G>A 62 2G/1G (Mellerio et al., 1999) 
5 M EB-pr  p.Gly1791Glu  c.5372 G>A 62 2G/2G (Mellerio et al., 1999) 
6 F EB-pr  p.Gly1860Arg c.5578 G>A 66 2G/1G This study 
7 F EB-pr  p.Gly1860Arg c.5578 G>A 66 2G/1G This study 
8 M EB-pr  p.Gly1913Arg c.5737 G>C  69 2G/1G This study 
9 F EB-pr  p.Gly2040Asp c.6119 G>A 73 1G/1G (Whittock et al., 1999) 
10 F EB-pr  p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
11 M EB-pr  p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
12 F EB-pr  p.Gly2043Arg* c.6128 G>A 73 2G/1G (Christiano et al., 1995a) 
13 F EB-pr  p.Gly2043Arg* c.6129 G>A 73 2G/1G (Christiano et al., 1995a) 
14 F EB-pr  p.Gly2159Glu c.6476 G>A 79 1G/1G This study 
15 F EB-pr  p.Gly2159Glu c.6476 G>A 79 1G/1G This study 
Table 6.1 COL7A1 mutations and MMP1 promoter polymorphisms associated with the various DEB 
subgroups analysed in this study. 
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16 F EB-pr  p.Gly2159Glu c.6477 G>A 79 1G/1G This study 
17 F EB-pr  p.Gly2213Arg c.6637 G>A,  83 2G/1G This study 
19 M EB-pr  p.Gly2242Arg c.6724 G>A 85 1G/1G (Lee et al., 1997) 
20 M EB-pr  p.Gly2251Glu c.6752 G>A 86 2G/2G (Shimizu et al., 1999) 
21 F EB-pr  p.Gly2251Glu c.6752 G>A 86 1G/1G (Shimizu et al., 1999) 
22 F EB-pr  p.Gly2251Glu c.6752 G>A 86 2G/1G (Shimizu et al., 1999) 
23 F EB-pr  p.Gly2251Glu c.6752 G>A 86 2G/1G (Shimizu et al., 1999) 
24 F EB-pr  p.Gly2251Glu c.6752 G>A 86 2G/1G (Shimizu et al., 1999) 
25 M EB-pr  p.Gly2287Arg c.6859 G>A 87 2G/2G (Shimizu et al., 1999) 
26 M EB-pr  p.Gly2287Arg c.6859 G>A 87 2G/1G (Shimizu et al., 1999) 
27 F EB-pr  p.Gly2290Ala c.6869 G>C 87 1G/1G This study 
28 F EB-pr  p.Gly2366Val c.7097 G>T 92 2G/2G (Chuang et al., 2004) 
                
Non-EB Pruriginosa (Dominant) 
                
29 F BDN p.Gly1483Asp c.4448 G>A 42 2G/2G This study 
30 M BDN p.Gly1522Glu* c.4565 G>A 45 1G/1G (Fassihi et al., 2005) 
31 M BDN p.Gly1522Glu* c.4565 G>A 45 2G/1G (Fassihi et al., 2005) 
32 M DDEB p.Gly1773Asp c.5318G>A 61 2G/1G This study 
33 F DDEB p.Gly2009Ala  c.6026G>C 73 2G/2G This study 
34 M DDEB p.Gly2028Glu c.6083 G>A 73 1G/1G This study 
35 F DDEB p.Gly2034Arg c.6100 G>A 73 2G/2G (Kon et al., 1997b) 
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36 M DDEB p.Gly2034Arg c.6100 G>A 73 2G/1G (Kon et al., 1997b) 
37 M DDEB p.Gly2037Arg c.6109 G>A 73 1G/1G (Iwata et al., 2006) 
38 M DDEB p.Gly2037Glu c.6110 G>A 73 2G/1G (Jonkman et al., 1999) 
39 F DDEB p.Gly2043Arg* c.6127 G>A 73 1G/1G (Christiano et al., 1995a) 
40 F DDEB p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
41 M DDEB p.Gly2043Arg* c.6127 G>A 73 2G/2G (Christiano et al., 1995a) 
42 M DDEB p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
43 M DDEB p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
44 M DDEB p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
45 F DDEB p.Gly2043Arg* c.6127 G>A 73 1G/1G (Christiano et al., 1995a) 
46 M DDEB p.Gly2043Arg* c.6127 G>A 73 2G/1G (Christiano et al., 1995a) 
47 M DDEB p.IVS 37+1 G>T c.IVS 37+1 G>T 73 1G/1G This study 
48 F DDEB p.Gly2055Glu c.6164 G>A 73 2G/2G (Christiano et al., 1996) 
49 F DDEB p.Gly2067Ala c.6200 G>C 73 2G/2G This study 
50 F BDN p.Gly2233Glu c.6698 G>A 73 2G/1G This study 
51 F DDEB p.Gly2239Asp c.6716 G>A 85 2G/2G (Tamai et al., 1998) 
Mutations in bold are novel, *mutations identified in this study with both EB-pr and non EB-pr phenotypes.DDEB-dominant dystrophic 
epidermolysis bullosa, EB-pr - epidermolysis bullosa pruriginosa, BDN- bullous dermolysis of the newborn, IVS, intervening sequence 
(intron);  SNP-single nucleotide polymorphism 
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Table 6.2 The incidence of the 1G/2G SNP in the MMP1 promoter area in 




EB-pr               
n (%) 





Controls   
n (%) 
Total patient no. n=27 n=23 n=25 n=50 
Total allele no. 54 46 50 100 
1       bg§1G/1G   7 (25.9) 6 (26.1) 2 (8.0) 16 (32.0) 
2G/1G   15 (55.5) 10 (43.5) 15 (60.0) 26 (52.0) 
2G/2G   5 (18.5) 7 (30.4) 8 (32.0) 8 (16.0) 
Total 2G alleles/ 
Total 1G+2G 
alleles 
25/54 24/46 31/50 42/100 
GG allelic 
frequency 
46.30% 52.20% 62%* 42% 
*p<0.02 compared to controls. DDEB-dominant dystrophic 
epidermolysis bullosa, EB-pr- epidermolysis bullosa pruriginosa, 
RDEB- recessive dystrophic epidermolysis bullosa. 
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In an attempt to explain the phenotypic heterogeneity encountered in 
subjects with the p.Gly2043Arg mutation in this study, the incidence of the 
1G/2G alleles was analysed in 12 individuals with this mutation. 11 subjects 
expressed the 2G polymorphism on at least one allele, while one individual 
was homozygous for the 1G polymorphism and had non EB-pr dominant DEB 
phenotype. The 1G/2G allelic differences between the 2 clinical subgroups 
were not statistically significant.  
Intra-familial variability was also noted in a previously reported 
pedigree affected by EB-pr  (Ee et al., 2007). Four family members from two 
generations demonstrated a variable clinical phenotype including BDN and 
EB-pr despite inheriting the same heterozygous GS mutation; p.Gly2251Glu. 
However, findings in this Chapter showed that there was no correlation 
between the presence or absence of the 2G allele and the EB-pr phenotype. 
Furthermore, a clinically unaffected 9-year-old offspring in the third generation 
was also found to harbour a heterozygous p.Gly2251Glu mutation, in addition 
to the 2G/1G SNP in the MMP-1 promoter area. The inconsistency of the 2G 
SNP expression in this family probably excludes MMP-1 as a cause for the 
phenotypic heterogeneity.  Other subjects with the heterozygous GS mutation 
p.Gly2043Arg had classical DDEB, EB-pr or BDN. However phenotypic 
heterogeneity could not be explained by the MMP-1 promoter 2G 
polymorphism alone (Figure 6.3).  
In addition, the incidence of the 2G/1G SNP was studied in six subjects 
within the recessive DEB group known to have developed cutaneous squamous 
cell carcinoma before the age of 30 years. All were found to harbour the 2G 
variant on one or both MMP1 alleles. 
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Figure 6.3 Phenotypic heterogeneity for the COL7A1 glycine substitution 
mutation, p.Gly2043Arg. (A) p.Gly2043Arg heterozygosity results in EB-pr 
in a 65-year-old lady with prurigo-like lesions on the legs. (B) In contrast, the 
same mutation results in non EB-pr dominant DEB, with mild blistering and 
scarring on the shin in an 18 year-old male. Pruritus was not present in this 
young patient however, it is not possible to rule out development of a pruritic 




 Molecular analysis in this study has identified 12 new heterozygous 
glycine substitutions mutations underlying EB-pr and non-pruritic (non EB-pr) 
dominant DEB expanding the current COL7A1 glycine substitution mutation 
database to 133 mutations (71 dominant, 62 recessive). These new mutations 
were also  incorporated into the novel mutation database outlined in Chapter 4. 
However, no significant differences were observed between the various 
subgroups when studying the nature or location of the EB-pr GS mutations 
compared to other dominant or recessive forms of DEB. Furthermore, analysis 
of the 1G/2G MMP1 gene promoter polymorphism in this study showed that 
there is no association between the 2G allele and the EB-pr phenotype. 
Therefore it is unlikely that this particular polymorphism acts a genetic 
modifier for the pruritic EB-pr phenotype. 
Nevertheless understanding the role of MMPs and TIMPs is potentially 
promising for future phenotype-genotype correlation in EB. As proteolytic 
enzymes, MMPs play a significant role in tissue remodelling, inflammation, 
healing and cancer invasiveness in DEB through degradation of the 
extracellular matrix (Ala-aho and Kahari, 2005; Chakraborti et al., 2003; 
Ghilardi et al., 2001; Ye et al., 2001; Kivisaari et al., 2008; Changotade et al., 
2007; Bodemer et al., 2003). MMP7 facilitates cancer progression through 
cleavage of surface molecules such as E-cadherin and syndecan-1, as well as 
extracellular matrix proteins including fibrillin and collagen VII (Kivisaari et 
al., 2008; Changotade et al., 2007). Moreover, various MMPs were found to 
influence disease severity in RDEB as evidenced by varying clinical severity in 
3 siblings affected with RDEB which was also shown to correlate with 
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increased levels of MMP2, MMP3 and MMP9 and reduced levels of TIMP1 
(Bodemer et al., 2003). In contrast, the study outlined in this Chapter did not 
identify a correlation between the MMP-1 functional polymorphism and the 
various subtypes of dominant DEB. However, given the role of MMPs and 
TIMPs in various pathophysiological aspects of DEB, other genetic variants 
might be elucidated in the future as potential genetic modifiers in DEB. In 
addition, anti-proteolytic therapies might prove a useful clinical option 
particularly for recessive DEB, given the role of increased MMP-1 expression 
and collagen VII degradation in some cases (Titeux et al., 2008). Findings in 
this Chapter however, do not suggest that EB-pr subjects will specifically 
benefit from this form of treatment compared to other individuals with DEB. 
 In addition, the above results support the published data showing that 
the -1607 1G/2G polymorphic variant in the MMP1 promoter may be 
associated with greater clinical severity in recessive DEB. It was also observed 
in this study that six subjects within the recessive DEB group developed 
cutaneous squamous cell carcinoma before the age of 30 years and each was 
found to harbour the 2G variant on one or both MMP1 alleles. This observation 
is perhaps not surprising, given the role of MMPs in cancer invasion and 
progression (Chakraborti et al., 2003; Ghilardi et al., 2001; Ye et al., 2001; 
Zinzindohoue et al., 2005). In particular, the 2G MMP1 polymorphism has 
been associated with an increased risk of developing colorectal, breast, ovarian, 
head and neck cancers where the expression levels of MMP-1 was found to 
correlate negatively with survival. 
In conclusion, despite recent studies demonstrating a significant effect 
of the -1607 1G/2G polymorphic variant in the MMP1 promoter on RDEB 
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phenotypic severity, the findings outlined in this Chapter did not demonstrate 
similar results in its dominantly inherited counterpart. This suggests that other 
genetic or environmental modifying factors play a role in the uniquely pruritic 
variant, EB-pr, and are yet to be identified. This would have important 
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The natural correction of somatic mutations; revertant mosaicism (RM) 
has been described in several inherited disorders including JEB and EBS.  The 
occurrence of this phenomenon in EB is likely to be more prevalent than 
anticipated, but at the time of thesis work there had been no reports of RM in 
DEB. This Chapter investigates the occurrence of non-fragile patches of skin in 
a 41-year-old patient with RDEB-sev gen as a possible consequence of RM. 
Genomic analysis of the peripheral leukocyte DNA revealed a compound 
heterozygote mutation; c.1732C>T (p.Arg578Stop) in exon 13 and c.7786delG 
(p.Gly2593fsX4) in exon 104. The same mutations were found in genomic 
DNA extracted from whole skin taken from both affected and unaffected skin. 
However, sequencing of cDNA from both areas revealed only a heterozygous 
nonsense mutation in unaffected skin compared to the compound heterozygous 
loss of function mutations found in blister-prone skin. Further analysis revealed  
nearly undetectable levels of collagen VII expression in unaffected skin 
fibroblasts indicating that keratinocytes are the site of mutation reversion and 
the source of functional collagen VII. Long-range sequencing was consistent 
with an intragenic crossover occurring somewhere between exons 21 and 104 
resulting in a wild type allele and subsequent non blister-prone areas of skin. 
The detection of RM in RDEB offers an exciting model of ‘natural cell 
therapy’ with an unlimited resource for cell therapy and reflects a phenomenon 
that is probably overlooked in RDEB. 
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7.1 Introduction 
Revertant mosaicism (RM) refers to the natural presence of two 
genetically distinct populations of cells as a result of spontaneous mutation 
correction during mitosis (Hall, 1988; Jonkman et al., 1997). This naturally 
occurring phenomenon and through various potential mechanisms, results in 
restoration of wild type phenotype. 
The RM phenomenon has been reported in several inherited diseases, 
including X-linked severe combined immunodeficiency (Stephan et al., 1996), 
Bloom’s syndrome (Ellis et al., 1995), Fanconi’s anaemia (Kalb et al., 2007), 
X-linked Wiscott–Aldrich syndrome (Ariga et al., 2001), Duchenne muscular 
dystrophy (Klein et al., 1992), tyrosinemia type I (Demers et al., 2003), Lesch-
Nyhan adenosine deaminase deficiency (Hirschhorn et al., 1994), Omenn 
syndrome (Wada et al., 2005), X-linked ectodermal dysplasia (Nishikomori et 
al., 2004), T-cell immunodeficiency (Rieux-Laucat et al., 2006) and leucocyte 
adhesion deficiency (Tone et al., 2007; Uzel et al., 2008). It has also been 
increasingly described in genodermatoses including EB as well as ichthyosis en 
confetti (Choate et al., 2010; Burger et al., 2012) and dyskeratosis congenita  
(Vulliamy et al., 1999; Jongmans et al., 2012). 
At the time this thesis began, with reference to EB, RM had only been 
reported in EBS and JEB as a result of in vivo reversion of mutations in 
LAMB3, COL17A1 and KRT14 (Darling et al., 1999; Schuilenga-Hut et al., 
2002; Smith et al., 2004; Pasmooij et al., 2005; Pasmooij et al., 2007; Jonkman 
and Pasmooij, 2009; Jonkman et al., 1997) . 
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7.2 The incidence of revertant mosaicism 
The reported incidence of RM generally, has been variable. It has been 
estimated to occur in up to 11% of patients with Wiskott-Aldrich syndrome 
(Stewart et al., 2007), 18% of individuals with Fanconi’s anaemia (Kalb et al., 
2007) and 23% of patients with Bloom syndrome (German et al., 1977). 
Higher rates were reported in nHJEB (35%) (Jonkman and Pasmooij, 2009; 
Pasmooij et al., 2012) and tyrosinemia type I (85%) (Demers et al., 2003). 
However despite rare reports of RM, this phenomenon is thought to be more 
prevalent than expected, with many cases likely going unnoticed. One report 
by Pasmooij et al., even suggested that in vivo reversion might occur in all 
patients with generalized nHJEB (Pasmooij et al., 2012). In their Dutch cohort 
of 10 nHJEB patients, 6 patients with generalized disease showed genetic 
evidence of revertant mosaicism, where as the other four demonstrated clinical 
and photographic evidence of revertant skin patches. Also, in support of a high 
prevalence of RM is the fact that multiple in vivo correcting mutations can 
occur in the same individual as will be discussed later in this Chapter. In 
addition, revertant cells can be found in normal tissue as in the case of JEB 
where keratinocytes expressing collagen XVII were found in both clinically 
affected and unaffected skin, adding to the hypothesis that many cases of 
revertant mosaicism are undetected (Pasmooij et al., 2005). 
 
7.3 Mechanisms of revertant mosaicism 
Various corrective mechanisms have been observed in RM, including 
back mutations, second-site mutations, intragenic crossovers and mitotic gene 
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conversions (Jonkman et al., 1997; Pasmooij et al., 2005; Frank and Happle, 
2007; Kvittingen et al., 1994; Ellis et al., 1995; Jonkman and Pasmooij, 2009; 
Jonkman et al., 2003; Chen et al., 2007). Back mutation refers to the 
restoration of wild type sequence, whereas second-site mutations involve 
additional exonic or intronic compensatory mutations that lead to the 
restoration of the open reading frame. Intragenic cross-over results from the 
exchange of genetic material between two alleles whereas in mitotic gene 
conversion one allele is altered by genetic material received from a donor allele 
that remains unchanged. Different corrective phenomena have also been 
observed in the same patient (Pasmooij et al., 2005; Jonkman and Pasmooij, 
2009). Another rare mechanism for RM is that of DNA slippage, which occurs 
during replication, particularly in genes with a high GC content. This was 
observed in 3 patients with Wiskott-Aldrich syndrome from the same family in 
whom a known 6 base pair insertion mutation was deleted as a result of 
proposed DNA slippage resulting in restoration of wild type sequence (Wada et 
al., 2001; Wada et al., 2004). Another mechanism observed in mammals, is 
that involving transposons also known as the ‘jumping genes’. These are 
sequences of genetic material that can alter their position leading to induction 
or reversion of mutations (McClintock, 1956; Druker and Whitelaw, 2004; 
Whitelaw and Martin, 2001). Although transposons have been observed in 
Duchenne muscular dystrophy their role in RM is yet to be verified (Bittar and 
Happle, 2005; Pizzuti et al., 1992). 
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7.3.1 Revertant mosaicism: a random or directed process? 
It is still unclear whether the occurrence of RM represents a directed 
corrective process or merely a random natural phenomenon. Some hypotheses 
in support of the former, suggest that the presence of an ancestral RNA-
sequence cache could lead to a template-directed mutation reversion (Lolle et 
al., 2005). However, there are abundant proposals in support of a random 
corrective process. In particular is the observation that the average rate of 
human mutagenesis is around 2.5 x 108 per nucleotide per generation with in 
vivo reversion estimated at 0.39 per cell division (Nachman and Crowell, 
2000). This not-so-rare-process might also be influenced by several potential 
modulators including innate DNA instability, mutagenic metabolites, UV 
radiation, as well as feto-maternal factors (Choate et al., 2010; Demers et al., 
2003; Pasmooij et al., 2012; Bergeron et al., 2004). In tyrosinemia type I, the 
high rate of RM, estimated to occur in 85% of cases, is thought to result from 
the intracellular accumulation of mutagenic metabolites fumarylacetoacetate 
and maleylacetoacetate as a consequence of fumarylacetoacetate hydrolase 
deficiency (Demers et al., 2003). In ichthyosis en confetti the abnormal 
localisation of keratin 10 within the nucleus is thought to lead to an increased 
recombination mutation rate and silencing of the mutant allele resulting in the 
characteristic widespread confetti-like revertant patches (Choate et al., 2010). 
On the other hand, in DNA instability syndromes such as Fanconi’s anaemia 
and Bloom syndrome, the increased mutation rate is thought to contribute to 
the high occurrence of RM (Lai-Cheong et al., 2011). Moreover, UV radiation, 
through an increase in mutagenesis has also been implicated in RM, although 
this has not been validated (Pasmooij et al., 2012). It has also been proposed 
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that feto-maternal cell trafficking could explain the occurrence of two 
genetically distinct population of cells in RM cases, however studies in 
tyrosinemia type I, did not support this hypothesis (Bergeron et al., 2004). 
 
7.3.2 Revertant mosaicism: a single or multiple event? 
The occurrence of multiple corrective somatic reversions affecting 
different cell lineages in the same patient also weakens the argument for a 
directed corrective process in RM (Pasmooij et al., 2007). Multiple revertant 
clones have been observed in tyrosinemia type I (Bliksrud et al., 2005), Omenn 
syndrome (Wada et al., 2005), severe combined immunodeficiency disease 
(Rieux-Laucat et al., 2006), Wiskott–Aldrich syndrome (Boztug et al., 2008), 
as well as JEB (Pasmooij et al., 2007; Pasmooij et al., 2005). Differing somatic 
reversions were also shown to involve B-lymphocytes, T-lymphocytes as well 
as natural killer cells in 2 siblings with Wiskott-Aldrich syndrome (Boztug 
2008). Although the mechanisms by which these multiple events occur are still 
unclear, the potential mutagenic modulators outlined above could contribute to 
an increased mutation rate, as do potential mutational hot spots such as direct 
repeats or homonucleotide tracts (Hamanoue et al., 2006).  
Moreover, the multiple reversion mutations can occur by differing 
mechanisms as demonstrated in one cohort of 14 patients with nHJEB 
(Pasmooij et al., 2012). In this study, the COL17A1 mutation, c.2237delG, was 
shown to be corrected by five different in vivo reversion events in the same 
patient with no predilection for a particular correction mechanism (Pasmooij et 
al., 2012). This was also observed in Wiskott–Aldrich Syndrome where over 
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30 different corrective mutations were observed within the same patient (Davis 
et al., 2010a). This is in contrast to ichthyosis en confetti, an autosomal 
dominant disease, where only mitotic combination revertant mutations are 
observed (Choate et al., 2010). It is possible though, that other unidentified 
mutations with differing reversion mechanisms are yet to be discovered. 
 
7.4 The clinical effects of revertant mosaicism 
The implications of RM on phenotype are dependent on various factors 
including the timing of reversion and its relation to stem cells, the mechanism 
of genetic correction and whether it leads to complete restoration of wild type 
sequence, as well as the extent of selective advantage of revertant cells. 
The precise timing of RM phenomena is still unclear. However, the 
expanding nature of many revertant patches noted in EB, suggests that this 
phenomenon occurs earlier on during embryogenesis to affect regenerative 
stem cells (Davis and Candotti, 2010b). It might also explain why RM is a 
common phenomenon in inherited conditions affecting self-regenerating 
organs such as skin, liver and blood. The timing of RM events during 
embryogenesis is also reflected by the type of reverted cells, such as 
hepatocytes, lymphocytes, muscle cells and fibroblasts (of mesodermal origin), 
as well as keratinocytes (of ectodermal origin).  Involvement of the latter for 
example, would suggest reversion after the formation of the 3-layered embryo 
and following the completion of blashko lines, owing to the clinical appearance 
and distribution of the revertant patches (Pasmooij et al., 2012; Pasmooij et al., 
2007; Pasmooij et al., 2005). 
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The mechanism of RM could also affect the degree of phenotypic 
amelioration. Reversions resulting in complete restoration of wild type such as 
back mutations result in normal protein expression and wild-type phenotype. 
However, mechanisms such as second-site mutation might not result in a 
completely normal protein owing to an abnormal intervening genetic sequence 
and therefore, although reversion might result in clinical amelioration the wild-
type phenotype is not fully restored (Lai-Cheong et al., 2011; Pasmooij et al., 
2005). Furthermore, clinical improvement may not be seen in cases of partial 
RM. This phenomenon has been described in nHJEB and EBS secondary to 
mutations in COL17A1 and KRT14 respectively. In one case, a deletion 
mutation in COL17A1 was partially corrected leading to the expression of an 
immunohistochemically reactive, albeit non-functional, protein. In another 
example, an EBS patient homozygous for the splice site mutation c.526-2A>C 
showed immunohistochemical expression of K14 in some areas, yet no 
reversion was detected on genomic DNA. However, mRNA analysis revealed 
an additional transcript, which led to the expression of a semifunctional protein 
that was detected immunohistochemically and ultrastructurally but that did not 
result in any clinical amelioration.  
In addition, revertant cells have been associated with selective growth 
advantage in vivo, which is reflected by the occurrence of large expanding 
patches of revertant skin in some cases. This could also be a reflection of the 
degree of stem cell reversion or possibly the effects of wild-type protein on cell 
function (Pasmooij et al., 2005; Hamanoue et al., 2006; Davis et al., 2010a; 
Stewart et al., 2007; Stephan et al., 1996; Wada et al., 2003; Jonkman and 
Pasmooij, 2012). 
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In this Chapter, an individual with RDEB found to have 2 areas of non-
fragile skin is studied. Somatic revertant mosaicism is explored as a potential 
explanation for this unique clinical finding. 
 
7.5 Case study 
A 41-year-old Caucasian British man was diagnosed with RDEB-sev 
gen resulting in mutilating scars with bilateral mitten deformities, nutritional 
deficiencies, growth retardation, oesophageal strictures and recurrent squamous 
cell carcinomas. Despite generalised skin fragility, two small patches of skin 
on his left wrist and right shin never blistered despite repeated trauma. 
Examination of these two non-fragile areas, that measured approximately 85 
cm2, revealed skin of normal appearance and texture (Figure 7.1). 
To explain this phenotypic heterogeneity, and following ethics 
committee approval (St Thomas’ Hospital Ethics Committee: 07/H0802/104) 
and informed consent and in accordance with the Declaration of Helsinki 
principles. Blood samples were taken from the patient, his brother and parents 
for mutational analysis. The skin from the left wrist was also investigated with 
biopsies that I took from both the blister-prone (unreverted) and the normal-
appearing (reverted) areas and I performed collagen VII immunolabelling 
(Figure 7.2), as well as the reverse transcriptase PCR and mutational analysis 
including long range sequencing as described in Chapter 2. TEM was 
performed by Patricia Dopping-Heppenstal at  the Robin Eady National 
Diagnostic Epidermolysis Bullosa Laboratory. The area of potential RM on the 
patient’s right shin was not investigated in this study. 
 199 
Figure 7.1 Clinical assessment of two clinically revertant areas of skin. In a 
40-year-old male patient with severe RDEB, two patches of skin on the left 
wrist and right shin showed no evidence of skin fragility. These were clinically 
and texturally similar to normal skin. 
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Figure 7.2 Immunohistochemical and ultrastructural findings in reverted, 
unreverted and normal skin. Immunohistochemical analysis revealed 
complete absence of collagen VII expression at the basement membrane in 
unreverted skin with absence of anchoring fibrils and blister formation on 
ultrastructural level (arrows depict DEJ, asterisk indicates a blister) (A).  This 
is in contrast to reverted skin, which shows bright linear collagen VII labelling 
at the basement membrane comparable to that of normal skin, as well as 
demonstrable anchoring fibrils (B). However, these seem shorter and less 
discernable than in normal skin (C). Bars for immunofluorescence microscopy 







C    Normal control 
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7.6 Results and discussion 
 
Genomic analysis of the proband’s peripheral leukocyte DNA revealed 
a compound heterozygote mutation involving two COL7A1 loss-of-function 
mutations; c.1732C>T (p.Arg578Stop) in exon 13 (maternal) and c.7786delG 
(p.Gly2593fsX4) in exon 104 (paternal) (Figure 7.3). Both of these mutations 
were shown to be recurrent within the white British population (Mellerio et al., 
1997). The brother was a carrier for the p.Arg578Stop mutation.  
 
Figure 7.3 Peripheral blood genomic DNA analysis. Mutation analysis revealed 
a compound heterozygous mutation in the affected proband. His brother was a 
carrier of the deletion mutation c.7786delG in exon 104. 
Exon 13 +/- p.Arg578Stop 
Exon 104 
Wild type 
+/- c.7786delG +/- c.7786delG 
Wild Type Brother RDEB 
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To explain the phenotypic heterogeneity genomic DNA was extracted 
from whole skin taken from both reverted and unreverted skin, which revealed 
similar findings to those observed in peripheral genomic DNA (Figure 7.4A). 
To explore the phenotypic heterogeneity further, genomic RNA extraction and 
reverse transcriptase-PCR across the sites of both mutations was performed. 
This was done to identify any genotypic heterogeneity on a transcriptional 
level. Sequencing of cDNA from both reverted and unreverted areas revealed 
only a heterozygous nonsense mutation in reverted skin compared to the 
compound heterozygous loss of function mutations found in unreverted skin 
(Figure 7.4B). To explore the discordance between the whole skin gDNA and 
cDNA analysis, RNA was extracted from fibroblasts in both affected and 
unaffected areas. Real time RT-PCR revealed that the collagen VII expression 
in revertant whole skin was similar to that observed in the brother who was a 
heterozygous carrier. However the level of expression in fibroblasts harvested 
from revertant skin was nearly undetectable (Figure 7.5). This indicates that 
keratinocytes are the site of mutation reversion and the source of functional 
collagen VII. The latter was reflected by the presence of anchoring fibrils on 
TEM and positive BM labelling on immunofluorescence. The presence of both 
unreverted fibroblast and reverted keratinocyte mixture in whole skin samples 
could explain the inability to detect reversion on whole skin gDNA analysis. 
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Figure 7.4 COL7A1 mutational analysis in reverted, unreverted and normal skin. (A) Sequencing of gDNA from unreverted skin reveals 
compound heterozygosity for the mutations c.1732C>T (p.Arg.578Stop) in exon 13 and c.7786delG (p.Gly2593fsX4) in exon 104. Both 
mutations are present in gDNA from the reverted skin compared to wild type. (B) Sequencing of cDNA extracted from unreverted skin shows 




Figure 7.5 COL7A1 expression in whole skin and fibroblasts. Real-time RT-PCR shows barely detectable COL7A1 expression in affected skin 
or cultured fibroblasts derived from unreverted areas. In contrast, reverted skin shows COL7A1 expression levels similar to those in the patient’s 
brother (a heterozygous carrier). However, cultured fibroblasts from the reverted area fail to show a similar increase in COL7A1 gene expression. 
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To explore the mechanism of loss of compound heterozygosity, long-range 
sequencing of the patient’s reverted skin cDNA was performed using 
LongAmp Taq DNA polymerase as described in Chapter 2. In addition, 
polymorphism analysis was performed to distinguish between maternal and 
paternal alleles. This identified differences for a common PvuII polymorphism 
in exon 21 (c.2817G/A; rs1264194 A allele- paternal, G –allele- maternal). The 
heterozygosity was present at the level of cDNA and gDNA in both the 
affected as well as the unaffected skin. However, sequencing revealed a 
COL7A1 allele bearing neither the c.1732C>T (p.Arg578Stop) in exon 13 
(maternal) nor the c.7786delG (p.Gly2593fsX4) in exon 104 (paternal). This 
was detected in combination with a paternally derived A nucleotide for the 
exon 21 polymorphism.  Collectively, this data is consistent with an intragenic 
crossover occurring somewhere between exons 21 and 104 resulting in a wild 
type allele (Figure 7.6). This results in the expression of collagen VII which is 
reflected clinically by the presence of a patch of skin that is functionally 
similar to that present in the proband’s brother who is a heterozygous carrier 





Figure 7.6 A schematic outlining the proposed intragenic crossover. The maternal nonsense mutation in exon 13 occurs on the same 
allele bearing a G nucleotide for a PvuII polymorphism in exon 21, but in the reverted skin the wild-type sequence for exon 104 occurs on 
the same allele bearing a paternal A nucleotide for the exon 21 polymorphism. This suggests that intragenic crossover has occurred 
somewhere between exons 21 and 104, and that the patient has restored one functional COL7A1 allele.  
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The occurrence of RM in genodermatoses in particular, provides an 
exciting model for studying RM, as the occurrence and behaviour of revertant 
patches, in addition to effects of therapy can be easier to identify clinically. In 
RDEB, the novel identification of a RM patch of skin that shows functional 
properties similar to those of a heterozygous carrier is likely to provides new 
therapeutic opportunities for patients. This potentially unlimited resource of 
‘natural cell therapy’ can be utilized for skin directed therapy such as skin 
grafts or even for the induction of pluripotent stem cells (iPSCs) capable of 
differentiating into both haematopoietic and mesenchymal stem cells.  
With regards to skin directed therapy, Gostynski et al. used adhesive 
stripping to remove the epidermis from revertant skin patches in a patient with 
nHJEB (Gostynski et al. 2009). This was followed by the culture of 
keratinocytes to create skin grafts that were later transplanted onto affected 
skin. However, the level of revertant keratinocytes in the biopsies and 
subsequently the grafts was insufficient to achieve full functional repair. This 
could be explained by the low level of mosaicism in culture, estimated at 30% 
of revertant keratinocytes. This reduced to only 3% in transplanted grafts 
(Gostynski et al., 2009). It is also likely to reflect a low number of revertant 
stem cells within the graft, an observation that was explored in another study 
by Mavilio et al. (Mavilio et al., 2006). Multiple biopsies of revertant patches 
were taken from a patient with nHJEB for gene therapy. Holoclone-forming 
cells were only identified in 2 palmar biopsies but were undetectable in other 
biopsies from most of the patient’s skin. This is thought to be due to the 
continuous proliferative stimulus induced by chronic wound healing observed 
in nHJEB. The palmar biopsies were then subjected to retroviral LAMB3 
 208 
genetic correction followed by culture of corrected keratinocytes, which were 
used for subsequent grafting. This resulted in full functional correction that was 
sustained on a molecular and clinical level for over 5 years with no reported 
long-term side effects (Mavilio et al., 2006; De Luca et al., 2009). 
 One potential method of increasing the yield of epidermal stem cells in 
grafts would be the use of punch grafting which utilizes full thickness skin 
obtained by punch biopsies for the purpose of wound healing (Nordstrom and 
Hansson, 2008; Thami et al., 2004; Kirsner et al., 1996; Yuen et al., 2013). 
This has only been applied in RM recently, where revertant skin was punch 
grafted into chronic ulcers in patients with nHJEB. Complete ulcer re-
epithelialization occurred within 14 days of grafting with no subsequent loss of 
skin integrity during the 18 months follow-up period (Gostynski et al., 2014). 
However, a more definitive way of generating an unlimited resource of 
gene corrected cells is that by inducing iPSCs from revertant colonies. This is 
an exciting emerging technique by which patient-specific iPSCs can be used 
for skin directed cell therapy or even bone marrow transplantation. Gene 
corrected iPSCs have already been generated from patients with recessive 
dystrophic EB, which were capable of differentiating to both hematopoietic 
and non-hematopoietic lineages including keratinocytes (Tolar et al., 2011; 
Tolar et al., 2014; Itoh et al., 2011). In addition, iPSCs were shown to 
differentiate into both hematopoietic and mesenchymal stem cells capable of 
homing into blistered skin following bone marrow transplantation (Tolar et al., 
2011; Wagner et al., 2010). iPSCs generated from reverted colonies has the 
potential of providing an unlimited patient specific resource of corrected cells 
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obviating the need for induced genetic correction. 
In conclusion, this Chapter outlines the first description of RM in an 
individual with RDEB. In the case studied, RM is likely a result of intragenic 
cross-over in the COL7A1 gene, which resulted in the generation of wild type 
alleles and the restoration of collagen VII expression at the basement 
membrane with detectable anchoring fibrils in reverted skin. The RM 
phenomenon is likely to be more common than initially thought as evidenced 
by the publication of 3 subsequent cases of RDEB and Kindler syndrome with 
proven RM (Pasmooij et al., 2010; van den Akker et al., 2012; Lai-Cheong et 
al., 2012). This represents an exciting resource for patient directed cell therapy 










Cell therapy: The role of 
intradermal allogeneic fibroblasts on 












Intradermally injected allogeneic fibroblasts in individuals with RDEB 
survive for only a few days but can increase collagen VII at the DEJ for several 
weeks or months. The precise mechanism and duration of the response, 
however, are not known. A more detailed analysis was undertaken in one 
RDEB individual and found that a single fibroblast injection led to increased 
collagen VII labelling at the DEJ for ~9 months (returning to baseline levels by 
12 months) and increased COL7A1 expression for ~3 months (back to baseline 
by 6 months). The elevated COL7A1 expression was paralleled by increased 
expression of HB-EGF, encoding heparin-binding EGF-like growth factor. 
Treatment of control and RDEB cultured keratinocytes and fibroblasts with 
recombinant HB-EGF led to increased COL7A1 gene expression, with 
increased AP-1 transcription factor levels. Injection of fibroblasts into the 
margins of chronic wounds in the RDEB subject led to rapid re-
epithelialization. The collective data indicate that HB-EGF may be a key 
cytokine in the response of RDEB keratinocytes to allogeneic fibroblast 
injections in increasing mutant but partially functional collagen VII at the DEJ, 
and that a single injection of cells can improve wound healing and alter the 









Significant advances have been made in the last decade with regards to 
cell therapy in DEB as discussed in Chapter 1. Understanding of the cellular, 
molecular and ultrastructural pathology underlying DEB has paved the way for 
the delivery of cell based therapy utilising keratinocytes, fibroblasts, stem cells 
and bone marrow derived progenitors to increase collagen VII expression at the 
BMZ. Moreover, progress has been made in the mode of delivery of cell 
therapy to involve cutaneous applications, systemic infusion as well as bone 
marrow transplantation (Table 8.1). 
 
8.2 Skin directed cell-therapy 
Local cell therapy in the form of allografts (McGrath et al., 1993b; 
Falabella et al., 2000; Falabella et al., 1999), ex-vivo genetically corrected 
keratinocyte sheets or organotypic skin cultures (Woodley 2003, Ortiz-Urda 
2002) have been utilised to restore skin integrity and to treat intractable skin 
ulcers in RDEB. However, this mode of localised cell therapy is limited by 
variable success of engraftment, infection, fragility of keratinocyte sheets, 
difficult gene transfer into epidermal keratinocyte and biosafety issues, as well 
as, low level of maintained collagen VII expression (Sat et al., 2000; 
Ghazizadeh et al., 1999). Similarly, allogeneic dermal substitutes did not alter 
collagen VII expression as evidenced by immunohistochemical and 
ultrastructural studies (Kubo and Kuroyanagi, 2004; Natsuga et al., 2010; 
Hasegawa et al., 2004).   
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Table 8.1 An outline of the evolution of cell therapy in RDEB at the time of this study. 
Study 
Reference 
Cell Source Recipient Method Outcome 
 







In vivo grafting 
Clinically there was little improvement in wound 
healing. Transient expression of some collagen VII 




thickness graft from 
unaffected skin covered 




In vivo grafting 
Clinically there was stable improvement in wound 










In vivo grafting 
Clinically there was accelerated wound healing with 





fibroblast skin equivalent 
(Apligraf) 
Human paediatric 
RDEB and JEB 
In vivo grafting 
Clinically there was accelerated wound healing but 
collagen VII expression was not assessed. 
Wollina et al., 
2001 
Autologous keratinocytes 





In vivo grafting 
Clinically there was stable improvement in wound 
healing for over 12 months but collagen VII 






fibroblast skin equivalent 
(Apligraf) 
Human paediatric 
RDEB and JEB 
In vivo grafting 
Clinically there was accelerated wound healing but 










Clinically there was accelerated wound healing but 
collagen VII expression was not assessed. 










Clinically there was accelerated wound healing 
although there was no demonstrable increase in 
collagen VII expression. 
Chen et al., 
2002b 
Gene-corrected human 





In vivo grafting 
There was increased expression of collagen VII at the 
DEJ with formation of anchoring fibrils in human 
grafts. 
Goto et al., 
2006 
Gene-corrected human 
DEB keratinocytes and 
fibroblasts 





grafts into rat 
wounds 
Expression of collagen VII in the DEJ of the 
transplanted grafts was higher using gene-corrected 






keratinocytes were mixed 




In vivo grafting 
This study showed that iPSCs could differentiate into 
keratinocytes capable of regenerating a fully 
differentiated epidermis in vivo. 
 215 
Skin Directed Injectable Cell Therapy    
Ortiz-Urda et 
al., 2003 
Human RDEB fibroblasts 
overexpressing collagen 
VII, RDEB fibroblasts 






intact mouse skin 
and human RDEB 
organotypic skin-
equivalents 
COL7A1 gene-corrected fibroblasts produced stable 
collagen VII and anchoring fibril expression in vivo 
for the length of the study (16 weeks). 
Woodley et 
al., 2003 
Human RDEB fibroblasts 
overexpressing collagen 
VII, RDEB fibroblasts 






intact mouse skin  
COL7A1 gene-corrected fibroblasts produced stable 
collagen VII and anchoring fibril expression in vivo 
for 4 months. Also normal human fibroblasts 
increased collagen VII expression at the DEJ as 
effectively as gene-corrected fibroblasts when injected 
at a density of 5x106 cells. 
Fritsch et al., 
2008 







10% of normal 
collagen VII levels) 
2 Intradermal 
injections 7 days 
apart 
Stable expression of collagen VII at the DEJ was 
noted with improved skin integrity for at least 100 
days. 




RDEB fibroblasts or 





10% of normal 
collagen VII levels) 
2 Intradermal 
injections 7 days 
apart 
Stable expression of collagen VII at the DEJ was 
noted with improved skin integrity for at least 100 
days but no significant side effects or immune 
response to collagen VII. 
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An increase in collagen VII expression and anchoring 
fibril formation was maintained at 3 months mainly 
due to increase in the patient's own collagen VII with 
subsequent formation of rudimentary anchoring 
fibrils. None of the 5 patients developed collagen VII 
antibodies. 
Conget et al., 
2010 






There was evidence of increased collagen VII 
expression at the DEJ at 4 months with accelerated 
skin healing. 














There was evidence of migration of USSCs into 
wound from a distant intradermal injection site as well 
as following systemic injection with subsequent 
accelerated healing. 











COL7A1 gene-corrected fibroblasts homed to mouse 
skin wounds with accelerated skin healing. There was 
increased expression of collagen VII at the DEJ with 
formation of anchoring fibrils that was sustained for 
the duration of the study (8 weeks). 
Tolar et al., 
2009 
Wild type mouse bone 
marrow cells 
Col7a1-/- mouse  BM infusion 
Proof of principle study showing that wild type BM 
cells homed to wounded skin with increased collagen 
VII expression and anchoring fibril formation at the 
DEJ as well as improved overall survival.  
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Chino et al., 
2008 
CD90 depleted mouse 
bone marrow cells 
Col7a1-/- mouse  BM infusion 
BM cells homed to skin even without prior injury with 
increased collagen VII expression and fibrillar 
structure formation at the DEJ, as well as improved 
overall survival. 
Wagner et al., 
2010 
Whole human bone 








All patients demonstrated skin and marrow chimerism 
and clinical improvement. 5 out of 6 recipients 
showed increased levels of collagen VII at the DEJ. 
Tolar et al., 
2011 
Whole bone marrow 
from siblings, unrelated 
donor and unrelated cord 
blood donor and 
allogeneic MSCs 
Human paediatric 
RDEB and JEB 
Intravenous 
infusion 
4 out of 12 patients died due to complications or 
disease progression. There was clinical improvement 
in all assessed patients and increased collagen VII 
expression in 3 RDEB patients. There was increased 
laminin-332 expression at the DEJ in 1 JEB patient. 
BM; bone marrow, DEJ; dermoepidermal junction, iPSCs; induced pluripotent stem cells, JEB; junctional epidermolysis bullosa, MSCs; 




Therefore, to enhance delivery and increase bioavailability of cells in vivo, 
intradermal injection of keratinocytes and fibroblasts was initially attempted in 
animal models. In one study, regeneration of normal skin was demonstrated in vivo 
by infusion of lentivirus transduced DEB keratinocytes and fibroblasts into the 
skin of severe combined immunodeficiency (SCID) mice (Chen et al., 2002b). 
This was followed by other studies where gene-corrected fibroblasts were 
intradermally injected into RDEB organotypic skin-equivalents, which have been 
grafted onto immunodeficient mice. In both animal models, intradermal cell 
injection resulted in restoration of collagen VII expression at the DEJ (Ortiz-Urda 
et al., 2003; Woodley et al., 2003). 
Both keratinocytes and fibroblasts were used for cell therapy up until this 
point. However, although keratinocytes were shown to produce more collagen VII 
in vivo, studies in murine models revealed that gene-corrected RDEB fibroblasts 
resulted in greater collagen VII expression at the DEJ compared to gene-corrected 
RDEB keratinocytes (Goto et al., 2006). Therefore, these findings coupled to the 
optimization in fibroblast delivery, paved the way for intradermal allogeneic 
fibroblast injections in RDEB patients and will be discussed in more details later 
in this Chapter (Wong et al., 2008; Yan and Murrell, 2010). Moreover, 
understanding of stem cell biology and the role of BM derived progenitors on 
wound healing, has led to the intradermal infusion of allogeneic BM derived 
mesenchymal stromal cells (MSCs) in RDEB patients (Conget et al., 2010). In a 
study by Conget et al., a single injection resulted in increased collagen VII 
expression at the DEJ and improved healing of chronic ulcers that lasted for 4 
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months. In addition, in vivo studies have demonstrated that local and systemic 
injection of human umbilical cord blood-derived unrestricted somatic stem cells 
(USSCs) was found to promote wound healing and skin regeneration in mouse 
models. The USSCs even if injected intradermally at a distant site were found to 
be capable of migrating to areas of wounding (Liao et al., 2013). 
 
8.3 Systemic delivery of cell therapy 
Further attempts to increase the bioavailability of cell therapy led to the 
intravenous injection of human fibroblasts into transgenic RDEB mice (Woodley 
et al., 2007). In this study, fibroblasts were shown to home to skin, leading to 
increased collagen VII expression at the BMZ and promoting wound healing. 
Similarly, preclinical studies in COL7A1 null animal models demonstrated that the 
systemic infusion of bone marrow derived stem cells resulted in amelioration of 
collagen VII expression and subsequent reduction of skin fragility. Survival was 
also extended in the treated mouse embryos (Tolar et al., 2009; Chino et al., 
2008). 
More recently, in vivo studies have demonstrated that local and systemic 
injection of human umbilical cord blood-derived USSCs was found to promote 
wound healing and skin regeneration in immunocompromised mouse models with 
full-thickness excisional wounds (Liao et al., 2013). In this study, it was shown 
that USSCs specifically migrate to wounds even following distant intradermal or 
systemic injection of USSCs. 
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These studies paved the way for clinical trials using bone marrow 
transplantation in a murine model of RDEB (Tolar et al., 2009) and subsequently 
the infusion of matched allogeneic bone marrow stem cells with chemoablative 
pre-conditioning in children with RDEB (Wagner et al., 2010). This led to partial 
correction of collagen VII expression with amelioration of skin fragility. However, 
this procedure is fraught with risks relating to immunosuppression, carcinogenesis 
and incomplete correction. Therefore, measures under consideration to reduce 
morbidity and mortality include use of reduced intensity chemoablation and co-
infusion of MSCs  (Uitto et al., 2012; Petrova et al., 2010; Conget et al., 2010). 
Other promising alternatives include the infusion of homologous transgenic stem 
cells or patient specific-RDEB iPSCs cells in an attempt to achieve safer patient 
specific therapy (Tolar et al., 2011; Murauer et al., 2011; Uitto, 2011b). RDEB 
iPSCs derived from fibroblasts and keratinocytes were found to differentiate into 
both mesenchymal and haematopoietic stem cells and produced collagen VII in 
vivo  (Tolar et al., 2011; Uitto, 2011b; Bilousova et al., 2011). A significant draw 
back with the use of iPSCs however, relates to the increased risk of malignancy 
owing to the use of transcription factors that could potentially lead to oncogenic 
effects (Liang et al., 2012). 
 
8.4 The evolution of fibroblasts cell therapy 
Although initial studies involving allogeneic skin grafts, keratinocytes 
sheets as well as skin bio-equivalents offered novel therapeutic options they were 
faced with multiple limitations (Eisenberg and Llewelyn, 1998; Fivenson et al., 
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2003; McGrath et al., 1993b; Verplancke et al., 1997; Wollina et al., 2001). These 
include the high risk of graft loss, which was estimated at 40% in transplanted 
burn wounds (Woodley et al., 1988; Gallico et al., 1984). In addition grafting is 
associated with technical limitations, pain, infection, scarring and requires 
intensive wound care. Therefore the emergence of fibroblast cell therapy offered a 
long awaited novel therapeutic option that was relatively safe and less invasive 
than skin grafting. 
The application of fibroblast cell therapy in RDEB was first attempted in 
animal models by 2 independent studies (Ortiz-Urda et al., 2003; Woodley et al., 
2003). Ortiz-Urda et al. demonstrated that intradermal injection of COL7A1 gene 
corrected human RDEB fibroblasts overexpressing collagen VII directly into 
immune deficient mouse skin as well as regenerated RDEB human skin led to 
localisation and restoration of collagen VII expression at the BMZ for up to 4 
months (Ortiz-Urda et al., 2003). Woodley et al. achieved similar results in both in 
vitro and in vivo animal studies but also noted that normal fibroblast can secrete 
and deposit collagen VII at the BMZ as effectively as gene corrected fibroblasts, a 
finding that could be related to the higher number of fibroblasts used in this study 
(5 x 106 for intradermal injections as opposed to 1 x 106 fibroblasts in the previous 
study) and possibly earlier passage cells (Woodley et al., 2003). The same group 
later explored the intradermal injection of self -inactivating lentiviral vector 
expressing human collagen VII  (Woodley et al., 2004b) as well as recombinant 
collagen VII into mouse skin (Woodley et al., 2004a). The latter confirmed that 
there is a dose dependent expression of collagen VII in the skin either by 
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increasing the amount of recombinant collagen VII injected or the fibroblast 
density. 
The relevance of fibroblast cell therapy on cell healing was demonstrated 
in a later study by Woodley et al. in which they showed that normal human 
fibroblasts or genetically corrected RDEB fibroblasts over-expressing collagen VII 
injected intradermally into athymic mice homed to wounded skin leading to an 
increase in collagen VII at the BMZ as well as anchoring fibril formation. 
Significantly, this was associated with significant enhancement of wound healing 
at multiple sites (Woodley et al., 2007). 
This encouraging data in animal models paved the way for intradermal 
injection of allogeneic fibroblasts in humans. In a study by Wong et al. a single 
intradermal injection of 5 x106 allogeneic human fibroblasts in non-blistered 
RDEB skin was found to increase collagen VII deposition at the DEJ and 
anchoring fibril formation, for up to three months (Wong et al., 2008).  This was 
reflected by reduced skin fragility at a clinical level. The type-VII collagen at the 
DEJ was shown to increase at 2 weeks and at 3 months following injection, which 
was associated with an increase in anchoring fibrils, however, none of these had 
normal morphology. No clinical or immunopathologic side effects were noted. The 
sustained increase in collagen VII expression was despite the fact that allogeneic 
fibroblasts where shown to be absent at 2 weeks. In the 5 RDEB patients enrolled 
in this study, the ones with mild reduction of collagen VII at baseline 
demonstrated higher and more sustained collagen VII expression following 
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allogeneic fibroblast injection raising question about the source of collagen VII 
production and pathways involved in expression upregulation. 
 
8.5 Intradermal allogeneic fibroblast therapy: how does it work? 
Multiple studies have suggested that the increase in collagen VII 
expression noted following allogeneic fibroblast injection is due to an increase in 
the patient’s own mutant collagen VII production rather then wild type collagen 
secreted by the allogeneic fibroblasts. This is supported by findings by Wong et al. 
of an increase in structurally defective anchoring fibrils following intradermal 
fibroblast injections (Wong et al., 2008). In addition, the increased expression was 
despite the fact the allogeneic fibroblast were no longer viable by 2 weeks. This 
led to the suggestion that allogeneic fibroblasts, and through a paracrine effect on 
keratinocytes and possibly fibroblast, could lead to increased synthesis of mutant 
yet partially functional collagen VII. This might explain the observation that 
patients with the highest baseline expression of collagen VII showed better 
response to allogeneic fibroblast injections as opposed to those subjects with little 
or no baseline expression. However, the increased expression at 2 weeks and 3 
months observed in this study was not coupled by a matched cytokine gene 
expression. The study also observed intraepidermal collagen VII in patients 
receiving allogeneic but not autologous fibroblasts emphasizing yet again that at 
least a proportion of newly generated collagen VII is mutant protein. 
A dose related effect corresponding to either the cells injected or the 
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protein generated was debated. In support of this is the finding in mouse models 
that increasing the amount of fibroblast cell number or amount of recombinant 
collagen VII leads to increased expression of collagen VII (Woodley et al., 2003; 
Woodley et al., 2004b; Woodley et al., 2004a; Ortiz-Urda et al., 2003). This was 
also supported in human studies where RDEB patients showed a lower expression 
of collage VII expression following parent carrier fibroblast injections compared 
to unrelated donor fibroblast. This might be a reflection of a lower collagen VII 
expression known to occur in carriers of COL7A1 mutations (Wong et al., 2008). 
 
8.6 Limitations of fibroblast cell therapy 
Although intradermal delivery of fibroblasts presents a less invasive form 
of therapy, it is not a definitive form of therapy and is associated with side effects 
including significant pain at the multiple sites of injection. It would also require a 
vast number of cells to cover large treatment areas. Genetically modified cells 
have the potential of tumourigenesis and allogeneic fibroblast injections could 
potentially lead to antibody formation and rejection. However, the latter was not 
observed in studies involving allogeneic fibroblast therapy (Wong et al., 2008; 
Griffiths et al., 2004; Falanga et al., 1998; Woodley et al., 2007; Price et al., 
2004). This could be explained by several factors including the short life span of 
allogeneic fibroblasts found to be as short as 1 and 2 weeks in animal and human 
studies respectively (Price et al., 2004; Wong et al., 2008). In addition, fibroblasts 
have a low immunological impact as they lose their cell surface HLA proteins in 
culture (Theobald et al., 1993), a process that also leads to the loss of professional 
 225 
antigen presenting cells such as the Langerhans cells (Phillips et al., 2002), in 
addition to their ability in reducing T cell proliferation (Haniffa et al., 2007). 
 
8.7 Case study  
For this study a 24-year-old Caucasian female with RDEB-sev gen was 
selected.  She had been one of five subjects studied by our group in the first human 
intradermal fibroblast cell therapy study by Wong et al. (case 5; Wong et al., 
2008). This patient is known to be compound heterozygous for the COL7A1 
nonsense mutation c.2044C>T (p.Arg682Stop) in exon 15 of the NC1 domain and 
the splice site mutation IVS87+4A>G in intron 87. This particular donor splice-
site mutation creates a leaky splice site, which leads to either in-frame skipping of 
exon 87 (69-bp) or wild-type sequence allowing some expression of full-length 
collagen VII (Whittock et al., 1999). This also allows for tracking of the mutant 
allele in skin biopsy complementary DNA. 
Of particular interest is that this patient showed higher levels of collagen 
VII expression at the BMZ at baseline compared to the other subjects in the study 
with only a slightly reduced collagen VII immunolabelling at the DEJ and 
anchoring fibril-like structures on TEM. She was subsequently shown to develop a 
higher collagen VII expression following allogeneic fibroblast injection, which 
was sustained for 3 months. To investigate this further, cutaneous allogeneic 
fibroblasts injections were performed in this patient but clinical, 




8.8 Materials and Methods 
For this study, I identified a 10 x 10cm area on the subject’s upper back 
that was suitable for allogeneic fibroblast injections (non-blistered). At day 0, the 
fibroblasts or saline were injected intradermally into the mid-to- superficial dermis 
after applying topical anaesthesia with lidocaine/prilocaine cream (EMLATM) for 
30minutes. The injections were performed by the Principal Investigator Prof. John 
McGrath using an insulin syringe. Each injection contained 5 x 106 neonatal 
allogeneic fibroblasts in 0.25ml of buffer sufficient to cover a 1cm2 area. A similar 
volume of normal saline was also injected to adjacent skin for comparison 
following observations by Venugopal et al. that saline can also increase collagen 
VII in RDEB skin (Venugopal et al., 2010) and took biopsies at days 15 and 90 
from these saline injected areas . 
Unlike the allogeneic fibroblasts used by Wong et al., the cell product 
(ICX-RHY- 013) used in this study, was supplied in pre-packed vials by Intercytex 
Ltd, Manchester, UK. The suspension consisted of allogeneic human dermal 
fibroblasts in Hypothermosol
®
-FRS in a sterile solution. The human dermal 
fibroblasts were isolated from neonatal foreskin from donors whose mothers had 
been screened for a range of diseases. The fibroblasts were cryopreserved, thawed 
and expanded in culture under good manufacturing practice (GMP) principles. 
Each vial contained 20 x 106
 
cells/ml and the dose used was 0.25ml of 20 x106
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cells/ml (ICX-RHY- 013) per 1cm2. 
Skin biopsies (6mm punch biopsies) were taken at days 7, 15, 30, 90, 180, 
270, and 360.  I took all biopsies following informed consent and under aseptic 
techniques as described in Chapter 2. Tissue was then subdivided for 
immunofluorescence microscopy, transmission electron microscopy, storage in 
RNA later for microarray analysis and quantification of collagen VII gene 
expression (identical to protocols described in the Wong et al. study, Wong et al., 
2008). The end point of the study was 12 months after the initial injections. 
The study was approved by the Guy’s and St Thomas’ Hospital local 
Ethical Committee (REC reference 04/Q0702/121) and was conducted according 
to the Declaration of Helsinki Principles. I made the amendments to the ethics 
application that was supplied by Dr. Wong for the study described above (Wong et 
al., 2008), outlining the aims of the study, supporting evidence, the revised 
protocol and consent form. This was submitted to the local ethics committee and 
subsequently approved. 
I performed Immunofluorescence studies, quantification of collagen VII 
fluorescence, RNA extraction from skin biopsies, cDNA synthesis, in vitro HB-
EGF studies and COL7A1 gene expression by quantitative real-time RT-PCR were 
performed as described in Chapter 2. The latter was carried out using COL7A1 
TaqMan® Gene Expression Assays (COL7A1 Hs01574745_g1, Applied 
Biosystems; Foster City, CA, USA) which measured the amplification of the exon 
54-55 fragment of the COL7A1 cDNA. The exon skipped allele of the investigated 
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RDEB patient was separately amplified and quantified using qRT-PCR with a 
SYBR Green protocol (Applied Biosystems) using the following primers: 
COL7A1 cDNA exon 86 forward 5`-GTGCCAGTGGAAAAGATGGA-3`, 
COL7A1 cDNA exon 87 forward 5`- CGGACCTAAAGGAGAACCTG-3` and 
COL7A1 cDNA exon 90 reverse 5`-AGTCCTCGGTCACCTTTGG-3`. 
Gene expression microarray experiments were performed using total RNA 
extracted from baseline (day 0), fibroblast injected sites at days 7, 15 and 90, and 
the saline injected site at day 15. Whole genome gene expression microarray in 
each extracted RNA sample was performed using Sentrix Human-6 Whole 
Genome Expression Beadchips (Illumina Inc, San Diego, CA) as described in 
Chapter 2. The microarray data were confirmed with validated Taqman assays 
(FOS Hs00170630_m1, JUN Hs01103582_s1, IL1R2 Hs01030385_m1, LAMC2 
Hs01043707_m1, GAL Hs01032385_m1, STAT1 Hs01014002_m1, TNFSF13B 
Hs00198106_m1, IRF1 Hs00971960_m1, VCAM1 Hs01003372_m1, COL1A1 
Hs01076756_g1, COL4A1 Hs01007434_g1, COL7A1, COL17A1 
Hs00166711_m1, CCL18 Hs00268113_m1, HB-EGF Hs00181813_m1) 
purchased from Applied Biosystems (Foster City, CA, USA) using qRT-PCR). 
 
8.9 Results 
Following allogeneic fibroblast injection collagen VII expression at the 
BMZ increased after 15 days and was maintained for at least 270 days returning to 
baseline levels by 360 days. Using the saline control, a slight increase in collagen 
VII labelling was noted at day 15, but this returned to baseline by 90 days as 
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shown in Figure 8.1 and Table 8.2. 
Using quantitative RT-PCR, COL7A1 gene expression following fibroblast 
injection, showed a >20-fold increase at days 15 and 90, but this returned to 
baseline at day 180 (Figure 8.2A). Saline negative control injections resulted in an 
approximately 5-fold increase in COL7A1 gene expression at day 15, but were 
similar to baseline levels at day 90. Using primers spanning the splice-site 
mutation in intron 87, the ratio of wild-type to mutant transcripts, at baseline, was 
approximately 2:3 (Figure 8.2B), which persisted in all biopsy material following 
allogeneic fibroblast injections. 
Using whole genome microarray analysis, no differences were noted in 
gene expression for cytokines already known to increase COL7A1 expression 
(supplementary electronic material). However, a >3-fold increase in expression of 
the gene for heparin-binding epidermal growth factor-like growth factor (HB-
EGF) (Iwamoto and Mekada, 2000) was noted. Quantitative real-time RT-PCR 
showed a similar temporal pattern to the COL7A1 quantitative real-time RT- PCR 
data (linear correlation, r = 0.978; P<0.0001; Figure 8.2C). It was also noted that 
gene expression profiles of FOS (linear correlation, r = 0.864; P<0.0006) and JUN 
(linear correlation, r = 0.945; P<0.0001) were also highly similar to the pattern of 
increased COL7A1 expression at the different time points (figure 8.3). JUN and 
FOS form the AP-1 transcription complex, which can bind to the COL7A1 
promoter and enhance gene expression (Nakano et al., 2001) 
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Figure 8.1. Immunofluorescence labelling of collagen VII at the DEJ at 
baseline and following allogeneic fibroblast injection as well as saline 
control. Values of mean fluorescence intensities are also shown. Bars = 50 
μm. 
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    D 
  F 
G   H 
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Table 8.2. Quantification of mean immunofluorescence intensity reveals 
increased collagen VII expression at the DEJ following allogeneic 
fibroblast injection and following intradermal saline injection to a lesser 









Normal Human Skin 133.8 
+
/- 2.9 
RDEB D0 60.4 
+
/- 3.9 
RDEB D7 87.3 
+
/- 1.6 
RDEB D180 90.0 
+
/- 9.6 
RDEB D270 92.2 
+
/- 1.7 
RDEB D360 61.8 
+
/- 1.5 
RDEB S15 74.1 
+
/- 1.4 




Figure 8.2. Quantitative real-time RT-PCR (qRT-PCR) studies. There is 
increased expression of COL7A1 (A,B) and heparin-binding epidermal growth 
factor-like growth factor (HB-EGF) (C) for at least 90 days following a single 
injection of allogeneic fibroblasts and a smaller, more transient increase 
following saline injection. 
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To investigate whether there is a temporal relationship between the 
upregulation of HB-EGF and increased COL7A1 expression, HB-EGF studies 
were performed using subconfluent cultured keratinocytes and fibroblasts taken 
from normal controls and from two subjects with RDEB (including the subject 
of this study and an unrelated patient with the COL7A1 mutations c.1732C>T 
(p.Arg578Stop) and c.7786delG (p.Gly2593fsX4). HB-EGF treatment led to 
upregulation of COL7A1 mRNA in keratinocytes and fibroblasts in all cells 
(Figure 8.3A), as did treatment with transforming growth factor-β1. There was 
also an increase in JUN and FOS expression levels in all cells (Figure 8.3B and 
C).  
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Figure 8.3. Relative fold change in COL7A1, JUN and FOS mRNA levels 
following keratinocytes and fibroblasts treatment with recombinant 
heparin-binding epidermal growth factor-like growth factor (HB-EGF). 





This study analysed the effects of intradermal allogeneic fibroblast 
injection for up to 360 days and demonstrated that a single injection capable of 
increasing collagen VII labelling at the DEJ almost by 1.5 fold and this was 
maintained for >9 months. COL7A1 gene expression was upregulated for >3 
months and was mirrored by an increase in the expression of HB-EGF. In vitro, 
the incubation of keratinocytes and fibroblasts with HB-EGF was shown to 
lead to increased COL7A1 expression, potentially via increased AP-1 
transcription factor. Saline controls injections were also associated with a mild 
but short-lived increase in collagen VII. The hypothesis for this is that 
allogeneic fibroblasts (and to a much lesser extent saline) induce subclinical 
inflammation that leads to the upregulation of HB-EGF. This upregulation is 
potentially mediated by the recipients’ own keratinocytes and may be sustained 
for several months in an autocrine manner  (Hashimoto et al., 1994; Goishi et 
al., 1995). The study also shows that HB-EGF can increase the COL7A1 gene 
expression in cultured normal or RDEB keratinocytes and fibroblasts, 
supporting that HB-EGF might mediate the increase in COL7A1 expression. 
This in turn is likely to stimulate an increase synthesis of mutant, but partially 
functional, collagen VII. However, the study does not define categorically the 
source of the new collagen VII and whether it originates from the donor 
fibroblasts or indirectly from recipient keratinocytes/fibroblasts but this has 
been addressed in previous studies (Ortiz-Urda et al., 2003; Woodley et al., 
2003; Fritsch et al., 2008; Kern et al., 2009b; Conget et al., 2010; Yan and 
Murrell, 2010). However, this study does outline a trend in the upregulation of 
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COL7A1 gene and protein expression which provides further insight into the 
pathways involved in the upregulation of COL7A1 expression including 
immune responses that might act as the trigger for upregulation of COL7A1. It 
was suggested that perhaps the same mechanism apply to cases of bone 
marrow transplantation where the immune response to the transplantation 
rather than the bone marrow derived cells lead to upregulation of COL7A1 
expression (Uitto, 2011a). If proven then targeted therapy by the administration 
of HB-EGF can be trialled although this carries risks of tumourigenicity that 
needs to be taken into consideration particularly as RDEB patients have a 
significantly increased risk of developing squamous cell carcinoma  (Kivisaari 
et al., 2010). It also remains to be seen if EGF has similar signalling effects as 












Great progress has been made over the last 2 decades in the clinical, 
immunohistochemical and molecular diagnostics of EB, including the 
discovery of the COL7A1 gene on chromosome 3p21 as the gene underlying 
DEB (Ryynanen et al., 1991), cloning of COL7A1 (Christiano et al., 1994b; 
Christiano et al., 1994c; Parente et al., 1991) and the subsequent identification 
of the first recessive COL7A1 mutation; p.Met2798Lys and dominant mutation; 
p.Gly2040Ser in 1993 and 1994 respectively (Christiano et al., 1994d; 
Christiano et al., 1993). The subsequent plethora of published literature 
analysing the ultrastructural, molecular and clinical aspects of DEB has 
resulted in general paradigms for genotype-phenotype correlation and evolving 
classifications for EB that have seen the substitution of confusing historical 
eponyms with more clinically relevant ones. Phenotype-genotype correlation 
has been instrumental in making the various clinical distinctions, however, 
significant work stills need to be done, particularly in the field of DEB, to 
establish accurate and comprehensive paradigms that will address many yet 
unanswered questions. There is a need for deep phenotyping in association 
with comprehensive genotyping to answer questions such as: why is there 
considerable inter- and intra- familial heterogeneity and why do some 
mutations result in both dominant and recessive disease? What modifies 
disease expression to result in the various unique clinical subtypes such as EB 
pruriginosa? How can immunohistochemical and ultrastructural studies- the 
results of which are often non-specific- aid the process of genotype-phenotype 
correlation? And finally how can we optimize personalised and targeted 
therapies for DEB?  
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Studies outlined in this thesis have attempted to address some of these 
issues in a bid to refine genotype-phenotype correlation. Not only will this 
increase our understanding of DEB and the factors modulating phenotype 
expression but it will also have an impact on diagnosis, counselling, 
translational research and therapy, away from palliative medicine and towards 
personalised, specific and more definitive treatment.  
In Chapter 3, the molecular, immunohistochemical and ultrastructural 
aspects of BDN, previously known as ‘transient’ BDN, were explored. Not 
only does BDN represent a distinct clinical entity with a very favourable 
outcome, but it also displays unique and striking features on 
immunofluorescence and electron microscopy that were worth addressing. The 
aim was to establish whether immunohistochemical and ultrastructural findings 
in these cases could provide an adjunct for the genotype-phenotype correlation. 
If so, then the relatively rapid immunofluorescence and electron microscopic 
studies could provide initial insight into subsequent disease severity aiding 
initial diagnosis and counselling. Moreover, the concept of intracytoplasmic 
collagen VII was previously generally synonymous with BDN. However, this 
Chapter sought to explore whether this finding was unique to this particular 
subtype of DEB. 
The conclusion of Chapter 3, outlining one of the largest case series of 
BDN, highlights that intracytoplasmic retention of collagen VII is not 
exclusive to cases of BDN and can be associated with DDEB, RDEB, JEB, 
EBS as well as normal skin. This has also been supported by a recent study by 
Berk et al. (Berk et al., 2013). Thus, on an immunohistochemical level, the 
finding of intra-epidermal retention of collagen VII could have diverse 
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diagnostic, phenotypic and prognostic implications. Similarly, variable 
ultrastructural patterns of dilated RER, including stellate bodies, have been 
elucidated on TEM not only in BDN but also in other forms of EB, as well as 
non-EB cases and even normal skin. Therefore, the definition of the 
ultrastructural stellate body, which has been used synonymously with BDN, 
should be referred to as a variant of dilated RER. In addition, correlation of 
TEM with IF studies should still be performed in all cases, as definitive 
diagnosis will always require prospective clinical assessments and mutational 
analysis.  
Moreover, at the start of this thesis, GS mutations have been shown to 
underlie nearly half of dominant and recessive forms of DEB. In some cases 
there was unexplained overlap between the 2 inheritance patterns. In addition, 
a small number of non-GS mutations had been identified, mainly in RDEB but 
also in some DDEB cases. However, the genotype-phenotype correlation was 
far from characterised and the impact of these mutations on collagen VII 
expression was not quite clear. The key aims of Chapters 4 and 5 were to 
expand the collective COL7A1 mutation database and to study whether the type 
or location of GS and non-GS mutations could predict phenotype expression 
and subsequently explain the genotype-phenotype heterogeneity encountered in 
DEB. Fifty seven novel mutations (40 GS and 17 non-GS mutations) were 
identified and analysed along with >200 published GS and non-GS mutations. 
Polymorphisms were ruled out by excluding mutations in 100 controls and 
performing in silico analysis where necessary. The novel mutations identified 
in this thesis have already been published and added to the various COL7A1 
specific databases including www.deb-central.org and www.col7.info.  
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Analysis of the findings in Chapters 4 and 5, in conjunction with the 
published literature was in keeping with the general paradigms established for 
DEB attributing dominant-negative mutations, particularly GS mutations to 
dominant forms of DEB cases and loss-of-function COL7A1 mutations to its 
recessive counterpart. Analysis of my data confirmed frequent inter- and intra-
familial heterogeneity that was further complicated by the finding of some GS 
mutations with both dominant and recessive modes of inheritance to which 4 
novel mutations were added (12 in total).  
However, no relation could be found between the type or location of 
GS and non-GS mutations and the clinical phenotype. Similarly, and largely 
owing to small numbers, no conclusion could be drawn about GS mutations 
resulting in both dominant and recessive disease, although a mixed pattern of 
inheritance is likely to exist. Of particular interest were those GS mutations 
resulting in a myriad of clinical phenotypes of variable severity including the 
more extensive DDEB and EB-pr as well as, nail dystrophy or no disease at all. 
One explanation could be related to the possibility of undetected mutations 
using the Sanger sequencing technique including larger deletion and insertions 
(Kern et al., 2009a) which can lead to wrongly attributing a recessive disease 
to dominant mutations or even to erroneous diagnoses. This technical 
limitation is likely to explain the less than expected mutation pick up rate, 
which has been estimated in the EB National Diagnostic Laboratory in London 
at around 90% (Prof McGrath personal communication). Indeed, a recent study 
has highlighted the increased mutation rate in EB when new technology such 
as whole exome sequencing is used in a diagnostic setting. Therefore, the 
diagnosis of RDEB -and EB in general- should not be excluded based on non-
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confirmatory molecular analysis particularly where there is strong clinical 
suspicion.  
Phenotype heterogeneity could also be explained by genetic, epigenetic 
or even environmental factors. Unpredicted consequences of nucleotide 
substitutions on splicing as a result of proximity to exonic splicing enhancers 
(ESE) for example, can affect protein expression, as can biochemical effects on 
collagen VII by altering helix formation, protein folding, thermal stability, 
intracellular transport, secretion, and assembly into anti-parallel dimers or 
anchoring fibrils (Shimizu et al., 1996; Christiano et al., 1996a; Hammami-
Hauasli et al., 1998b; Lee et al., 2000; Sato-Matsumura et al., 2002; Kern et 
al., 2006; Chiaverini et al., 2010; Chen et al., 2001; Chen et al., 2002a; 
Brittingham et al., 2005; Fritsch et al., 2009; Hyde et al., 2006). Other 
influencing factors include the effects of endoplasmic reticulum stress and 
mutant proteins on apoptosis and gene expression, as well as gene promoter 
polymorphisms and transcriptional regulators such as MMP-1 and the high 
mobility group box 1 (HMGB1) respectively, which were found to correlate 
with disease severity in RDEB (Petrof et al., 2013a). 
Taking this into consideration, it becomes clear that although the type 
and location of COL7A1 mutations might offer general paradigms for genotype 
phenotype correlation, the missing piece of the puzzle is likely to lie beyond 
the COL7A1 gene and within genetic and epigenetic modulators that are likely 
to become evident with the introduction of whole genome and exome 
sequencing as well as data mining studies. This is supported by emerging data 
from the ENCODE (encyclopaedia of DNA elements) project suggesting that 
>80% of the human genome including non-coding DNA contains functional 
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elements that could influence gene expression compared to the previously 
thought 1.2% exonic DNA  (ENCODE Project Consortium et al., 2012). An 
interplay between multiple genetic, epigenetic and environmental modifiers is 
likely to be involved and further functional studies applying proteomic and 
transcriptomic principles are needed to verify the effects of the various 
modulators on gene expression as well as protein folding, secretion and 
degradation.  
Therefore, refining genotype-phenotype correlation based on COL7A1 
analysis alone and in the absence of detailed information on genetic, epigenetic 
and environmental modifiers will prove to be difficult and suboptimal. 
However, attempts to understand disease expression as outlined in this thesis, 
might offer minor refinement and improvement to the general genotype-
phenotype correlation that might also help to identify distinct subtypes of DEB 
amenable for targeted analysis and scrutiny. One example is the MMP-1 
promoter polymorphism, whose role in the itchy EB-pr phenotype was studied 
in Chapter 6. As outlined in this study, examination of the GS mutations 
associated with EB-pr - including 6 novel mutations- revealed that the nature of 
the pathogenic COL7A1 mutations in EB-pr did not seem to differ from those 
found in patients with dominant DEB subtypes without pruritus. In addition, 
although the findings in this Chapter support the published evidence that the -
1607 1G/2G polymorphic variant in the MMP1 promoter may be associated 
with a more severe RDEB phenotype, similar effects on its dominantly 
inherited counterpart were not identified. There were no significant differences 
in the frequency of the -1607 1G/2G MMP-1 promoter polymorphism between 
patients with dominantly inherited EB-pr and those with other forms of DDEB 
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or controls and therefore it is unlikely to play a role in the modulation of the 
pruritic EB-pr phenotype. Since the publication of this study, the above results 
were supported by a subsequent publication by Kern et al. in which no 
correlation was found between the MMP-1 2G promoter polymorphism and 
disease severity in DDEB (Kern et al., 2009a). In addition, no relation was 
found to RDEB severity or the development of aggressive SCC. Therefore 
what accounts for the unique pruritic phenotype of EB-pr remains unclear as 
evident by more recent longitudinal studies and case series (Fortuna et al., 
2013; Brick et al., 2012; Tang et al., 2013; Takiyoshi et al., 2012; Covaciu et 
al., 2011), although in one recent study co-infestation with scabies was 
highlighted as a potential environmental modifier triggering the pruritic EB-pr 
phenotype (Kim et al., 2013). The cytokine IL-31 that plays a role in atopic 
eczema was not found to be implicated in EB-pr  (Nagy et al., 2010). 
Unfortunately, this lack of disease explanation is an impediment to the 
development of direct and specific anti-pruritic therapy for EB-pr. Several 
agents have been explored in the past including ciclosporin and thalidomide 
with disappointing results and the effect of others recently trialled in eczema is 
yet to be established in EB-pr including the immunomodulators apremilast; a 
phosphodiesterase 4 inhibitor and dupilumab; a monoclonal antibody that 
inhibits both IL-4 and IL-13 signalling (Harskamp and Armstrong, 2013).   
However, although the ‘inside-out’ approach to genotype-phenotype 
correlation scrutinizing the implications of molecular, immunohistochemical 
and ultrastructural findings on clinical expression as outlined in Chapters 3-6 
has been integral to genotype-phenotype correlation in EB, an exciting concept 
with tremendous pathophysiological and therapeutic implications is the 
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‘outside-in’ dimension represented by somatic mosaicism, where the 
observation of normal patches of skin reflects the presence of natural gene 
correction within a subpopulation of cells. Prior to this thesis, reports of RM in 
DEB did not exist, however the RM phenomenon was described in other forms 
of EB including nHJEB (Darling et al., 1999; Pasmooij et al., 2005; Pasmooij 
et al., 2007; Jonkman and Pasmooij, 2009; Jonkman et al., 1997) and EBS 
(Schuilenga-Hut et al., 2002; Smith et al., 2004). 
In Chapter 7, the first case of revertant mosaicism in DEB was studied. 
This revealed intragenic cross-over in the COL7A1 gene as the mechanism 
underlying RM in this case. The correction, which occurred in keratinocytes 
and not fibroblasts, resulted in subsequent generation of wild type alleles and 
restoration of collagen VII expression at the basement membrane. Anchoring 
fibrils were also detectable in reverted skin. Therefore, it is likely that the RM 
phenomenon, which was historically exclusive to nHJEB cases, is more 
common than initially thought as evidenced by the publication of 3 subsequent 
cases of RDEB and Kindler syndrome with proven RM (Pasmooij et al., 2010; 
van den Akker et al., 2012; Lai-Cheong et al., 2012). Pasmooij et al. reported a 
case of RM due to a correcting somatic COL7A1 nucleotide deletion; 
c.6528delT (Pasmooij et al., 2010). This also occurred in keratinocytes only 
and led to the occurrence of an expanding revertant patch but it was not clear 
whether this occurred during embryogenesis or later in life. More recently, van 
den Akker et al. described another case with a nucleotide substitution 
c.6510G>T that reverted the nonsense mutation p.Gln2170Stop to 
p.Gln2170Tyr resulting in amelioration of collagen expression (van den Akker 
et al., 2012). Therefore, the publication of 3 cases of RDEB with RM within a 
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short space of time is probably a reflection of a not-so-rare phenomenon that is 
under reported.   
However, further work needs to be done to understand whether the RM 
phenomenon is a random event or is triggered by genetic or environmental 
factors. In support of the latter is the observation that RM generally occurs in 
high turnover tissue and is not noted at birth. Furthermore, it is still not clear 
whether RM arises in the skin through unknown events or in epithelial 
progenitor cells in the bone marrow that are subsequently recruited to injured 
skin via signalling mediators such as HMGB1. The latter might explain the 
multiple and simultaneous appearance of revertant patches. In addition, 
understanding of the timing at which reversion occurs and the predilection for 
keratinocytes and not fibroblasts will have clinical implications particularly 
when it comes to harnessing this phenomenon for therapeutic purposes. 
Nevertheless, the discovery of RM in RDEB is exciting as it provides a 
much-needed model for the study of natural gene correction mechanisms in 
DEB that could potentially be recapitulated in vivo. Also it offers an endless 
resource of autologous patient specific cell therapy, including localised cell 
therapy such as punch grafting (Gostynski et al., 2014), BM transplantation 
and generation of iPSCs (Aasen et al., 2008; Tolar et al., 2009; Tolar et al., 
2011; Itoh et al., 2011; Jonkman and Pasmooij, 2012). The reprogramming of 
revertant cells into iPSCs capable of differentiating into autologous 
keratinocytes would preclude the use of retroviral vectors for gene correction 
and would circumvent issues related to rejection (Itoh et al., 2011; Tolar et al., 
2011; Tolar et al., 2014; Woodley et al., 2013a). iPSCs can also be 
differentiated into hematopoietic or mesenchymal stem cells obviating the need 
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for risky BM transplantation.  
The discovery of RM in DEB is just an example of the advances made 
in the last couple of decades in terms of understanding the pathophysiology of 
DEB and its underlying molecular, immunohistochemical and ultrastructural 
associations. Yet for a long time this has not been paralleled by advances in 
therapy, which until recently have been largely preventative or palliative. At 
the time this thesis began, only a limited experimental medications were tried. 
However, in the last few years, significant developments have been made in the 
field of translational medicine involving protein, cell and gene therapy. Earlier 
proof of principal studies using pre-clinical models, have led to the 
implementation of several clinical trials with promising results. Ironically, 
advances in therapy have also provided further insight into DEB 
pathophysiology. For example, cell therapy and as demonstrated in Chapter 8, 
does not only result in clinical amelioration of skin fragility but also provides a 
model from which we could elucidate which mediators and genetic modifiers 
influence collagen VII expression when the inducing cells are no longer 
present.  
At the start of this thesis, fibroblasts were used in DEB as an off label 
therapy. In a study by Wong et al. in 2008 a single intradermal injection of 5 
x106 allogeneic human fibroblasts in non-blistered RDEB skin was found 
to increase collagen VII expression and anchoring fibril formation, for up 
to three months (Wong et al., 2008). The key questions arising from that 
study were regarding the mechanism behind this clinical and ultrastructural 
amelioration and the lasting effects of allogeneic fibroblast injections.  
 248 
The follow-on study in Chapter 8 was carried out in 1 patient from the 
previous study by Wong et al. This patient, known to be compound 
heterozygous for the COL7A1 nonsense mutation c.2044C<T (p.Arg682Stop) 
and the splice site mutation IVS87+4A>G, was chosen because she showed 
higher levels of collagen VII expression at the DEJ at baseline compared to the 
other subjects and was subsequently shown to develop a higher collagen VII 
expression following allogeneic fibroblast injection, which was sustained for 3 
months. Following the intradermal injection of 5 x 106 allogeneic fibroblasts 
per cm2, the effects were analysed for up to 360 days and results demonstrated 
that a single injection is capable of increasing collagen VII labelling at the DEJ 
by almost 1.5 fold and that this was maintained for >9 months. COL7A1 gene 
expression was upregulated for >3 months and was mirrored by an increase in 
the expression of HB-EGF. Subsequent in vitro incubation of keratinocytes and 
fibroblasts with HB-EGF revealed an associated increase in COL7A1 
expression, potentially via increased AP-1 transcription factor. It is likely that 
allogeneic fibroblasts (and saline to a much lesser extent) and through 
induction of subclinical inflammation leads to the upregulation of HB-EGF. 
This in turn is likely to stimulate an increased synthesis of mutant, but partially 
functional, collagen VII. However, the study does not define categorically the 
source of the new collagen VII and whether it originates from the donor 
fibroblasts or indirectly from recipient keratinocytes/fibroblasts but this has 
been addressed in previous studies (Ortiz-Urda et al., 2003; Woodley et al., 
2003; Fritsch et al., 2008; Kern et al., 2009b; Conget et al., 2010; Yan and 
Murrell, 2010). However, what this study does outline is a trend in the 
upregulation of COL7A1 gene and protein expression following allogeneic 
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fibroblast injection, which provides further insight into the pathways involved 
in COL7A1 expression including the potential role of immune responses. The 
latter, as suggested in a commentary by Prof. Uitto might have implications on 
bone marrow transplantation in RDEB, where the immune response to the 
transplantation procedure itself rather than the bone marrow derived cells 
might be what leads to upregulation of COL7A1 expression (Uitto, 2011a). If 
proven, then optimized and targeted therapy utilizing key-molecules that 
modulate COL7A1 expression such as HB-EGF can be trialled. However the 
risks of tumourigenicity would need to be taken into consideration particularly 
as RDEB patients have a significantly increased risk of developing squamous 
cell carcinoma  (Kivisaari et al., 2010). It also remains to be seen if EGF has 
similar signalling effects as HB-EGF with less effects on tumourigenicity.  
Since the completion of the above study, several clinical trials have 
taken place and several are ongoing involving allogeneic fibroblast therapy in 
humans (Petrof et al., 2013b; Venugopal et al., 2013). In a recent study by 
Petrof et al. a single intradermal injection of allogeneic fibroblasts in subjects 
with RDEB was shown to increase the initial rate of erosion healing within the 
first 28 days but not thereafter (Petrof et al., 2013b). In another study by 
Venugopal et al. the injection of either allogeneic fibroblasts or suspension 
solution alone in patients with RDEB-sev gen was shown to improve wound 
healing in chronic wounds independently of collagen VII expression 
(Venugopal et al., 2013). However, studies exploring the effects of cell therapy 
on chronic wounds should be put in context with the normal healing process 
occurring in RDEB and a longitudinal study looking into this is yet to be 
conducted. Therefore, an ideal prospective trial exploring cell therapy should 
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involve a 3-arm study comparing the effects of injectable cells vs. vehicle 
compared to untreated wounds. Furthermore, studies are needed to address the 
potential benefit of re-treatment as well as the optimal mode of cell delivery. 
More recently, stem cell therapy has emerged as a unique method of 
treatment owing to the plasticity and regenerative potential of stem cells with a 
capacity to differentiate into keratinocytes as well as fibroblasts. Moreover, it 
has been shown that in addition to the bone marrow, effective stem cells can be 
derived from various sources including the readily accessible adipose tissue 
and cord blood or through induction of iPSCs. The latter refers to the 
reprogramming of somatic cells by the use of a multitude of transcription 
factors into embryonic stem cells capable of differentiating into epithelial cells 
and fibroblasts (Aasen et al., 2008; Aasen and Izpisua Belmonte, 2010; 
Takahashi and Yamanaka, 2006; Uitto, 2011b; Tolar et al., 2011; Bilousova et 
al., 2011).  
Intradermal infusion of allogeneic BM derived mesenchymal stromal 
cells (MSCs) in RDEB patients resulted in increased collagen VII expression at 
the DEJ and improved healing of chronic ulcers (Conget et al., 2010). 
Similarly, preclinical studies in COL7A1 null animal models demonstrated that 
the systemic infusion of bone marrow derived stem cells resulted in 
amelioration of collagen VII expression and subsequent reduction of skin 
fragility. Survival was also extended in the treated mouse embryos (Tolar et 
al., 2009; Chino et al., 2008).   
These studies paved the way for clinical trials using infusions of 
allogeneic bone marrow derived stem cells in children with RDEB following 
chemoablative pre-conditioning. This led to partial correction of collagen VII 
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expression with amelioration of skin fragility. However, this procedure is 
fraught with risks relating to immunosuppression. Therefore, measures 
currently being assessed to reduce morbidity and mortality include use of 
reduced intensity chemoablation and co-infusion of mesenchymal stem cells 
(Uitto et al., 2012; Petrova et al., 2010; Conget et al., 2010).  Another 
consideration is the infusion of homologous transgenic stem cells or patient 
specific-RDEB iPSCs as a way to achieve safer patient specific therapy (Tolar 
et al., 2011; Murauer et al., 2011; Uitto, 2011b). RDEB iPSCs derived from 
fibroblasts and keratinocytes have been used to generate both mesenchymal 
and haematopoietic stem cells that can produce collagen VII in vivo (Tolar et 
al., 2011; Uitto, 2011b; Bilousova et al., 2011). A significant draw back with 
the use of iPSCs however, relates to the increased risk of malignancy owing to 
the use of transcription factors that could potentially lead to oncogenic effects  
(Liang et al., 2012). 
 More recently, in vivo studies have demonstrated that local and 
systemic injection of human umbilical cord blood-derived unrestricted somatic 
stem cells (USSCs) resulted in wound healing and skin regeneration in mouse 
models. USSCs, even if injected intradermally at a distant site, were capable of 
migrating to areas of wounding  (Liao et al., 2013). 
Therefore stem cell therapy is an exciting therapeutic platform with 
potential to provide sustained and widespread correction of collagen VII 
expression if applied earlier in life. However, the next challenge lies in 
ascertaining whether the amelioration of collagen VII expression is related to 
increased wild type collagen VII production by transplanted cells or as a result 
of increased production of mutant yet partially functional collagen VII 
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(Prockop, 2009; Tolar et al., 2010; Chen et al., 2008; Nauta and Fibbe, 2007). 
Also it is still not clear which specific progenitor effector cells are capable of 
collagen VII production and the mechanism by which its expression is induced. 
So far, studies have established that BM cells homing to skin are derived from 
haematopoietic or mesenchymal stromal cell populations with an ability to 
differentiate into keratinocytes and also fibroblast-like cells (Badiavas et al., 
2003; Borue et al., 2004; Fathke et al., 2004; Abdul-Wahab et al., 2012). 
However, the exact nature of this subpopulation of progenitor cells is yet to be 
determined.  Recent work by Tamai et al. has established that a subpopulation 
of bone-marrow platelet-derived growth factor receptor α-positive 
(Lin−/PDGFRα+) MSCs contained epithelial progenitors. These cells were 
also found to be mobilised into wounded skin by HMGB1 (Tamai et al., 2011), 
a nuclear protein capable of modulating gene expression (Harris and Raucci, 
2006), as supported by the above study, where HMGB1 was shown to facilitate 
recruitment of BM subpopulations with epithelial regenerative potential into 
wounded skin leading to increased local expression of COL7A1 (Tamai et al., 
2011). This provides exciting insight into mechanisms of stem cells 
differentiation and migration with implications for cell and drug therapies. 
Since the publication of the study outlined in Chapter 8, leaps have 
been made in the field of gene, drug, protein and cell therapy in EB that have 
seen the application of silencing small molecules and SMarT technologies 
(Chamcheu et al., 2012), as well as engineered transcription activator-like 
effector nucleases (TALEN) and clustered regulatory interspaced short 
palindromic repeats (CRISPR) associated RNA-guided DNA endonucleases 
for precise genome editing in vivo to increase collagen VII expression  
 253 
(Pendaries et al., 2012; Murauer et al., 2011; Murauer et al., 2013; Turczynski 
et al., 2012; Osborn et al., 2013; Gruber et al., 2013; Umov et al., 2010; 
Carroll, 2011). Not only will these technologies inadvertently lead to an 
increase in the functional level of wild type collagen VII but they will also 
circumvent the use of retroviral vectors providing a safer and more patient 
specific therapeutic option. 
With regards to protein therapy and since the completion of this thesis, 
intradermal injection of purified recombinant collagen VII was attempted in 
collagen VII null mice. However, this treatment was limited by the extensive 
mucosal and cutaneous involvement in DEB, as well as the limited diffusion of 
intradermally injected collagen VII  (Woodley et al., 2013b). In addition, this 
approach was associated with the formation of antibodies to the foreign 
collagen VII protein but in another study anti-CD40L monoclonal antibody has 
been utilised with success in blocking this reaction  (Remington et al., 2009).  
Moreover, in a recent study by Woodley et al. 12 out of 22 patients with RDEB 
were found to have low level of circulating anti- collagen VII autoantibodies. 
However, the antibodies did not bind to the DEJ and were  thought to be non-
pathogenic (Woodley et al. 2014). 
In a recent study by Woodley et al.; recombinant collagen VII was 
injected intravenously in 2 animal models; athymic nude mice with full 
thickness skin wounds, as well as an RDEB skin transplantation mouse model. 
Recombinant collagen VII incorporated into the DEJ after 2 weeks and was 
sustained for 8 weeks post injection, leading to immunohistochemical and 
ultrastructural amelioration of collagen VII expression and improved skin 
fragility and healing (Woodley et al., 2013b). Topical application of 
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recombinant collagen VII was also attempted in animal models with similar 
results (Wang et al., 2013). 
From a therapeutic perspective, microneedling is being explored in a 
randomized controlled trial as a way to promote wound healing in DEB 
(Australian New Zealand Clinical Trials Registry). Etanercept (Gubinelli et al., 
2010) and mycophenolate mofetil (Eldarouti et al., 2013) were used in RDEB 
patients with some success, however, more specific drug therapies have 
recently emerged with promising results. Some, such as aminoglycosides took 
advantage of the proofreading properties leading to read-through correction of 
mRNA bearing premature termination codons (PTCs) (Rowe and Clancy, 
2009). Others targeted potential disease modifiers such as aberrant splicing. 
The histone deacetylase inhibitor; sodium butyrate (NaBu), has been shown to 
modulate the expression of splicing factors with subsequent implications on 
functional protein expression (Garcia-Blanco et al., 2006; Nissim-Rafinia et 
al.; Kerem et al., 2005). Also, inhibition of MMP-1, a collagenase that 
degrades collagen VII could potentially lead to amelioration of protein 
expression in severe RDEB  (Titeux et al., 2008).  
The progress in drug therapy has also been accompanied by advances in 
the modes of delivery of various treatments including topical applications, as 
well as local and intravenous injections. More recently, nanotechnology has 
emerged as a promising new application for drug delivery. This utilises 
nanoparticle systems to increase bioavailability but without unwanted side-
effects  (Chamcheu et al., 2012). If published results are reproducible, then this 
technology has the potential of enhancing the delivery of any novel drug 
therapy with increased tolerability and efficacy. 
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Moreover, advances in stem cell biology including the identification of 
stem cell subpopulations contributing to skin recovery and mechanisms 
involved in tissue regeneration, as well as the recognition of modulating 
cytokines and transcription factors, will enable the use of specific and targeted 
molecules capable of recruiting effector progenitor cells into diseased skin. 
Furthermore, the use of iPSCs as a model to recapitulate EB disease 
mechanisms will be instrumental in identifying similar drug targeting 
pathways. 
In conclusion, at the heart of EB gene discovery, translational research 
and personalized medicine lies the genotype-phenotype correlation. Not only 
has this triggered the analytical questioning behind this thesis and EB research 
in general but it is likely to continue to modify how we approach EB, whether 
it is by adapting classifications, recognizing the role of genetic, epigenetic and 
environmental modulators or through optimization of patient specific therapies. 
Although studies carried out in this thesis offered minor refinement to the 
general genotype-phenotype correlation, they identified key repair mechanisms 
for natural gene therapy and showed that a single growth factor can increase 
COL7A1 expression and protein synthesis. Several directions for the future 
have been mentioned in the general discussions sections, however, it is clear 
that significant improvement to the genotype-phenotype correlation will 
require greater insight into gene-gene and gene-environment modulation, likely 
to be provided in the near future by emerging data from the ENCODE project. 
Molecular, proteomic and transcriptomic studies will be needed to 
subsequently characterise and validate newly-found pathogenic modulators and 
their effects on disease expression, while phenotype correlation will continue 
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